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Abstract
Development of a decision support tool for primary care 
management of patients with abnormal liver function 
tests without clinically apparent liver disease: a record-
linkage population cohort study and decision analysis 
(ALFIE)
PT Donnan,1* D McLernon,1 JF Dillon,2 S Ryder,3 P Roderick,4 F Sullivan1 
and W Rosenberg5
1Tayside Centre for General Practice, Community Health Sciences, University of Dundee, 
Dundee, UK
2Division of Pathology and Neurosciences, Ninewells Hospital and Medical School, University of 
Dundee, Dundee, UK
3Directorate of Medicine, Division of Gastroenterology, Queen’s Medical Centre, University Hospital 
NHS Trust, Nottingham, UK
4Public Health Sciences and Medical Statistics Group, School of Medicine, University of 
Southampton, UK
5School of Medicine, Division of Infection, Inflammation and Repair, University of Southampton, UK
*Corresponding author
Objectives: To determine the natural history of 
abnormalities in liver function tests (LFTs), derive 
predictive algorithms for liver disease and identify the 
most cost-effective strategies for further investigation.
Data sources: MEDLINE database from 1966 to 
September 2006, EMBASE, CINAHL and the Cochrane 
Library.
Methods: Population-based retrospective cohort study 
set in primary care in Tayside, Scotland, between 1989 
and 2003. Participants were patients with no obvious 
signs of liver disease and registered with a general 
practitioner (GP). The study followed up those with an 
incident batch of LFTs in primary care to subsequent 
liver disease or mortality over a maximum of 15 years. 
The health technologies being assessed were primary 
care LFTs, viral and autoantibody tests, ultrasound and 
liver biopsy. Measures used were the epidemiology 
of liver disease in Tayside (ELDIT) database, time-to-
event modelling, predictive algorithms derived using the 
Weibull survival model, decision analyses from an NHS 
perspective, cost–utility analyses, and one-way and two-
way sensitivity analyses.
Results: A total of 95,977 patients had 364,194 initial 
LFTs, with a median follow-up of 3.7 years. Of these, 
21.7% had at least one abnormal liver function test 
(ALFT) and 1090 (1.14%) developed liver disease. 
Elevated transaminases were strongly associated with 
diagnosed liver disease, with hazard ratios (HRs) of 
4.23 [95% CI (confidence interval) 3.55–5.04] for mild 
levels and 12.67 (95% CI 9.74–16.47) for severe levels 
versus normal. For gamma-glutamyltransferase (GGT), 
these HRs were 2.54 (95% CI 2.17–2.96) and 13.44 
(10.71–16.87) respectively. Low albumin was strongly 
associated with all cause mortality, with ratios of 2.65 
(95% CI 2.47–2.85) for mild levels and 4.99 (95% CI 
4.26–5.84) for severe levels. Sensitivity for predicting 
events over 5 years was low and specificity was high. 
Follow-up time was split into baseline to 3 months, 
3 months to 1 year and over 1 year. All LFTs were 
predictive of liver disease, and high probability of liver 
disease was associated with being female, methadone 
use, alcohol dependency and deprivation. The shorter-
term models had overall c-statistics of 0.85 and 0.72 
for outcome of liver disease at 3 months and 1 year 
respectively, and 0.88 and 0.82 for all cause mortality 
at 3 months and 1 year respectively. Calibration was 
good for models predicting liver disease. Discrimination 
was low for models predicting events at over 1 year. 
In cost–utility analyses, retesting dominated referral as 
an option. However, using the predictive algorithms to Abstract
iv
identify the top percentile at high risk of liver disease, 
retesting had an incremental cost–utility ratio of £7588 
relative to referral. 
Conclusions: GGT should be included in the batch of 
LFTs in primary care. If the patient in primary care has 
no obvious liver disease and a low or moderate risk of 
liver disease, retesting in primary care is the most cost-
effective option. If the patient with ALFTs in primary 
care has a high risk of liver disease, retesting depends on 
the willingness to pay of the NHS. Cut-offs are arbitrary 
and in developing decision aids it is important to treat 
the LFT results as continuous variables.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Executive summary
Background
Liver function tests (LFTs) are routinely performed 
in primary care, and are often the gateway to 
further invasive and/or expensive investigations. 
Little is known of the consequences in people with 
an initial abnormal liver function test (ALFT) in 
primary care and with no obvious liver disease. 
Further investigations may be dangerous for the 
patient and expensive for the health service but, on 
the other hand, could lead to earlier diagnosis and 
intervention with benefits to the patient.
Objectives
The aims of this study were to determine the 
natural history of abnormalities in LFTs before 
overt liver disease presents in the population, 
derive predictive algorithms for liver disease and 
identify the most cost-effective strategies for further 
investigation with the potential for reduction in 
National Health Service (NHS) costs.
Methods
A population-based retrospective cohort study, 
Abnormal Liver Function Investigations Evaluation 
(ALFIE), followed up all those who had had 
an incident batch of LFTs in primary care to 
subsequent liver disease or mortality over a 
maximum period of 15 years (approximately 2.3 
million tests in 95,000 people). The study was set 
in primary care in the region of Tayside, Scotland 
(population approximately 429,000) between 1989 
and 2003. The target population consisted of 
patients with no obvious signs of liver disease and 
registered with a general practitioner (GP). The 
health technologies being assessed are primary care 
LFTs [transaminases, gamma-glutamyltransferase 
(GGT), albumin, alkaline phosphatase, bilirubin 
below level of jaundice], viral and autoantibody 
tests, ultrasound and liver biopsy.
The study utilised the epidemiology of liver 
disease in Tayside (ELDIT) database to determine 
the outcomes of liver disease. The database links 
hospital admission data [Scottish Morbidity Record 
1 (SMR1)], dispensed medication records, death 
certificates, biochemistry, virology, immunology 
and examination of medical records from Tayside 
hospitals, and diagnosis is obtained by means of 
diagnostic algorithms.
Time-to-event modelling was used to explore 
factors which predicted the outcomes of liver 
disease, liver mortality and all cause mortality. 
The main predictors were the results of the LFTs; 
alanine transaminase/aspartate aminotransferase 
(ALT/AST) (transaminases), alkaline phosphatase, 
GGT, albumin and bilirubin. As well as the results 
of the tests, other potential predictors were 
comorbidities such as cancer and cardiovascular 
disease, as well as social deprivation, age, gender, 
alcohol and methadone dependence. The Tayside 
prescription database also allowed assessment of 
recent community-prescribed medications such as 
antibiotics and non-steroidal inflammatory drugs 
(NSAIDs). Predictive algorithms were derived 
using the Weibull survival model after assessment 
of proportional hazards. Terms in the model were 
assessed using Akaike’s information criterion, 
which penalises large models. Model performance 
was assessed by calculating discriminative ability 
(c-statistic) and calibration.
Decision analyses from an NHS perspective 
were used to model the decision in primary care 
following an ALFT. Probabilities of outcomes of 
liver disease or not were obtained mainly from 
the population cohort or estimated from clinical 
judgement. A sample of patients (n = 99) with 
recent initial ALFTs or invitation to biopsy (n = 45) 
completed questionnaires to obtain quality of 
life data and anxiety measures in those awaiting 
a diagnosis. Some utilities were also obtained 
from a systematic review of the literature. Costs 
were obtained from UK sources on health service 
costs. Cost–utility analyses were performed from 
health service perspectives using standard NHS 
costs over a time horizon of 1 year. One-way and 
two-way sensitivity analyses were also carried out 
to assess the results over a range of values for the 
parameters.Executive summary
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Results
A total of 95,977 patients in primary care with 
no obvious liver disease had 364,194 incident 
initial LFTs from 1989 to 2003. This cohort had a 
median follow-up of 3.7 years. Of these, 21.7% had 
at least one ALFT and 1090 (1.14%) developed 
liver disease. Elevated transaminases were strongly 
associated with diagnosed liver disease, with hazard 
ratios (HRs) of 4.23 [95% CI (confidence interval) 
3.55–5.04] for mild levels and 12.67 (95% CI 
9.74–16.47) for severe levels versus normal. For 
GGT, these HRs were 2.54 (95% CI 2.17–2.96) and 
13.44 (10.71–16.87) respectively. Low albumin was 
strongly associated with all cause mortality, with 
ratios of 2.65 (95% CI 2.47–2.85) for mild levels 
and 4.99 (95% CI 4.26–5.84) for severe levels. 
Sensitivity for predicting events over 5 years was 
low and specificity was high.
As a consequence of non-proportional hazards, 
follow-up time was split into baseline to 3 months, 
3 months to 1 year and over 1 year. Predictive 
algorithms were developed for the three time 
periods for liver disease diagnosis, liver mortality 
and all cause mortality using the Weibull regression 
model. All LFTs were predictive of liver disease, 
and high probability of liver disease was associated 
with being female, methadone use, alcohol 
dependency and deprivation.
The shorter-term models had overall c-statistics 
of 0.85 and 0.72 for outcome of liver disease 
at 3 months and 1 year respectively, and 0.88 
and 0.82 for all cause mortality at 3 months 
and 1 year respectively. This means that the 
probability that the model allocates a high risk 
to those who actually develop liver disease in 3 
months compared with those who do not is 0.85. 
Calibration was also good for models predicting 
liver disease. Discrimination was generally low for 
models predicting events at over 1 year (≈ 0.5), 
which is no better than chance.
The systematic review identified utility estimates 
from the literature, and a valuable liver disease-
based utility resource was created in which 
researchers and policy-makers can easily view 
utility estimates. We have also estimated health-
state utilities for major states of hepatitis C. In 
addition, a patient survey estimated that utility 
had a mean (SE) of 0.79 (0.02) for patients with an 
ALFT awaiting diagnosis and 0.73 (0.04)  for those 
awaiting biopsy. Anxiety tended to be reduced 
after seeing a consultant for both groups and was 
consistently higher for those awaiting biopsy both 
before and after seeing the hospital consultant.
A decision tree was developed over a time horizon 
of 1 year to model the decision in primary care 
after a patient had an ALFT but otherwise no 
obvious liver disease.
Probabilities for each pathway were estimated from 
the population cohort and predictive algorithms. 
In cost–utility analyses, for all patients with ALFTs 
and no obvious liver disease, retesting dominated 
referral as an option. However, using the predictive 
algorithms to identify the top percentile at high 
risk of liver disease, retesting had an incremental 
cost–utility ratio of £7588 relative to referral. 
Therefore, retesting depends on the willingness to 
pay (WTP) of the NHS.
Our study suggests that:
•	 GGT should be included in the batch of LFTs 
in primary care.
•	 If the patient in primary care has no obvious 
liver disease and a low or moderate risk of liver 
disease, retesting in primary care is the most 
cost-effective option.
•	 If the patient with ALFTs in primary care has 
a high risk of liver disease, retesting depends 
on the WTP of the NHS. At a WTP of £7000, 
retesting is still the most cost-effective option.
•	 Cut-offs are arbitrary and in developing 
decision aids it is important to treat the LFT 
results as continuous.
Conclusions
Using the data-linkage capabilities in Tayside, 
Scotland, a large database of LFTs in primary care 
(n = 95,977) linked with outcomes of liver disease 
diagnosis as well as mortality was created. From this 
resource a number of predictive algorithms have 
been developed.
Recommendations for further research include:
1.  development of user-friendly computerised 
decision support systems (CDSSs) for GPs
2.  exploration of further varying the cut-off point 
for determining high risk and subsequent 
recommendation of referral
3.  investigation into whether, having developed 
a usable CDSS, such a system for the 
management of ALFTs would improve decision DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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making and whether it would be more cost-
effective in the long run, thus making the 
development of a cluster randomised trial 
appropriate
4.  the possibility of analysing this extensive data 
set with other non-liver disease end points, 
such as coronary heart disease and cancer, for 
example, as abnormal liver tests are often a 
sign of general illness and not necessarily of 
liver disease.
The results of this study will be widely 
disseminated to primary care, as well as to hospital 
gastrointestinal specialists, through publications 
and presentations at local and national meetings. 
This will facilitate optimal decision making for the 
benefit of both the patient and the NHS.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 1  
Introduction
L
iver function tests (LFTs) are performed 
routinely in primary and secondary care, and 
are often the gateway to further invasive and/or 
expensive investigations. Little is known of the 
consequences in people with an initial abnormal 
liver function test (ALFT).1 Further investigations 
such as liver biopsy and endoscopic retrograde 
cholangiopancreatography may be dangerous 
for the patient and/or expensive for the National 
Health Service (NHS). Guidelines for primary care 
have been published for evaluation of abnormal 
liver enzyme results in asymptomatic patients 
but did not cover other tests or take account of 
costs to the patient or the health service.2 Despite 
the increasing use of LFTs, patients continue to 
present with potentially fatal complications of 
undiagnosed end stage liver disease, which may 
have been preventable by earlier diagnosis. These 
include: autoimmune hepatitis which is responsive 
to steroids; hepatitis C which can be cured in a 
significant proportion of patients by antiviral 
drugs; and alcohol misuse.3 The abnormality of 
LFTs may be secondary to serious disease elsewhere 
that requires treatment, such as malignancy where 
its early detection may improve the prognosis. 
Improved patient care demands integration of data 
from all stages of the patient’s illness in order to 
redesign services appropriately.4,5 There is a need 
for quality measures used in the redesign process 
to be based on routinely collected data rather 
than instituting specific record searches to address 
current problems.6
Most of the published epidemiological studies 
report only the prevalence of liver disorders rather 
than addressing the absolute or relative risks of 
subsequent liver injury following abnormal liver 
enzyme tests.7–9 One study examined incidence 
rates derived from selected hospitalised patients 
using data from mortality registries.10 Duh et 
al.11 quantified the incidence of liver enzyme 
abnormalities in the general population but 
neglected those subjects that subsequently 
retested normal or did not retest at all, with no 
long-term follow-up to possible liver disease. 
Although the latter are minor and do not indicate 
serious disease, they do utilise considerable 
resources. Recently, a large cohort study in Korea 
(n = 142,055) reported the association between 
a key LFT serum aminotransferase [aspartate 
aminotransferase (AST) and alanine transaminase 
(ALT)] and mortality from liver disease, indicating 
that even values that were borderline within 
the normal range were associated with poor 
outcome.12,13
Pilot work in Tayside demonstrated that 
approximately 25% of patients with ALFTs are 
dead within a year of their first abnormal test 
result, although this includes those with existing 
liver disease. A study from Nottingham has 
reported a similar prevalence of ALFTs and has 
gone on to investigate the causes, intervening 
where investigation had not been performed or was 
inadequate.14
Research objectives
The objectives of this study were:
1.  To quantify and characterise incident ALFTs 
in the UK population using data from Tayside 
and Nottingham. The subjects studied are 
those with no clinically apparent liver disease, 
with subsequent follow-up over a maximum 
15-year period of further investigations, liver 
disease, liver mortality, all cause mortality 
and hospitalisation. The study will determine 
those with no health consequences, those who 
develop liver disease such as cirrhosis and 
its complications, or other liver diseases (see 
Appendix 2 for a detailed list), as well as those 
who develop serious non-hepatic illness such 
as cancer. Those who have an initially normal 
test may also have further tests or no further 
tests and may or may not develop liver disease. 
This important group enables estimation of 
specificity and sensitivity of LFTs.
2.  To devise estimates of the probabilities of 
disease outcomes following an ALFT with 
or without further investigations and to 
determine what information would be most 
useful to clinicians for predicting future patient 
outcomes and guiding management.
3.  To estimate and compare the costs to the 
NHS in terms of LFTs, ultrasound and other Introduction
2
investigative procedures for those with an 
initial ALFT or normal LFT.
4.  To derive decision trees for the various 
pathways following ALFTs and to estimate 
optimum management of patients in primary 
care with cost–utility and cost-effectiveness 
analyses.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Chapter 2  
Methods
Target population
A number of exclusions were used to define the 
study population. Patients with no obvious clinical 
signs and symptoms of liver disease, with at least 
one LFT and registered with a Tayside general 
practitioner (GP) between 1989 and 2003 were 
eligible. A window of 6 months was used to screen 
out individuals with previous ALFTs for monitoring 
purposes. Any patients with a history of liver 
disease were excluded. This ensured that only 
new incident tests in primary care were included 
on patients with no clinically obvious liver disease 
(Figure 1).
The following exclusions ensured that the study 
population of patients had no clinically obvious 
liver disease and included only LFTs referred from 
primary care:
•	 patients under 16
•	 patients with liver disease or ALFT in the 
previous 6 months
Design
A UK population-based observational cohort study, 
Abnormal Liver Function Investigations Evaluation 
(ALFIE), followed up all those who had had an 
incident ALFT, as well as those who were initially 
normal (to allow calculation of sensitivity and 
specificity), to subsequent liver disease or mortality. 
Probabilities of outcomes from cohort data were 
derived from survival models such as Weibull and 
these were used to create a decision analysis tree, 
which covers clinically relevant pathways. Finally, 
the patient survey and systematic review provided 
quality of life measures or utilities to enable cost–
utility and cost-effectiveness analyses to be carried 
out.
Setting
The study was set within primary care in the 
region of Tayside, Scotland (population ≈ 429,000) 
between 1989 and 2003.
FIGURE 1  Selection of the study population of LFTs with no clinically obvious liver disease.
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abnormal test
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1/1/1989–31/12/2003
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•	 patients whose initial LFTs were hospital-
referred ALFTs, based on electronic 
biochemistry records, leaving all possible 
initially abnormal tests requested from primary 
care
•	 patients with a positive initial bilirubin test 
(clearly jaundiced at presentation, bilirubin 
> 35 µmol/l)
•	 patients with ascites, encephalopathy or 
variceal bleeding within 6 weeks of their initial 
LFTs, who were admitted to hospital and could 
be identified from the epidemiology of liver 
disease in Tayside (ELDIT) database, Scottish 
Morbidity Record 1 (SMR1) record and 
spironolactone prescriptions from the Health 
Informatics Centre (HIC) database.15
Health technologies 
being assessed
These comprised mainly LFTs, but also antibody 
tests, ultrasound and liver biopsy (see Appendix 1 
for full list).
Data sources
Epidemiology of liver disease 
in Tayside (ELDIT) database
The ELDIT project created a liver database in 
Tayside linking administrative clinical data with 
laboratory data.16 Briefly, all electronic medical 
records (including laboratory tests) for Tayside were 
electronically linked with a unique identifier, the 
community health index (CHI).15 The community 
health index is used for all health encounters 
in Tayside for the population registered with a 
general practice. The following independent data 
sources were record linked electronically, by means 
of the CHI, to maximise the accuracy of diagnosis 
and disease ascertainment:
•	 prescribing database: the HIC has person-
specific dispensing information for the whole 
of Tayside17
•	 hospitalisation records: SMR (SMR1 – general 
admissions, SMR4 – alcohol-related psychiatric 
admissions and SMR6 – cancer admissions)
•	 death registry from the General Registry Office
•	 Carstairs categories for social deprivation 
based on the decennial census18
•	 endoscopy, regional biochemistry, pathology, 
irology and immunology databases.
Diagnostic algorithms for liver diseases have been 
created, and this database has already been used to 
assess the epidemiology and economic burden of 
viral hepatitis19 and other liver diseases.
The HIC prescription database is complete for all 
encashed prescriptions for the Tayside population 
from 1989 to 2003. The hospitalisation records 
(SMR) and mortality records are 100% complete 
for all admissions for Tayside residents. There 
were some gaps in the biochemistry database, as 
in the past, obscure databases were used in some 
peripheral hospitals and could not be recovered. 
However, this represented less than 1% of the total 
data on LFTs. Given that we had approximately 2 
million tests after exclusions, bias due to missing 
tests would be minimal.
The ELDIT database, as described above, 
provided robust probabilities of outcomes. Costs of 
procedures were obtained from standard published 
values. The ELDIT database was updated to 2003, 
and this was funded by the British Liver Trust.
Prospective questionnaire data from patients 
undergoing ALFTs, as well as patients undergoing 
liver biopsy, provided utility-based quality of 
life measures in order to populate the decision 
trees. Other utility values were obtained from 
the literature and an expert panel of GPs and 
hepatologists.
Ethics and data protection
The proposal had Research Ethics Committee 
approval as well as the Caldicott Guardians to 
ensure compliance with the Data Protection Act. All 
data were anonymised according to the Standard 
Operating Procedures (SOPs) of the HIC so that 
the research was conducted on non-identifiable 
electronic data.
Proposed sample size
The annual incidence of ALFTs ranges from 489 
to 869 per 100,000 people in the whole Tayside 
population, depending on type of test and year. 
With a total of approximately 70,000 ALFTs over 
a 14-year period, of which approximately 5500 
demonstrate liver disease as defined by the ELDIT 
database, power would be more than adequate 
(> 90%) to detect relative hazards of the order of 
≥ 1.2 at the 5% significance level.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Statistical methods
Descriptive epidemiology for each LFT included 
analysis of continuous and categorical data on 
subject characteristics using c2 tests for categorical 
variables and t-tests for continuous variables or 
non-parametric equivalents. For the baseline 
population, LFTs were extracted, and number and 
frequency were tabulated by year.
The LFTs were:
•	 liver function
  – bilirubin
  – albumin
•	 liver damage
  – alkaline phosphatase (AP)
  – gamma-glutamyltransferase (GGT)
  – ALT
  – AST (not routinely measured).
Normal, moderately and severely abnormal 
categories were defined for each test using regional 
laboratory standard cut-offs, which vary by age and 
sex for some tests (Table 1).
Patterns of test results were explored and 
described. For example, the following may be 
possible patterns:
•	 raised ALT + normal AP + normal GGT 
(suggesting hepatitis)
•	 Raised AP ± raised GGT + normal ALT 
(suggesting biliary cirrhosis)
•	 any one abnormal
•	 any two or more abnormal and/or explore 
patterns.
Sensitivity, specificity, positive predictive value and 
likelihood ratios were calculated for LFT results 
compared with actual outcome. Kaplan–Meier plots 
of time to outcomes were plotted for individual 
tests.
Derivation of probabilities
Probabilities of outcome of liver disease or all cause 
mortality could be calculated using survival models 
such as the Cox proportional hazards regression 
model20 adjusting for confounders (such as age, 
sex, comorbidities, social deprivation), possibly 
incorporating time-dependent covariates and 
between-subject heterogeneity using frailty terms.21 
As deriving probabilities from the Cox model is 
not trivial, involving estimation of the baseline 
hazard, an alternative is the Weibull parametric 
regression model, which easily allows estimation of 
probability of outcome over any time period. The 
Weibull accelerated failure time model has been 
used to derive the Framingham coronary heart 
disease (CHD) risk equation22 and a CHD risk score 
for type 2 diabetes from Tayside data.23 This gives 
greater flexibility in modelling over different time 
periods.
The main outcomes were:
•	 liver disease such as non-alcoholic fatty liver 
disease (NAFLD)
•	 liver disease mortality (yes/no)
•	 all cause mortality (yes/no).
The above models also allowed derivation of risks 
of outcomes stratified by factors entered in the 
regression model. For example, the risk of liver 
disease is clearly greater in patients with known 
alcohol abuse than in those without alcohol 
abuse. The following factors were entered in the 
regression models to assess their effect on risk and 
to estimate factor-specific risks:
•	 Age – derived from the first six digits of the 
patient identifier (CHI) (may be categorised as 
< 40 or 40+ depending on age distribution).
•	 Gender – derived from the ninth digit of the 
patient identifier (CHI).
•	 Pregnancy – from hospitalisation records 
(SMR2). This will, of course, exclude home 
births.
•	 Opioid abuse – a proxy measure will be 
obtained using methadone prescribing from 
the HIC prescription database.
•	 Alcohol dependence – we used hospitalisation 
records from SMR1 and SMR6, which include 
ICD-10 codes F10, X65 and T51. Y90 and Y91 
may be used as supplementary information. 
This represented the more extreme end of 
alcohol abuse, demonstrating a weakness by 
missing others with mild or moderate alcohol 
abuse. On the other hand, this is also a 
strength, giving a clear definition and measures 
of the drivers of costs to the health service. 
The alternative of general practice notes 
would be prohibitively expensive and prone to 
classification error.
•	 Social deprivation – the Carstairs social 
deprivation score, assigned to postcodes 
for all residents of Tayside, is derived from 
the decennial census, incorporating the 
variables: housing density, car ownership, 
social class of the head of household and male 
unemployment.18 Although social deprivation 
is a marker for cigarette smoking and Methods
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TABLE 1  Liver function tests (LFTs) and definitions of normal and abnormal
LFT Range Normal (age and gender) Moderately abnormal Severely abnormal
Bilirubin (µmol/l) 0–1000 < 18 (M), < 16 (F) 18–42.5 (M), 16–37.5 (F) > 42.5 (M), > 37.5 (F)
Albumin (g/l) 11–60  > 35 30–35 < 30
AP (IU/l) 20–2000 120–455 (M 16–19) 456–1138 > 1138
45–195 (M 20–26) 196–488 > 488
30–105 (M 27–55) 106–263 > 263
45–130 (M 56–75) 131–325 > 325
65–150 (M 75+) 151–375 > 375
120–420 (F 16–19) 421–1050 > 1050
25–90 (F 20–26) 91–225 > 225
20–80 (F 27–55) 81–200 > 200
40–150 (F 56–75) 151–375 > 375
50–190 (F 75+) 191–475 > 475
GGT (IU/l) 5–2000 7–42 (All 16–24) 41–105 > 105
9–70 (M 25–34) 71–175 > 175
11–75 (M 35–44) 76–188 > 188
11–82 (M 45–55) 83–205 > 205
11–70 (M 55+) 71–175 > 175
5–35 (F 25–34) 36–88 > 88
5–42 (F 35–44) 43–105 > 105
5–65 F (45–55) 56–163 > 163
5–75 (F 55+) 76–188 > 188
ALT (IU/l) 12–9999 
depending on 
age and sex
 14–40 (M 16–18) 41–100 > 100
15–55 (M 19–55) 56–138 > 138
12–35 (F 16–18) 36–88 > 88
12–40 (F 19–55) 41–100 > 100
13–43 (All 55–75) 44–108 > 108
6–30 (All 75+) 31–75 > 75
AST (IU/l)  3–30 (M 16–75) 31–75 > 75
10–45 (F 16–75) 46–113 > 113
10–30 (All 75+) 31–75 > 75
ALT, alanine transaminase; AP , alkaline phosphatase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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comorbidity, we will also be able to assess the 
affect of individual comorbidities on risk.
•	 Diabetes defined from the Diabetes Audit 
and Research in Tayside, Scotland (DARTS) 
database, which is 97% sensitive for 
ascertainment of diabetes in the population.24
•	 The Hearts database (sensitivity 95%), 
identifying those who have definite CHD 
(myocardial infarction or demonstrated 
coronary artery disease) in the Tayside 
population.25
Other major comorbidities (see Appendix 3), such 
as respiratory disease, cerebrovascular disease, 
renal disease, ischaemic heart disease and cancers 
other than liver cancer, were defined by the SMR, 
which contains details of all hospital admissions, 
including ICD-9 and ICD-10 codes, for all Tayside 
residents, and is held in the HIC.
The HIC also contains the database of all encashed 
prescriptions in Tayside. This resource was used to 
create comorbidity variables such as:
•	 analgesics [non-steroidal inflammatory drugs 
(NSAIDs)]
•	 antibiotics
•	 lipid-lowering agents, such as statins.
Importantly, this resource allowed us to identify 
receipt of prescribed hepatotoxic drugs at the time 
of any ALFT.
Statistical analysis was performed on Statistical 
Analysis Software (SAS) version 8.0 (SAS Institute, 
Cary, NC). Decision analyses were performed in 
TreeAge Pro software, 2006 (TreeAge Software, 
Williamstown, MA). More details of the databases, 
methods and protocol are available from Donnan 
et al.26DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 3  
Results: descriptive analyses of liver 
function tests and outcomes
Outcomes
The primary outcomes following the initial LFT 
results were:
•	 liver disease
•	 liver mortality
•	 all cause mortality.
For descriptive purposes, other outcomes including 
hospital admission, diagnosis of ischaemic heart 
disease (IHD), cancer, respiratory disease, diabetes 
and biliary disease were tabulated. The individual 
liver disease outcomes were also recorded by LFT 
and are listed in Appendix 4. Note that Gilbert’s 
disease is not included as a liver disease outcome.
Statistical analysis
For the baseline population, all LFTs were 
extracted and the numbers of patients plotted 
by year of first LFT. Normal, mildly elevated 
and severely elevated categories were defined 
for each test using regional laboratory standard 
cut-offs which vary by age and sex for some tests 
(see Table 1). Severely elevated was defined as 2.5 
times the normal range. Baseline characteristics 
were tabulated by level of abnormality for each 
test. These characteristics were age, gender, 
Carstairs category, comorbidities during the period 
1980 to study start (including cancer, diabetes, 
IHD, respiratory disease and biliary disease), 
alcohol dependency and drug misuse (from 
hospitalisations), methadone abuse, pregnancy 
and the use of statins, NSAIDs or antibiotics in the 
3 months before LFTs.
Outcomes from the initial test results were also 
tabulated. Sensitivity, specificity, positive predictive 
values (PPVs) and negative predictive values (NPVs) 
of the LFTs to diagnose liver disease and to predict 
death (any cause and liver caused) were calculated 
over 1 and 5 years. As some patients did not have 
all their LFTs tested, liver disease diagnosis by 
LFT testing can be subject to selection bias. The 
predicted probability of testing for each LFT 
was found by fitting a logistic regression model 
adjusted for all the predictors mentioned above.28,29 
The probability of testing was then used to weight 
Introduction
This chapter describes the LFTs initiated in 
primary care from the patient population with no 
obvious liver disease in Tayside, Scotland, aged 16 
years or over, between 1989 and 2003.
Methods
Study population
The study population was initially derived 
from a laboratory database which contained all 
electronically available LFT results from patients in 
the Tayside region of Scotland, UK during the 15-
year period from 1989 to 2003. Tayside is a mixed 
urban/rural region characteristic of Scotland, with 
a population of approximately 429,000. Liver 
function tests included bilirubin, albumin, AP, GGT, 
ALT and AST. As many laboratories measure only 
either ALT or AST, these two tests were combined 
in this study and are referred to in all subsequent 
text as transaminases.
More details of the methods were described in 
Chapter 2. In brief, patients aged 16 and over, with 
no obvious clinical signs and symptoms of liver 
disease and with at least two initial LFTs referred 
from a Tayside GP between 1989 and 2003 were 
eligible for inclusion. Exclusion criteria detailed 
elsewhere ensured that the study population of 
patients had no clinically recognised liver disease at 
presentation in primary care (see Figure 1).
Databases
Data were extracted from the HIC, which is 
described in detail elsewhere.26,27 The databases 
relevant to this study covered the entire study 
period and were used within procedures approved 
under the Data Protection Act and Caldicott 
Guardian.
All of the electronic databases described above were 
electronically linked with a unique identifier, the 
CHI.27 The CHI is used for all health encounters 
in Tayside for the population registered with 
a general practice and is contained in all the 
databases described above.Results: descriptive analyses of liver function tests and outcomes
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the logistic regression models for predicting 
outcome.
Survival analysis was conducted to investigate 
whether abnormality of an initial LFT had an effect 
on time to the specified outcomes, including all 
cause mortality, liver disease mortality and liver 
disease diagnosis. The starting point was taken 
as the date of the initial LFT test and the end 
point was 31 December 2003, date of outcome, 
emigration or death, whichever was earlier. All 
patients whose end point was not the outcome 
of interest were censored. Weibull regression 
models were fitted separately for each LFT by 
level of abnormality adjusted for the baseline 
characteristics. Initially, a univariate analysis was 
performed on each of these factors and those with 
a p-value > 0.3 were excluded from the stepwise 
regression technique. A multiple imputation 
technique was used to impute missing values for 
LFTs.30 The proportional hazards assumption was 
checked and survival curves were plotted by initial 
LFT result. Analyses were performed using the SAS 
(version 8) software package.
Results
Before exclusions, we extracted LFTs from 
310,511 patients. When we excluded patients 
under the age of 16, non-Tayside residents and 
those who had their initial ALFTs measured in 
secondary care, 99,165 patients were left. When 
the remaining exclusion criteria (bilirubin > 35 
µmol/l, complications within 6 weeks and history of 
liver disease) were applied, our study population 
contained 95,977 patients with 364,194 incident 
initial LFTs taken from1989 to 2003 in primary 
care. The median follow-up time was 3.7 years 
[interquartile range (IQR) 1.4, 7.6]. 57.9% of 
patients were female and the median age was 54.6 
years (IQR 39.2–68.8). Alkaline phosphatase was 
measured in 99.2% of patients, albumin in 99.2%, 
bilirubin in 93.6%, transaminases in 76.5% and 
GGT in10.9%. Use of these tests in primary care 
increased over time due to a combination of more 
testing and better laboratory coverage (Figure 2). In 
the initial tests, 21.7% of patients had at least one 
ALFT.
Baseline characteristics
The mean age of patients with ALFTs was 
approximately 52 years, with the exception of 
albumin which had a mean age of 69 (compared 
with 53 for patients with normal albumin). Patients 
with abnormal AP were slightly younger (mean 
age 48 years). GGT was the only LFT measured 
more often in males than in females, and the 
only one to have noticeably higher prevalence 
of testing and abnormal tests in deprived areas 
(Table 2). Abnormal GGT groups also had the 
highest percentage of patients dependent on 
alcohol (15.3%), drugs (0.9%) and methadone 
(0.7%). Patients with abnormal albumin had much 
more comorbidity in comparison with the other 
LFTs (Table 2). The percentage of patients with an 
initial ALFT prescribed statins in the 3 months 
FIGURE 2  Number of patients by year of first LFT tests.
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beforehand was less than in those with a normal 
LFT. The percentage of patients prescribed 
NSAIDs or antibiotics in the preceding 3 months 
was highest in those with lowered albumin 
(e.g. 14.3% versus 8.6% of those on antibiotics with 
normal albumin).
Outcomes
Table 3 contains the outcomes per 1000 patient-
years (TPY) by initial LFT level. Low albumin was 
associated with much higher rates of mortality 
from any cause compared with the other LFTs, 
with rates of 166.3 TPY and 260.4 TPY for mildly 
and severely elevated respectively. Severe AP had 
the next highest death rate of 99.8 TPY. For liver-
caused mortality, severely elevated GGT had the 
highest rate of 9.8 TPY followed by AP (8.43 TPY) 
and albumin (8.19 TPY). Albumin also had the 
highest rates for cancer death, and the rates of 
cancer diagnosis in those with a mild or severe 
albumin were 56.7 and 96.0 TPY respectively. 
Transaminase and GGT were most associated 
with liver diagnoses, with severely abnormal 
levels, having rates of 36.3 TPY and 41.0 TPY 
respectively. Rates of hospital admission after an 
abnormal albumin test were extremely high, with 
even a mildly lowered result having a rate of over 
500 TPY.
Performance measures
For the outcomes of all cause mortality, liver 
mortality and liver disease diagnosis, GGT, 
weighted by predicted probability of testing, had 
the best sensitivity scores compared with the other 
LFTs, with scores of 0.769 and 0.714 for liver 
mortality over 1 year and 5 years respectively 
(Table 4). However, all the tests had generally low 
sensitivity. Albumin had the poorest sensitivity 
overall; however, its specificity was the highest 
(0.98 for liver disease diagnosis). Gamma-
glutamyltransferase was the only LFT to have 
specificity scores below 0.90. All LFTs had NPVs 
of 0.99 or more for all outcomes except all cause 
mortality. However, all the tests had very low PPVs, 
between 0.002 and 0.052 for all outcomes except 
all cause mortality, for which albumin had the 
highest PPV (0.508 within 5 years).
Survival analysis
Liver disease diagnosis
All the LFTs were significantly predictive of liver 
disease even after adjusting for risk factors for liver 
damage (Table 5). Of the mildly elevated LFTs, 
transaminase had the highest HR of 4.23 (95% 
CI 3.55–5.04) (Figure 3a). All severely elevated 
LFTs had HRs over 8, with AP being the highest, 
followed by GGT and transaminase. Other factors 
predictive of liver disease were older age, Carstairs 
score, alcohol dependency, illicit drug use and 
methadone use. For the transaminase model, the 
HRs  for the last three factors were 4.48 (95% CI 
3.70–5.42), 2.25 (95% CI 1.51–3.36) and 4.52 
(95% CI 3.07–6.65) respectively. Statin use was 
significantly associated with lower risk of liver 
disease for the bilirubin models, showing a 36% 
reduction in risk.
Liver disease mortality
Of the mildly ALFTs, low albumin had the highest 
HR for liver mortality of 7.38 (95% CI 4.60–11.81). 
Severely elevated GGT had the highest HR overall, 
with a value of 25.32 (95% CI 15.27–41.97), 
followed by AP and albumin (see Table 5). The 
only baseline factors which predicted liver disease 
mortality were gender, older age, Carstairs score 
(deprived) and alcohol dependency. Alcohol 
dependency had HRs as high as 10.84 (95% CI 
7.28–16.14) for the albumin-adjusted model. The 
HR was lowest for the GGT model, however, with 
a value of 3.92 (95% CI 2.73–5.61). All models 
demonstrated approximate proportional hazards.
All cause mortality
All LFTs had significantly high HRs for all cause 
mortality. Albumin had the largest HRs for 
mortality [4.99 (95% CI 4.26–5.84) for severely 
lowered]. For mildly lowered albumin the HR 
was more than 2.5 times that for normal albumin 
(Figure 3b). GGT had similar HRs to AP, while 
transaminase had the lowest HRs for mortality. 
The baseline factors in the models predictive 
of death included gender, age, Carstairs score, 
IHD, renal disease, respiratory disease, diabetes, 
stroke, biliary cancer, all other cancers, statin, 
NSAID and antibiotic use, alcohol dependency, 
drug dependency and methadone use. With the 
exception of biliary cancer, which had a typical HR 
of 15.70 (95% CI 5.06–48.71) (for the albumin-
adjusted model), all HRs for these factors were less 
than 2. Statin use was associated with lower risk, 
with a typical HR of 0.56 (95% CI 0.49–0.65).
Discussion
The aim of this chapter was to follow up those 
patients who had no clinically obvious liver 
disease in primary care but who had the incidental 
discovery of ALFTs, in order to identify the Results: descriptive analyses of liver function tests and outcomes
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TABLE 2  Baseline and historical characteristics of the population (n = 95,977) by LFT
Characteristic
Population 
(%) Albumin (%) AP (%) Transaminase (%) GGT (%) Bilirubin (%)
(n = 95,977)
Normal 
(n = 93,240)
Abnormal 
(n = 1947) p-value
Normal 
(n = 85,329)
Abnormal 
(n = 9928) p-value
Normal 
(n = 68,314)
Abnormal 
(n = 5107) p-value
Normal 
(n = 8861)
Abnormal 
(n = 1623) p-value
Normal 
(n = 83,457)
Mildly 
elevated 
(n = 6365) p-value
Age 
[mean (SD)]
53.8 (18.6) 53.5 (18.6) 69.6 (18.5) < 0.001 54.5 (19.1) 48.8 (14.8) < 0.001 53.1(18.9) 52.6 (18.2) <0.05 50.7 (17.4) 52.5 (15.5) < 0.001 54.0 (18.6) 52.6 (20.0) < 0.001
Male 42.1 41.8 38.3 < 0.01 43.1 30.1 < 0.001 42.6 59.1 < 0.001 55.6 65.7 < 0.001 41.8 54.1 < 0.001
Carstairs category
Deprived 50.6 50.6 50.5 NS 57.4 49.8 < 0.001 48.6 49.8 NS 61.4 60.3 NS 51.0 46.3 < 0.001
Comorbidity
IHD 5.6 5.6 6.0 NS 6.0 2.7 < 0.001 5.9 4.4 < 0.001 4.2 4.4 NS 5.8 4.7 < 0.001
Diabetes 1.4 1.4 2.5 < 0.001 1.5 1.2 NS 1.6 1.7 NS 0.9 0.9 NS 1.4 1.4 NS
Respiratory 2.8 2.7 5.4 < 0.001 2.8 2.2 < 0.001 2.8 2.9 NS 2.5 2.0 NS 2.7 2.2 < 0.05
Cancera 3.8 3.7 9.3 < 0.001 4.0 2.4 < 0.001 4.0 3.5 NS 3.6 2.7 < 0.05 3.8 2.6 < 0.001
Biliary disease 1.8 1.8 2.4 < 0.05 1.7 2.1 < 0.05 1.7 1.8 NS 1.6 2.0 NS 1.8 1.4 < 0.05
Medication in previous 3 months
Statins 3.3 3.4 0.8 < 0.001 3.6 1.2 < 0.001 4.3 3.2 < 0.01 1.9 2.0 NS 3.5 2.6 < 0.001
NSAIDs 7.0 7.0 9.3 < 0.001 6.9 8.4 < 0.001 4.6 5.4 < 0.001 5.1 6.7 < 0.01 7.2 4.4 < 0.001
Antibiotics 8.7 8.6 14.3 < 0.001 8.6 9.1 NS 8.5 8.9 NS 8.3 9.1 NS 8.9 7.1 < 0.001
Abusive substance
Alcohol 2.7 2.7 2.8 NS 2.5 4.4 < 0.001 2.5 5.4 < 0.001 5.6 15.3 < 0.001 2.6 3.9 < 0.001
Drug 0.4 0.4 0.2 NS 0.3 0.7 < 0.001 0.4 0.5 NS 0.7 0.9 NS 0.4 0.2 NS
Methadone 0.4 0.4 0.6 NS 0.4 0.5 < 0.05 0.4 0.5 NS 0.5 0.7 NS 0.4 0.2 NS
AP , alkaline phosphatase; IHD, ischaemic heart disease; NSAIDs, non-steroidal inflammatory drugs.
Mann–Whitney test was used to compare median age in normal and abnormal groups, whereas continuity-corrected chi-
squared test was used for all other comparisons.
outcomes of this pool of patients with subclinical 
liver dysfunction. Patients with normal LFTs were 
also followed up as a reference category with which 
to compare them.
The most striking observations of this study are 
that: (1) liver disease is not common in those with 
ALFTs over a median follow-up time of 3.7 years; 
(2) GGT shows highest sensitivity for liver disease 
above other LFTs and is a good predictor of liver 
disease and liver mortality after adjustment for the 
bias of selective testing; (3) ALFTs are predictive 
of death from non-hepatic causes (particularly 
albumin); and (4) the rise in the number of 
LFTs requested does not alter the prevalence of 
abnormal tests.
This is the first large-scale population-based 
analysis of LFTs with a long follow-up period 
and complete determination of outcome. 
These results are derived from unselected ‘real-
world’ observations in a geographically-defined 
population. However, liver disease can suffer from 
under ascertainment as hospital discharge records 
and death certificates often omit liver disease if it 
was not the primary cause of death. The limitations 
of electronic data sources are that we have no 
information on alcohol intake, or body mass index 
or other anthropometry associated with NAFLD.
We found that the sensitivity of LFTs in detecting 
liver disease is generally poor, although GGT had 
the ‘best’ sensitivity at 72%, while, in contrast, DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 2  Baseline and historical characteristics of the population (n = 95,977) by LFT
Characteristic
Population 
(%) Albumin (%) AP (%) Transaminase (%) GGT (%) Bilirubin (%)
(n = 95,977)
Normal 
(n = 93,240)
Abnormal 
(n = 1947) p-value
Normal 
(n = 85,329)
Abnormal 
(n = 9928) p-value
Normal 
(n = 68,314)
Abnormal 
(n = 5107) p-value
Normal 
(n = 8861)
Abnormal 
(n = 1623) p-value
Normal 
(n = 83,457)
Mildly 
elevated 
(n = 6365) p-value
Age 
[mean (SD)]
53.8 (18.6) 53.5 (18.6) 69.6 (18.5) < 0.001 54.5 (19.1) 48.8 (14.8) < 0.001 53.1(18.9) 52.6 (18.2) <0.05 50.7 (17.4) 52.5 (15.5) < 0.001 54.0 (18.6) 52.6 (20.0) < 0.001
Male 42.1 41.8 38.3 < 0.01 43.1 30.1 < 0.001 42.6 59.1 < 0.001 55.6 65.7 < 0.001 41.8 54.1 < 0.001
Carstairs category
Deprived 50.6 50.6 50.5 NS 57.4 49.8 < 0.001 48.6 49.8 NS 61.4 60.3 NS 51.0 46.3 < 0.001
Comorbidity
IHD 5.6 5.6 6.0 NS 6.0 2.7 < 0.001 5.9 4.4 < 0.001 4.2 4.4 NS 5.8 4.7 < 0.001
Diabetes 1.4 1.4 2.5 < 0.001 1.5 1.2 NS 1.6 1.7 NS 0.9 0.9 NS 1.4 1.4 NS
Respiratory 2.8 2.7 5.4 < 0.001 2.8 2.2 < 0.001 2.8 2.9 NS 2.5 2.0 NS 2.7 2.2 < 0.05
Cancera 3.8 3.7 9.3 < 0.001 4.0 2.4 < 0.001 4.0 3.5 NS 3.6 2.7 < 0.05 3.8 2.6 < 0.001
Biliary disease 1.8 1.8 2.4 < 0.05 1.7 2.1 < 0.05 1.7 1.8 NS 1.6 2.0 NS 1.8 1.4 < 0.05
Medication in previous 3 months
Statins 3.3 3.4 0.8 < 0.001 3.6 1.2 < 0.001 4.3 3.2 < 0.01 1.9 2.0 NS 3.5 2.6 < 0.001
NSAIDs 7.0 7.0 9.3 < 0.001 6.9 8.4 < 0.001 4.6 5.4 < 0.001 5.1 6.7 < 0.01 7.2 4.4 < 0.001
Antibiotics 8.7 8.6 14.3 < 0.001 8.6 9.1 NS 8.5 8.9 NS 8.3 9.1 NS 8.9 7.1 < 0.001
Abusive substance
Alcohol 2.7 2.7 2.8 NS 2.5 4.4 < 0.001 2.5 5.4 < 0.001 5.6 15.3 < 0.001 2.6 3.9 < 0.001
Drug 0.4 0.4 0.2 NS 0.3 0.7 < 0.001 0.4 0.5 NS 0.7 0.9 NS 0.4 0.2 NS
Methadone 0.4 0.4 0.6 NS 0.4 0.5 < 0.05 0.4 0.5 NS 0.5 0.7 NS 0.4 0.2 NS
AP , alkaline phosphatase; IHD, ischaemic heart disease; NSAIDs, non-steroidal inflammatory drugs.
Mann–Whitney test was used to compare median age in normal and abnormal groups, whereas continuity-corrected chi-
squared test was used for all other comparisons.
specificity was high. In terms of prediction of future 
liver disease, NPV was high while PPV was low. A 
study in Italy found sensitivity and specificity values 
for ALT of 0.40 and 0.98 respectively for hepatitis 
C.31 These were similar to our values of 0.41 and 
0.93 respectively for any liver disease. Survival 
models showed that all the tests have high HRs 
relating to outcomes of liver disease and mortality 
from liver disease. Of 667 people who had a 
severely elevated transaminase, over 11% were 
diagnosed with chronic liver disease (with an HR 
of 12), and those with a mild elevation of the test 
had a high HR of over 4 for developing chronic 
liver disease, suggesting that transaminase may be 
a good predictor. 
In Tayside for much of the duration of this 
study, GGT was not routinely requested as part 
of the ‘batch of LFTs’ and had to be requested 
separately. This explains the low numbers of 
tests performed, and it is not surprising that the 
baseline characteristics of patients for GGT results 
differed from those in the other tests. It was the 
only test requested more frequently for males, 
illicit drug users and patients living in deprived 
areas, suggesting that GPs selected these patients 
for GGT testing. The patients not tested for 
GGT had their GGT results imputed using the 
‘gold standard’ multiple imputation technique to 
reduce verification bias.30 Even after this, severely 
abnormal GGT increases the risk of liver disease Results: descriptive analyses of liver function tests and outcomes
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TABLE 3  Outcome rates by first LFT level of severity (per 1000 person-years)
Outcome
Population Albumin AP Transaminase GGT Bilirubin
(n = 95,977)
Normal 
(n = 93,240)
Mildly 
lowered 
(n = 1710)
Severely 
lowered 
(n = 237)
Normal 
(n = 85,329)
Mildly 
elevated 
(n = 9598)
Severely 
elevated 
(n = 330)
Normal 
(n = 68,314)
Mildly 
elevated 
(n = 4440)
Severely 
elevated 
(n = 667)
Normal 
(n = 8861)
Mildly 
elevated 
(n = 1094)
Severely 
elevated 
(n = 529)
Normal 
(n = 83,457)
Mildly 
elevated 
(n = 6365)
Death
Any cause 26.60 24.78 166.26 260.41 26.88 23.83 99.75 22.96 31.66 41.19 20.52 33.38 54.40 26.38 31.06
Liver disease 0.50 0.44 4.47 8.19 0.37 1.27 8.43 0.31 2.43 4.08 0.39 2.41 9.82 0.42 1.77
Cancera 3.69 3.45 21.62 32.76 3.66 3.76 16.16 4.94 5.46 7.34 4.09 6.12 5.73 3.68 3.58
Biliary cancer 0.40 0.38 1.30 1.64 0.38 0.44 2.81 0.34 0.67 2.04 0.33 0.56 2.86 0.39 0.46
Liver disease 
diagnosis
2.37 2.24 9.70 26.01 1.88 5.35 31.45 1.84 10.42 36.33 2.26 10.51 40.95 2.22 4.72
Hospital admission 165.93 162.91 531.54 1149.98 166.95 159.20 393.26 170.71 187.22 264.21 149.35 183.59 262.36 165.23 166.83
Other diagnosis
IHD 10.68 10.59 21.92 21.77 10.96 9.07 7.94 9.39 10.59 12.62 8.65 9.55 9.23 10.87 9.34
Renal disease 3.58 3.39 19.18 27.12 3.61 3.53 5.02 3.03 3.79 5.73 2.44 3.73 5.37 3.60 3.21
Diabetes 4.61 4.57 11.23 3.28 4.52 5.45 8.79 4.17 9.28 5.80 3.09 5.26 8.36 4.52 5.79
Respiratory 10.75 10.31 49.70 58.98 10.85 10.22 21.30 9.48 11.23 14.30 9.04 10.82 18.16 10.78 10.86
Stroke 6.20 6.04 21.41 22.01 6.39 4.95 8.56 5.33 7.17 5.76 4.80 4.31 7.47 6.19 7.20
Cancera 12.63 12.10 56.68 96.01 12.55 12.77 55.89 12.16 13.80 13.28 10.36 17.62 18.33 12.68 12.19
Biliary disease 3.39 3.39 5.70 8.45 3.12 5.09 26.47 2.98 5.90 22.34 2.83 3.56 15.50 3.33 4.73
Biliary cancer 0.50 0.48 1.31 1.64 0.48 0.47 3.52 0.45 0.61 3.27 0.42 0.74 3.28 0.48 0.71
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase; IHD, ischaemic heart disease.
a  Not including biliary cancer or hepatocellular cancer (comes under liver disease).
by over 13 times compared with normal GGT 
and 2.5 times if mildly abnormal. This suggests 
strongly that GGT provides additional information 
over the other LFTs and should be considered as 
an important and informative part of the LFTs. 
In light of this finding, the practice by some 
laboratories of not routinely measuring GGT 
should be reviewed.
Why is the sensitivity of LFTs for liver disease so 
poor? Of those who subsequently develop liver 
disease their first LFT may be normal. The study 
in Korea found that patients with slightly raised 
transaminases, which were still in the normal 
range, developed liver disease and this suggests 
an adjustment of the normal limit.12 Also, many 
patients with ALFTs detected in this study may 
have had no subsequent formal diagnosis of liver 
disease because of a lack of investigation and a 
limited time interval to develop complications. 
It is possible, therefore, that there is a pool of 
undiagnosed liver disease within this cohort. 
It is likely on epidemiological grounds, that 
the majority of these abnormalities could be 
attributable to undiagnosed alcohol-related liver 
disease, hepatitis C or NAFLD. The fact that this 
group of patients did not come to harm during 
the study is reassuring. However, the study follow-
up period is medium term (a median of 3.7 years) 
compared with the natural history of these diseases. 
It does, however, illustrate a window of opportunity 
to intervene in these patients with lifestyle advice, 
alcohol intake reduction and therapies for drug 
abuse.
Conversely, although highly specific for liver 
disease, those with ALFTs are still mostly people 
who did not develop clinically apparent liver 
disease in the time-frame of this study. All cause 
mortality is a much more common outcome in this 
study than liver disease. This suggests that these 
tests may be better markers of poor health than 
liver disease, thus possibly justifying the increasing 
use of LFTs as a screen for general illness. In DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 3  Outcome rates by first LFT level of severity (per 1000 person-years)
Outcome
Population Albumin AP Transaminase GGT Bilirubin
(n = 95,977)
Normal 
(n = 93,240)
Mildly 
lowered 
(n = 1710)
Severely 
lowered 
(n = 237)
Normal 
(n = 85,329)
Mildly 
elevated 
(n = 9598)
Severely 
elevated 
(n = 330)
Normal 
(n = 68,314)
Mildly 
elevated 
(n = 4440)
Severely 
elevated 
(n = 667)
Normal 
(n = 8861)
Mildly 
elevated 
(n = 1094)
Severely 
elevated 
(n = 529)
Normal 
(n = 83,457)
Mildly 
elevated 
(n = 6365)
Death
Any cause 26.60 24.78 166.26 260.41 26.88 23.83 99.75 22.96 31.66 41.19 20.52 33.38 54.40 26.38 31.06
Liver disease 0.50 0.44 4.47 8.19 0.37 1.27 8.43 0.31 2.43 4.08 0.39 2.41 9.82 0.42 1.77
Cancera 3.69 3.45 21.62 32.76 3.66 3.76 16.16 4.94 5.46 7.34 4.09 6.12 5.73 3.68 3.58
Biliary cancer 0.40 0.38 1.30 1.64 0.38 0.44 2.81 0.34 0.67 2.04 0.33 0.56 2.86 0.39 0.46
Liver disease 
diagnosis
2.37 2.24 9.70 26.01 1.88 5.35 31.45 1.84 10.42 36.33 2.26 10.51 40.95 2.22 4.72
Hospital admission 165.93 162.91 531.54 1149.98 166.95 159.20 393.26 170.71 187.22 264.21 149.35 183.59 262.36 165.23 166.83
Other diagnosis
IHD 10.68 10.59 21.92 21.77 10.96 9.07 7.94 9.39 10.59 12.62 8.65 9.55 9.23 10.87 9.34
Renal disease 3.58 3.39 19.18 27.12 3.61 3.53 5.02 3.03 3.79 5.73 2.44 3.73 5.37 3.60 3.21
Diabetes 4.61 4.57 11.23 3.28 4.52 5.45 8.79 4.17 9.28 5.80 3.09 5.26 8.36 4.52 5.79
Respiratory 10.75 10.31 49.70 58.98 10.85 10.22 21.30 9.48 11.23 14.30 9.04 10.82 18.16 10.78 10.86
Stroke 6.20 6.04 21.41 22.01 6.39 4.95 8.56 5.33 7.17 5.76 4.80 4.31 7.47 6.19 7.20
Cancera 12.63 12.10 56.68 96.01 12.55 12.77 55.89 12.16 13.80 13.28 10.36 17.62 18.33 12.68 12.19
Biliary disease 3.39 3.39 5.70 8.45 3.12 5.09 26.47 2.98 5.90 22.34 2.83 3.56 15.50 3.33 4.73
Biliary cancer 0.50 0.48 1.31 1.64 0.48 0.47 3.52 0.45 0.61 3.27 0.42 0.74 3.28 0.48 0.71
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase; IHD, ischaemic heart disease.
a  Not including biliary cancer or hepatocellular cancer (comes under liver disease).
particular, reduced albumin levels are associated 
with serious illness,32,33 as substantiated by the fact 
that even a mildly reduced albumin level has a 
hazard of mortality over 2.5 times that of normal 
albumin. This raises uncertainty over what is the 
most appropriate investigation for patients with 
ALFTs if most do not have underlying liver disease 
but have increased risks of several other diagnoses, 
e.g. cancer and cardiovascular disease (CVD).
The upsurge in the number of requests for LFTs 
is in part attributed to the later contribution 
of electronic biochemistry data from two small 
hospital laboratories in Tayside to the main site in 
Ninewells Hospital. However, we have observed 
a 900% increase in incident rate of testing which 
would not be due to the additional data from two 
much smaller hospitals. The increase in testing 
was not associated with a fall in the proportion of 
abnormal tests, with 21.7% having an abnormal 
first test, indicating a large pool of subclinical 
liver dysfunction, the consequences of which were 
previously unknown.
In summary, this chapter has described the 
epidemiological association of abnormalities in an 
initial primary care panel of LFTs with important 
health outcomes. Until now, the strength of the 
association with death or liver disease in patients 
with abnormal levels of LFTs was not known. 
Subsequent chapters describe the development 
of predictive models for clinical decision support 
and conduct decision and cost–utility analyses on 
LFTs referred from primary care, to ascertain the 
optimal management strategies that will reduce 
costs to the NHS and optimise patient care.Results: descriptive analyses of liver function tests and outcomes
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TABLE 4  Percentage sensitivity, specificity, PPV and NPV of LFTs at the first GP consultation in patients with no obvious liver disease for 
1- and 5-year periods
LFT Performance measure
All death Liver death Liver disease
1 year 5 years 1 year 5 years 1 year 5 years
AP Sensitivity (%) 17.4 11.2 48.8 37.6 42.5 32.1
Specificity (%) 89.8 89.7 89.6 89.6 89.7 89.8
PPV (%) 4.9 9.7 0.2 0.5 1.5 2.5
NPV (%) 97.3 91.0 99.9 99.9 99.8 99.4
Albumin Sensitivity (%) 20.4 11.4 26.8 19.2 15.0 6.6
Specificity (%) 99.8 98.9 98.0 98.0 98.0 98.0
PPV (%) 29.4 50.8 0.6 1.2 2.6 3.5
NPV (%) 98.0 91.8 99.9 99.9 99.7 99.0
Transaminase Sensitivity (%) 11.5 9.5 37.5 40.2 42.1 35.8
Specificity (%) 93.2 93.3 93.1 93.1 93.2 93.3
PPV (%) 4.5 11.0 0.2 0.7 2.2 3.9
NPV (%) 97.3 92.0 99.9 99.9 99.8 99.5
GGT Sensitivity (%) 37.1 27.4 76.9 71.4 72.4 61.9
Specificity (%) 85.3 85.7 84.6 84.7 85.1 85.4
PPV (%) 7.4 15.2 0.4 1.0 3.1 5.2
NPV (%) 97.5 91.2 99.9 99.9 99.8 99.4
Bilirubina Sensitivity (%) 10.5 8.5 35.9 24.8 16.8 14.9
Specificity (%) 93.0 93.1 92.9 92.9 92.9 93.0
PPV (%) 4.3 11.0 0.2 0.5 0.9 1.7
NPV (%) 97.2 91.0 99.9 99.9 99.7 99.2
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase; NPV, negative predictive value; PPV, positive predictive value.
a  The sensitivity and PPV for bilirubin include only patients with bilirubin ≤ 35 at initial GP consultation.
All performance measures were adjusted for the probability of testing.28DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 5  Weibull regression model results by level of initial LFT abnormality (vs normal) for time to liver disease, all cause mortality and 
liver disease mortality
Variable
Liver disease All cause mortality Liver disease mortality
HR (95% CI) HR (95% CI) HR (95% CI)
Albumin
Mildly lowered 3.41 (2.55–4.55) 2.65 (2.47–2.85) 7.38 (4.60–11.81)
Severely lowered 8.48 (5.04–14.28) 4.99 (4.26–5.84) 16.17 (6.41–40.81)
AP
Mildly elevated 2.91 (2.49–3.39) 1.80 (1.69–1.91) 3.81 (2.72–5.32)
Severely elevated 14.42 (10.20–20.37) 2.88 (2.44–3.40) 17.81 (9.20–34.49)
Transaminasea
Mildly elevated 4.23 (3.55–5.04) 1.35 (1.26–1.44) 5.41 (3.80–7.71)
Severely elevated 12.67 (9.74–16.47) 1.88 (1.58–2.23) 7.17 (3.75–13.70)
GGT a
Mildly elevated 2.54 (2.17–2.96) 1.56 (1.48–1.63) 4.89 (3.43–6.99)
Severely elevated 13.44 (10.71–16.87) 2.90 (2.61–3.23) 25.32 (15.27–41.97)
Bilirubinb
Mildly elevated 2.02 (1.68–2.44) 1.20 (1.12–1.29) 3.89 (2.76–5.48)
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase; HR, hazard ratio.
a  The missing data from transaminase and GGT were imputed using a multiple imputation method for the modelling.
b   Patients with severely elevated bilirubin were omitted from the population and thus this cohort is not in the survival 
model for bilirubin.
Weibull models were fitted separately for each LFT and were adjusted for all baseline factors described in the text. Gilbert’s 
syndrome is not classified as a liver disease outcome.Results: descriptive analyses of liver function tests and outcomes
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FIGURE 3  Survival for (a) liver disease diagnosis in relation to transaminase level and (b) all cause mortality in relation to albumin 
severity.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Chapter 4  
Results: preliminary survival analyses on liver 
function tests as normal, mild and severe
Introduction
This chapter will focus entirely on the survival 
analysis of the cohort data from Tayside 
(n = 95,977) described in the previous chapter and 
the initial development of survival models which 
will lead to development of predictive algorithms 
to predict liver disease, liver mortality and all cause 
mortality. The results for the predictive algorithms 
appear in Chapter 5. Initially, we discuss how to 
estimate missing data or adjust the analysis for 
these, as some of the LFTs have missing results 
for each batch. ‘Missing’ data for each LFT do 
not necessarily mean that the data are lost; the 
reason is more likely to be due to the GP selecting 
certain LFTs to test rather than testing the whole 
batch. This chapter goes on to focus on the survival 
modelling and the assumptions of this modelling, 
and in particular, proportional hazards. The data 
will be analysed using separate models for each 
LFT from the first date of testing to outcomes:
•	 liver disease diagnosis
•	 liver mortality
•	 all cause mortality.
In Chapter 5, these investigative models will 
inform how the final predictive models will be 
constructed.
Methods
In this section we will review the various methods 
that can be used to adjust analyses for the common 
problem of missing data.34 This will be followed 
by discussion of the different methods of survival 
analysis and how to apply the most suitable 
technique to the data.
Missing data methods
As mentioned in Chapter 3, there were some 
missing data for each LFT in the initial batch. 
Table 6 shows that only 8.83% of patients actually 
had all five LFTs on the first date of testing.  This 
is due mainly to the fact that only 10.92% of 
patients were tested for GGT in the initial batch, 
and thus it had the largest amount of missing data 
(Table 6, column 2). The reason for this is most 
likely selective testing by the GP rather than actual 
missing or lost data. However, it is important to 
adjust the analysis for these missing data to reduce 
selection bias, as in a prospective study the protocol 
would be to test every patient with every LFT. 
Table 6 shows that albumin and AP have very small 
amounts of missing data (< 1%), bilirubin has more 
than 6% missing data and transaminase has more 
than 23% missing data. These, and GGT, can be 
allowed for using numerous methods of dealing 
with missing data. We shall discuss some of these 
methods in turn, starting with the most simple and 
concluding with the current ‘optimal’ method of 
multiple imputation.
Using the mean
Imputing the mean value has the benefit of 
simplicity but it does not really use all the 
information in the data and takes no account of 
the uncertainty in estimating the missing values. 
Consequently, this method is generally not 
recommended.
Inverse weighting by predicted 
probability of being tested
In this approach, a logistic model is fitted to 
predict probability of testing.34 Once this predicted 
probability is extracted it can be used in the 
analysis by weighting the analysis of complete 
data by the inverse of probability. This method is 
frequently used in surveys.
Multiple imputation
In multiple imputation, the missing values are 
estimated a number of times and so gives a spread 
of values to allow for uncertainty.34 Table 7 shows 
the number of imputations necessary to give good 
relative efficiency in the presence of different 
proportions of missing values. In most cases five 
repetitions are found to be sufficient. Relative 
efficiency (RE) is calculated as RE = (1 + λ/m)–1, 
where λ = percentage of missing data and 
m = number of imputations.30Results: preliminary survival analyses on liver function tests as normal, mild, and severe
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TABLE 6  Frequency of missing data for each LFT
LFT Frequency of missing data (%)
Albumin 790 (0.82)
AP 720 (0.75)
Bilirubin 6155 (6.41)
Transaminase 22,556 (23.50)
GGT 85,493 (89.08)
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase.
TABLE 7  Relative efficiency of using m imputation estimators by percentage (λ) of missing data
m
λ
10% 20% 30% 50% 70%
3 0.9677 0.9375 0.9091 0.8571 0.8108
5 0.9804 0.9615 0.9434 0.9091 0.8772
10 0.9901 0.9804 0.9709 0.9524 0.9346
20 0.9950 0.9901 0.9852 0.9756 0.9662
TABLE 8   Frequency of missing data for each LFT and the relative efficiency of the imputation technique
LFT Frequency of missing data (%) m RE
Albumin 790 (0.82) 5 0.9984
AP 720 (0.75) 5 0.9985
Bilirubin 6,155 (6.41) 5 0.9873
Transaminase 22,556 (23.50) 10 0.9770
GGT 85,493 (89.08) 30 0.9712
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase; m, number of imputations; RE, relative efficiency 
(RE = 1 + λ/m)–1.
Table 8 shows the percentage of missing values for 
the LFTs and gives an indication of the number of 
imputations necessary to give reasonable relative 
efficiency of 97% or above.
Survival analysis methods
Survival analysis using regression methods allows 
one to measure the effect that covariates have on 
the hazard of a particular outcome (usually death) 
over time. Various methods exist for this analysis 
such as the common semi-parametric method, 
Cox proportional hazards. Unfortunately, the Cox 
model has become embedded in clinical survival 
analysis as it provides clinically meaningful HRs, 
even when simpler models provide a good fit. This 
report concentrates on use of the Weibull model, 
which, unlike the Cox model, is a fully parametric 
model and hence more concise in form. Parameters 
are also easily estimated using full maximum 
likelihood. It still allows derivation of the clinically 
useful HRs but also more easily allows derivation of 
probabilities over any time period. This model was 
also the final model used to derive probabilities of 
events in the Framingham Cohort study.
Survival analysis methods 
using categorical LFT results
Survival analysis using the Weibull regression 
method was conducted to investigate whether 
abnormality of an initial LFT (normal, mild, DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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severe) was associated with time to outcomes 
including:
•	 liver disease diagnosis
•	 liver disease mortality
•	 all cause mortality.
The starting point was taken as the date of the 
initial batch of LFT tests and the end point was 
31 December 2003, date of outcome, emigration 
or death, whichever was earlier. All patients whose 
end point was not the outcome of interest were 
censored. Initially, Weibull regression models 
were fitted separately for each LFT and the 
level of abnormality adjusted for the baseline 
characteristics. Levels of abnormality were taken as 
normal, mildly elevated and severely elevated as 
defined in Table 1 (for bilirubin the levels were only 
normal and mildly elevated as those with jaundice 
were excluded). Initially, a univariate analysis was 
performed on each of the baseline factors and 
those that had a p-value > 0.3 were excluded from 
further multivariate analysis including stepwise 
regression. Survival curves were plotted to display 
the survival functions by initial LFT result. The 
proportional hazards assumption was checked 
using plots of the log of the negative log of the 
survival function and by fitting log (time) by factor 
interactions to test for significance. Analyses were 
performed using the SAS (version 8) software 
package
The HRs are not outputted automatically in 
SAS for each parameter in the model. Only the 
parameter estimate is displayed with its 95% CIs, 
its standard error (SE) and its p-value. The HR was 
calculated using the following formula:
HR = exp (β/–σ)
where β = parameter estimate and σ = scale 
parameter.
Hence, a negative coefficient for a factor represents 
increasing hazards with that factor.
If the hazard functions proved to be non-
proportional, the survival plots and log of the 
negative log of the survival function plots helped 
inform the approximate time points at which the 
hazard functions became non-proportional. Further 
analyses were then conducted using models where 
the time was split into these different periods. 
Survival plots and log of the negative log plots 
were drawn again for each of these separate time 
models.
Results
This section will begin by presenting the results 
from the logistic regression modelling the outcome 
of testing for an LFT. This followed on from 
weighting a model for the probability of testing to 
take account of verification bias due to ‘selective’ 
testing, discussed earlier in this chapter. It is 
followed by the survival analysis results using the 
Weibull regression method for the categorical LFT 
results.
Missing data results
This section will discuss the results from the 
logistic regression modelling to predict outcome 
of LFT testing arising from the analysis to adjust 
for verification bias (see inverse weighting in 
the Methods section). From the survival analysis 
modelling, where LFT categories were used, three 
missing data methods were applied and these 
results are compared here for the transaminase and 
GGT models (the two tests with the most missing 
data).
Predicting LFT testing
The predicted probabilities for LFT testing were 
used to weight the sensitivity and specificity 
analysis in Chapter 3 so that they could be adjusted 
for the effect of verification bias. The results from 
the logistic regression models predicting outcome 
(present/absent) are described below.
Gender was significantly associated with LFT 
testing for all LFTs, with males having a tenth of 
the chance of being tested for albumin and AP 
compared with females. However, males were 
significantly more likely to be tested for GGT 
[odds ratio (OR) =1.93, 95% CI 1.85–2.01], in 
comparison with bilirubin (OR = 1.45, 95% CI 
1.37–1.53) and transaminase (OR = 1.29, 95% CI 
1.25–1.33). Younger age was significantly predictive 
of testing for GGT and transaminase with odds of 
0.99. Number of ALFTs in the first batch of tests 
predicted testing for GGT with an increase in odds 
of 90% with each increase in number of abnormal 
tests. Bilirubin and transaminase testing was also 
predicted by the number of ALFTs but the odds 
were less than 1.20. The odds of testing for AP 
were 2.5 for a patient with a history of IHD. For 
albumin testing, the OR was 2.10 (95% CI 1.16–
3.77). For GGT, a history of IHD had significantly 
lower odds of testing (OR = 0.83, 95% CI 0.75–
0.93). Lower odds of testing for bilirubin and Results: preliminary survival analyses on liver function tests as normal, mild, and severe
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GGT were associated with a history of respiratory 
disease and a history of diabetes only. However, 
the chances of being tested for transaminase with a 
history of diabetes were significantly (57%) higher 
than with no history of diabetes. A history of cancer 
at baseline increased the odds of being tested for 
albumin by more than six times, while for AP the 
odds were over 5.
Patients prescribed statins during the 3 months 
before initial tests were 13.64 times (95% CI 10.88–
17.10) more likely to be tested for transaminase 
than those who were not. For albumin, AP and 
mild bilirubin the odds were 3, 2.5 and 1.6 
respectively. There was a lower chance of being 
tested for GGT while on statins (OR = 0.63, 95% CI 
0.54–0.73). NSAID use in the preceding 3 months 
was significantly associated with a lower chance of 
GGT and transaminase testing with odds of 0.31 
and 0.77 respectively. NSAID use was not predictive 
of albumin, AP or bilirubin testing. Patients on 
antibiotics had almost a 70% increased chance 
of being tested for AP than those who were not, 
while for albumin, bilirubin and transaminase 
the significant increases were 34%, 33% and 9% 
respectively. However, antibiotic use was not 
associated with GGT testing.
An alcohol-dependent patient had one-third of the 
chance of being tested for albumin or AP than a 
non-alcohol-dependent patient. However, alcohol-
dependent patients had an OR of 2.32 (95% CI 
2.11–2.55) of being tested for GGT. Patients taking 
methadone only had significant odds of being 
tested for transaminase (OR = 1.39, 95% CI 1.06–
1.81). Drug-dependent patients had only half the 
odds of being tested for albumin or bilirubin.
Comparing survival analysis results 
using different missing data methods
Appendices 5–7 present the results from the 
survival analysis using categorical LFT results for 
outcomes of liver disease diagnosis, liver mortality 
and all cause mortality respectively. Tables 45–50 
in these appendices show the results for the 
transaminase and GGT models. The missing data 
methods displayed include complete data analysis, 
weighting by predicted probability of testing 
analysis and multiple imputation.
For those outcomes with a large number of 
events, the results from the survival analyses using 
different missing data techniques were similar. For 
example, Table 49 in Appendix 7 shows HRs for 
all cause mortality; it can be seen that for a mildly 
elevated transaminase the HRs are 1.38 (95% CI 
1.25–1.52), 1.37 (95% CI 1.26–1.49) and 1.35 (95% 
CI 1.26–1.44) for complete data analysis, weighted 
analysis and multiple imputation respectively. For 
severely elevated transaminase, the hazards are 
similar. However, for models with smaller numbers 
of events, such as liver disease diagnosis and liver 
disease mortality, the results differ for the three 
methods, particularly for the GGT-adjusted model. 
For the liver disease diagnosis models (Appendix 
5), the HRs for transaminase abnormality and 
GGT abnormality differ more when the multiple 
imputation method used in comparison with the 
other two methods.
Survival analysis using 
categorical LFT results
The survival analysis results where the LFT results 
have been grouped into normal, mildly elevated 
(or lowered for albumin) and severely elevated are 
presented in this section. The results are split into 
the following outcomes:
•	 first liver disease diagnosis
•	 liver mortality
•	 all cause mortality.
Liver disease diagnosis
All the LFTs were significantly predictive of 
liver disease even after adjusting for risk factors 
for liver damage. Of the mildly elevated LFTs, 
transaminase had the highest HR of 4.23 (95% CI 
3.55–5.04). All severely elevated LFTs had HRs 
over 8, with AP being the highest followed by GGT 
and transaminase. Other factors predictive of liver 
disease were older age, Carstairs score, alcohol 
dependency, illicit drug use and methadone use. 
For the transaminase model the HRs for the last 
three factors were 4.48 (95% CI 3.70–5.42), 2.25 
(95% CI 1.51–3.36) and 4.52 (95% CI 3.07–6.65) 
respectively. Statin use was significantly associated 
with lower risk of liver disease for the bilirubin 
models, showing a 36% reduction in risk.
The Kaplan–Meier plots for time to liver disease 
diagnosis by LFT category of result (normal, mildly 
elevated and severely elevated) are shown in Figure 
4 for AP and transaminase. Severe AP can be seen 
to have high risk of liver disease, particularly in the 
first year.
Liver disease mortality
Of the mildly ALFTs, low albumin had the highest 
HR for liver mortality of 7.38 (95% CI 4.60–11.81). 
Severely elevated GGT had the highest HR overall, 
with a value of 25.32 (95% CI 15.27–41.97), 
followed by AP and albumin. The only baseline 
factors which predicted liver disease mortality DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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were gender, older age, Carstairs score (higher 
deprivation) and alcohol dependency. Alcohol 
dependency had HRs as high as 10.84 (95% CI 
7.28–16.14) for the albumin-adjusted model. It was 
lowest for the GGT model, however, with a value of 
3.92 (95% CI 2.73–5.61). Figure 5 shows the survival 
curves for albumin and GGT. Although the survival 
curves are very close together as a result of the 
low numbers of liver mortality, the HRs are large 
because of the flatness of the normal LFT curve.
All cause mortality
All LFTs had significantly high HRs for all cause 
mortality. Albumin had the largest HRs for 
mortality [4.99 (95% CI 4.26–5.84) for severely 
lowered]. For mildly lowered albumin the HR 
was more than 2.5 times that for normal albumin 
(see Figure 3b). GGT had similar HRs to AP, while 
transaminase had the lowest HRs for mortality. 
The baseline factors in the models predictive 
of death included gender, age, Carstairs score, 
IHD, renal disease, respiratory disease, diabetes, 
stroke, biliary cancer, all other cancers, statin use, 
NSAID and antibiotic use, alcohol dependency, 
drug dependency and methadone use. With the 
exception of biliary cancer, which had a typical HR 
of 15.70 (95% CI 5.06–48.71) (for the albumin-
adjusted model), all HRs for these factors were 
less than 2. Statin use was associated with lower 
risk, with a typical HR of 0.56 (95% CI 0.49–0.65). 
Figure 6a demonstrates how serious an abnormal 
albumin is in relation to all cause mortality.
Assessment of proportionality
Figure 7 displays the log of the negative log of the 
survival function curves for initial transaminase to 
liver disease diagnosis and liver mortality by level 
of result. The plots look approximately parallel, 
although there are places of slight overlapping, 
particularly between the mildly elevated and 
severely elevated curves for liver mortality. Each 
plot shows steep curvature at initial testing, which 
suggests that survival differs during the first few 
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FIGURE 4  Time from first LFT to liver disease diagnosis by level of abnormality. (a) Alkaline phosphatase; (b) transaminase.Results: preliminary survival analyses on liver function tests as normal, mild, and severe
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FIGURE 5  Survival from first LFT to liver mortality by level of abnormality. (a) Albumin; (b) gamma-glutamyltransferase.
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months or so after initial testing compared with 
the rest of the study period. This was confirmed 
when tests for non-proportionality such as adding 
a log (time) by factor interaction term were 
statistically significant. Hence, because of the slight 
non-proportionality of the hazards in the first 
few months, it was decided to conduct separate 
analyses for different time points of the study 
period. The time periods chosen were day 0 to 3 
months, 3 months to 1 year and 1 year to the end 
of the study. Any time period less than 3 months 
would result in very small numbers of events.
Survival analysis using 
categorical LFT results by 
follow-up time period
The survival analysis conducted in the previous 
section was repeated for different time periods 
and for all outcomes. In the interests of brevity, 
the results are described only for the outcome of 
liver disease diagnosis, with multiple imputation of 
missing values. The significant factors associated 
with this outcome are shown in Appendix 8 for 
time periods of 0–3 months, 3 months to 1 year 
and 1 year to study end for each LFT.
Liver disease
All the LFTs were significantly predictive of liver 
disease for all time periods even after adjusting 
for risk factors for liver damage (see Appendix 8) 
(the only exception was severely lowered albumin, 
which was not significantly predictive of liver 
disease from 1 year onwards). The HRs were much 
larger for the first 3 months than they were for the 
model using the whole length of the study. These 
HRs decreased as the time periods increased. For 
example, for the albumin-adjusted models, the 
HR of liver disease diagnosis within 3 months was 
10.89 (95% CI 6.19–19.17) for mildly lowered 
albumin and 35.20 (95% CI 15.60–79.45) for 
severely lowered albumin versus normal albumin. 
For the time period of 3 months to 1 year, the HRs 
were much lower, i.e. 4.29 (95% CI 2.27–8.10) DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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FIGURE 6  Survival from first LFT to all cause mortality by level of abnormality. (a) Albumin; (b) alkaline phosphatase.
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and 3.25 (95% CI 0.45–23.55) respectively. From 
1 year onwards, the hazards were lower again, 
with mild levels having an HR of 1.48 (95% CI 
0.87–2.52) and severe levels having an HR of 2.89 
(95% CI 0.93–9.00). The hazard of liver disease 
within 3 months for mildly lowered albumin was 
the highest out of the five mildly ALFTs. However, 
for severe levels, AP, GGT and transaminase were 
higher than albumin. Mildly elevated transaminase 
had the highest hazard out of the mildly elevated 
LFTs for the 3 months to 1 year model (HR = 6.37, 
95% CI 4.03–10.08); however, for severely elevated 
levels, AP and GGT had the highest HRs, of over 
23. AP and GGT had similar HRs for all levels and 
time periods for this outcome.
For the LFTs of transaminase, albumin, AP 
and bilirubin, age, Carstairs score, alcohol 
dependency and methadone were all significant 
factors predictive of liver disease for all three 
time periods. A history of respiratory disease and 
drug dependency was only significantly predictive 
from 1 year. A history of gallbladder disorders 
(excluding cholelithiasis) was also predictive from 
3 months to 1 year. For alcohol dependency, the 
HRs got larger with increasing time. For example, 
for transaminase, the HRs were approximately 2.1, 
3.0 and 5.7 for the time periods of 0–3 months, 3 
months to 1 year and over 1 year respectively. For 
methadone users, the HRs decreased with time, i.e. 
8.3, 7.7 and 3.6 respectively. Alcohol dependency 
only had a significant HR for the 1 year and over 
time period for the GGT model (HR = 3.99, 95% 
CI 3.16–5.03.
Proportionality of hazards within 
separate time periods of follow-up
As a final check, the log of the negative log of the 
survival function curves for initial albumin were 
plotted within the three time periods. Figure 8 
displays these for time to liver disease diagnosis. 
The plots look approximately parallel for the time 
periods of 0–3 months and 3 months to 1 year. As 
it probably does not make clinical sense to predict Results: preliminary survival analyses on liver function tests as normal, mild, and severe
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FIGURE 7  Plots of the log of the negative log of the survival function against log of time for transaminase. (a) Liver disease diagnosis; 
(b) liver mortality.
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events such as mortality and diagnoses over long 
time periods, that is, more than 1 year after a 
single batch of LFTs, we concentrate on models 
using short time periods after LFTs, and these 
satisfy the model assumptions. Therefore, for the 
predictive model building using continuous LFT 
results described in Chapter 5, it was decided to 
use these shorter time periods. Models predicting 
events after 1 year could be constructed, but the 
assumptions of the models are not met and also are 
clinically less useful.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Chapter 5  
Results: development of predictive algorithms
Introduction
This chapter will build on the initial model 
construction described in Chapter 4, and will 
concentrate on developing predictive algorithms 
based on the LFTs as continuous variables. As 
before, these were derived from the cohort data 
from Tayside (n = 95,977). Predictive algorithms 
were derived for the outcomes liver disease, liver 
mortality and all cause mortality.
The final models took account of interactions 
between individual LFTs and between LFTs and 
covariates. The performance of each model was 
then assessed by estimating discriminative ability 
and calibration.
Methods
Survival analysis methods
Survival analysis using regression methods allows 
one to measure the effect that covariates have on 
the hazard of a particular outcome (usually death) 
over time. As in previous chapters, this chapter 
concentrates on use of the Weibull model, which 
easily allows derivation of probabilities over any 
time period and is a fully parametric model.
Survival analysis using 
continuous LFT results
The modelling was repeated using the LFTs as 
continuous variables. This was implemented for a 
number of reasons:
•	 Cut-off points are somewhat arbitrary and may 
vary by location.
•	 Use of cut-off points reduces power.
•	 Using categorical factors increases the 
interaction terms and hence parameters to a 
large extent, especially with potential two-way, 
three-way and four-way interactions.
•	 In a clinical setting, using the whole scale gives 
more accurate estimates of probability of risk to 
inform decision making.
The categorical modelling allowed us to investigate 
graphically survival by degree of abnormality and 
proportional hazards. Prior to the modelling, 
transformations were calculated if the test results 
were not normally distributed. The significant LFTs 
from the models in Chapter 4 were entered into 
the Weibull models with all continuous LFT results. 
Any covariates which were non-significant were 
removed, and all other covariates which were non-
significant in the previous models were entered one 
by one, in case they were significant when other 
LFTs were in the model. Looser exclusion criteria 
were placed on the continuous LFT results, with 
any LFT having a p-value of less than 0.3 being 
considered for inclusion in the model at this stage.
Model building with 
interaction terms
All two-way LFT interactions were entered into 
the models and the most non-significant terms 
were excluded. The model was then refitted and 
the process repeated until all the highest-order 
interactions were still significant at the 5% level. 
For each model, the Akaike’s information criterion 
(AIC) statistic was calculated.35 This statistic is a 
measure of the goodness of fit of the model that 
penalises high parameter models and is calculated 
as:
AIC = –2(log likelihood – k)
where k = the number of parameters in the model.
With a large data set, it is likely that many spurious 
results could arise and use of AIC is considered 
equivalent to cross-validation methods. Akaike’s 
information criterion was also used to inform 
exclusion of model terms. If the difference in 
AIC between the model with a non-significant 
term included and the model without the term is 
greater than 4, then it was deemed a significant 
improvement in fit. If a situation arose where the 
significance of a term was borderline, e.g. p = 0.06, 
then AIC helped with the decision making process. 
All three-way interaction terms were also entered 
into the models and the exclusion process was 
repeated. The same was done for any four-way 
interactions between LFTs. The model with the 
lowest AIC was chosen as the best model thus far.
Following this process, interactions between the 
covariates and each other, and the covariates and Results: development of predictive algorithms
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the LFTs were also fitted one by one with any 
significant interactions kept in the model and any 
non-significant interactions excluded. Again, AIC 
was used to decide the optimal model.
Model assessment
Once the final models have been built they must be 
assessed to test that they are good at discriminating 
high from low risk and also are accurate in their 
predicted probabilities. Two types of analysis exist 
for this procedure – estimating discriminative 
ability (c-statistic) and testing calibration (Hosmer–
Lemeshow test).
Discrimination
Discrimination assesses how good the model is at 
identifying people at high risk relative to people 
at low risk. In logistic models, it is characterised as 
the area under the receiver operating characteristic 
(AUROC) curve, or c-statistic. In survival models, 
Pencina and D’Agostino36 developed an estimate 
of the overall c-statistic akin to Kendal’s tau. More 
recently, Chambless and Diao37 have developed 
methods of estimating a time variant c-statistic. 
Generally, values above 0.6 are considered 
reasonable indication of discriminative ability, 
although values close to 0.7–0.8 found with 
Framingham algorithms are considered good to 
excellent.38
Calibration
Calibration assesses the accuracy of the probability 
estimate from the prediction model across the 
range of values of predicted risk. In logistic 
regression, the Hosmer–Lemeshow test is standard 
and compares expected events with observed 
events across deciles of predicted risk. The test 
is compared with a chi-squared distribution and 
significance indicates a lack of fit. The Grønnesby–
Borgan method is an adaptation of this test, and 
May and Hosmer39 give guidance as to how many 
percentiles of predicted risk are optimal. This 
involves calculating the number of groups G as 
follows:
G = integer value of [max (2, min (10, number 
of failures/40))]
Calculating probabilities of risk
Once the models are derived, it is possible 
to calculate the probabilities of outcomes for 
hypothetical cases of patients. This is achieved 
by entering the various characteristics for each 
patient into the model. The values of each of these 
predictors for each patient (the Xs) are multiplied 
by their respective parameter estimates (βs) as in 
formula (1) below and added together to form the 
linear predictor. The result is subtracted from the 
log (time) and divided by the scale parameter (σ) 
to obtain U (2). The predicted probability is then 
calculated as in formula (3).
XB = intercept + β1X1 + β2X2 + ... + βkXk   (1)
where k is the number of predictors.
U = (log (time) – XB)/σ  (2)
Probability = 1 – exp (– exp(U))  (3)
95% CIs can be calculated for each probability 
of risk using the Delta method by multiplying 
the covariance matrix by a vector of first-order 
differentials of the parameter estimates.22 The 
vector of first-order differentials is found to be:
D = [–U, –1/σ, –x1/σ, ..., –xi/σ, ..., –xk/σ]
Multiplication of (D′) × COV(X) × D results in the 
variance of U and so must be square rooted to 
give the standard deviation. The 95% CIs are then 
calculated as:
(UL, UU) = U ± 1.96 × SD(U)
and therefore,
pL = 1 – exp(–exp(UL)), pU = 1 – exp(–exp(UU))
This process involves matrix multiplication and was 
implemented in PROC IML in SAS (version 9).
Results
Before any model fitting was done on the 
continuous LFT results, each test was plotted 
in a histogram to check its distribution. If 
the distribution was found to be skewed, 
transformations such as log transformations were 
assessed.
Table 9 shows the descriptive statistics for each 
LFT following estimation of missing data using 
multiple imputation. Figure 9 shows the histograms 
of each LFT. The left-hand side contains plots of 
the untransformed LFTs. All but albumin are quite 
clearly skewed to the left and thus are not normally 
distributed in their current form. The natural log 
transformation proved to be the best function to 
transform the LFTs to an approximate normal 
distribution.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
31
As GGT had the most missing data, the multiple 
imputation method imputed a high number of 
zero values, resulting in missing values again when 
the log transformation was applied. Therefore, 
GGT was transformed as log(GGT + 0.5) to allow 
these zero values to be included. Albumin was 
standardised by dividing it by its standard deviation 
(SD = 3.39). The histograms on the right-hand side 
of Figure 9 are for the transformed LFTs.
Final models
The final models arising are displayed in Tables 10–
12 for liver disease diagnosis. The final models for 
liver mortality and all cause mortality are displayed 
in Appendix 9. These tables contain the model 
terms, the parameter estimates (or coefficients) 
with 95% CIs and the p-value.
Liver disease diagnosis
Baseline to 3 months
In the model predicting liver disease within 
3 months there were four single LFTs and two 
two-way interactions (Table 10). Females were at 
increased risk of liver disease diagnosis within 
the first 3 months compared with males, as were 
younger people. Methadone interactions with LFTs 
(transaminase and albumin) were also predictive as 
were deprivation (Carstairs score) interactions (with 
transaminase and AP).
3 months to 1 year
From 3 months to 1 year, there were fewer model 
terms (k = 10), with only three LFTs included 
(no interactions). Increased GGT, increased 
transaminase and lowered albumin were significant 
predictors of liver disease in this time period. 
Females are still at greater risk of diagnosis than 
males; however, age is no longer significant. 
Alcohol and a history of gallbladder disorders were 
also predictive of greater risk, as was methadone 
use with Carstairs score (Table 11).
After 1 year
From 1 year after initial LFTs there were more 
interaction terms for liver disease diagnosis, 
particularly between transaminase and the other 
three LFTs in the model (Table 12). Methadone 
use was greatly associated with liver disease and 
had interactions with age and AP. Alcohol was also 
predictive of liver disease (as expected) and had 
interactions with a history of respiratory disease, 
drug dependency and transaminase result.
Liver mortality
Baseline to 3 months
Only four parameters were predictive of mortality 
due to liver disease within 3 months of the first 
LFTs – a history of biliary tract disorders, increased 
AP and bilirubin and lowered albumin. Gender 
was almost significant (p = 0.06) and age had no 
significant effect. This is not surprising, given that 
this is an unlikely event in a short time period for 
people with no obvious liver disease (see Appendix 
10).
3 months to 1 year
From 3 months, there were more predictors 
and many interaction terms between LFTs. 
Transaminase, GGT and bilirubin had significant 
interaction terms, while alcohol dependency 
increased risk with increasing albumin. Older age 
was significantly predictive; however, gender had 
no effect.
TABLE 9  Descriptive statistics for LFTs and transformed LFTs
LFT Mean (SD) Minimum Maximum Skewness (SE) Kurtosis (SE)
Albumin 43.47 (3.39) 14.00 63.00 –0.61 (0.01) 2.45 (0.02)
AP 82.53 (43.86) 9.00 3535.00 14.27 (0.01) 596.48 (0.02)
Bilirubin 9.80 (4.26) 1.00 35.00 1.87 (0.01) 5.27 (0.02)
Transaminase 23.9 (26.25) 2.00 2063.00 23.23 (0.01) 1030.30 (0.02)
GGT 42.98 (52.71) 0.50 3799.00 16.03 (0.01) 605.93 (0.02)
Albumin/SD 12.81 (1.00) 4.12 18.56 –0.62 (0.01) 2.48 (0.02)
Log (AP) 4.34 (0.35) 2.20 8.17 0.75 (0.01) 3.91 (0.02)
Log (bilirubin) 2.20 (0.38) 0.00 3.56 0.35 (0.01) 0.67 (0.02)
Log (transaminase) 3.01 (0.50) 0.69 7.63 0.90 (0.01) 3.45 (0.02)
Log (GGT) 3.38 (1.07) –0.69 8.24 –1.79 (0.01) 5.10 (0.02)
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase.Results: development of predictive algorithms
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FIGURE 9  Histograms of the LFTs.
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TABLE 10  Final model predicting risk of liver disease diagnosis within 3 months after first LFTs
Parameter Coefficient (95% CI) p-value
Intercept 16.995 (5.308–28.683) 0.004
Gender (male vs female) 0.376 (–0.171 to 0.924) 0.18
Age 0.021 (0.005–0.036) 0.008
Carstairs score –0.385 (–0.921 to 0.151) 0.16
Methadone user (yes vs no) 7.077 (–6.142 to 20.295) 0.29
Log (transaminase) –1.737 (–4.725 to 1.250) 0.25
Log (AP) –3.695 (–5.529 to –1.860) < 0.001
Log (GGT) –0.867 (–1.397 to –0.338) 0.001
Albumin/SD 1.932 (1.235–2.628) < 0.001
Log (transaminase) × albumin/SD –0.247 (–0.424 to –0.070) 0.006
Log (transaminase) × log (AP) 0.635 (0.246–1.024) 0.001
Methadone user × log (transaminase) 2.098 (0.560–3.635) 0.008
Methadone user × albumin/SD –1.451 (–2.439 to –0.463) 0.004
Carstairs score × log (transaminase) –0.111 (–0.187 to –0.036)  0.004
Carstairs score × log (AP) 0.139 (0.027–0.251) 0.02
Scale 1.743 (1.506–2.019)
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase.
Discrimination: Overall C was 0.85 (95% CI 0.76–0.91).
TABLE 11  Final model predicting risk of liver disease diagnosis from 3 months to 1 year after first LFTs
Parameter Coefficient (95% CI) p–value
Intercept 13.605 (10.984–16.227) < 0.001
Gender (male vs female) 0.373 (0.022–0.724) 0.04
Age –0.006 (–0.016 to 0.005) 0.29
Carstairs score –0.048 (–0.095 to –0.001) 0.05
Gallbladder disorder history (yes vs no)a –1.167 (–2.157 to –0.177) 0.02
Alcohol dependent (yes vs no) –0.729 (–1.306 to –0.152) 0.01
Methadone user (yes vs no) 1.017 (–2.776 to 4.809) 0.60
Log (transaminase) –0.689 (–0.992 to –0.385) < 0.001
Log (GGT) –0.805 (–1.103 to –0.508) < 0.001
Albumin/SD 0.340 (0.188–0.492) < 0.001
Carstairs score × methadone user –0.642 (–1.274 to –0.009) 0.05
Scale 1.089 (0.939–1.263)
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase.
a   Does not include cholelithiasis.
Discrimination: Overall C was 0.72 (95% CI 0.62–0.81).Results: development of predictive algorithms
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TABLE 12  Final model predicting risk of liver disease diagnosis from 1 year after first LFTs
Parameter Coefficient (95% CI) p-value
Intercept 6.758 (–0.080 to 13.595) 0.05
Gender (male vs female) –3.739 (–5.583 to –1.895) < 0.001
Age 0.043 (–0.007 to 0.094) 0.09
Carstairs score –0.023 (–0.043 to –0.003) 0.02
Respiratory disease history (yes vs no) –0.698 (–1.102 to –0.295) 0.001
Alcohol dependent (yes vs no) –3.692 (–4.747 to –2.637) < 0.001
Drug dependent (yes vs no) –1.928 (–2.514 to –1.342) < 0.001
Methadone (yes vs no) –11.269 (–17.031 to –5.507) < 0.001
Log (transaminase) 0.825 (–0.986 to 2.637) 0.37
Log (AP) –1.620 (–2.592 to –0.647) 0.001
Log (GGT) 1.645 (1.126–2.163) <0.001
Albumin/SD 1.013 (0.595–1.432) <0.001
Log (transaminase) × albumin/SD –0.259 (–0.365 to –0.152) < 0.001
Log (transaminase) × log (AP) 0.636 (0.394–0.878) < 0.001
Log (transaminase) × log (GGT) –0.264 (–0.376 to –0.151) < 0.001
Log (AP) × log (GGT) –0.223 (–0.344 to –0.102) < 0.001
Age × methadone 0.044 (0.002–0.085) 0.04
Sex × albumin/SD 0.295 (0.152–0.438) < 0.001
Age × albumin/SD –0.004 (–0.008 to –0.0003) 0.04
Respiratory disease history × alcohol dependent 1.353 (0.128–2.578) 0.03
Alcohol dependent × drug dependent 1.765 (0.851–2.678) < 0.001
Alcohol dependent × log (transaminase) 0.572 (0.275–0.868) < 0.001
Methadone × log (AP) 1.957 (0.653–3.261) 0.003
Scale 1.008 (0.949–1.071)
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase.
Discrimination: Overall C was 0.53 (95% CI 0.48–0.58).
All cause mortality
Baseline to 3 months
As would be expected there were many significant 
predictors of all cause mortality. The only LFT 
not predictive of mortality within 3 months was 
transaminase (see Appendix 10). Many LFTs had 
interactions with each other predictive of mortality. 
The only three-way interaction present was AP 
× GGT × bilirubin. Being male had greater risk 
than being female, and older age also presented a 
greater risk. Those patients prescribed statins or 
NSAIDs in the 3 months preceding initial LFTs 
had less chance of dying than those who were not. 
A history of cancer had significant interactions 
with albumin and age separately. Albumin also 
interacted with NSAID use and Carstairs score. A 
history of IHD, renal disease, respiratory disease or 
stroke were all predictors of mortality.
3 months to 1 year
For the time period of 3 months to 1 year after 
initial LFTs, transaminase was predictive of 
mortality in this model; however, bilirubin was not. 
As for the earlier model, gender, age, statin use, 
history of IHD, renal disease, respiratory disease, 
stroke, cancer were all significant predictors of 
mortality. NSAIDs were not included this time; 
however, a history of biliary cancer was borderline 
significant as was methadone use. Age interacted 
with a history of cancer, AP result, albumin result 
and Carstairs score. AP also interacted with a 
history of IHD and respiratory disease.
After 1 year
The model predicting mortality from 1 year after 
testing had 38 terms. Transaminase, GGT, albumin 
and AP were, once again, predictive while bilirubin DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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was not. There were six two-way interactions 
between LFTs and three three-way interactions. 
Age interacted with many covariates including 
gender, Carstairs score, alcohol dependency, 
drug dependency, and history of IHD, diabetes, 
respiratory disease, stroke and cancer. Age also had 
an interaction term with AP result as did alcohol 
dependency. As for the previous models, statin use 
was associated with lower mortality, although this 
time it also had an interaction with albumin result.
Assessing model 
performance
Having derived these algorithms, it is important to 
assess how well they predict the specific events. The 
next sections present and describe the results of the 
two procedures carried out to assess this internal 
validation.
Calibration
Liver disease diagnosis
Using the Grønnesby–Borgan method to calculate 
the goodness of fit of the model, the data was first 
of all split into percentiles of predicted probability 
according to the number of total events. These 
were calculated from baseline up to 3 months, 1 
year and 4 years for comparison. The number of 
groups of risk was obtained using the suggestion 
of May and Hosmer39 as follows: as 172 patients 
were diagnosed with liver disease during the first 3 
months of the study, when this figure was divided 
by 40 (and then rounded down to the nearest 
whole number), this implies that the data should 
be divided into quartiles of predicted probability.39 
The numbers of expected and observed events 
were then displayed in a bar chart for each quartile 
(Figure 10). The results of the goodness of fit test 
are shown in Table 13 as well as the comparison 
between each quartile and the 4th quartile. Using 
the –2 × log(likelihood ratio) goodness of fit test, 
the model shows significance (p = 0.01). From 
Figure 10 and the heterogeneity results (of each 
quartile versus the 4th quartile) in Table 13, it is 
clear that this lack of fit is due to the first quartile.
For the final model predicting liver disease between 
3 months and 1 year after initial LFTs, the data 
were again categorised into quartiles of predicted 
probability (167 events/40 = 4). Figure 11 shows the 
bar chart of expected and observed events for each 
quartile. The goodness of fit test for this model, 
however, was not significant (p = 0.08).
The model predicting liver disease from 1 year 
after testing fitted the data reasonably well 
(p = 0.08). Predicted probabilities were calculated 
for the time point of 4 years, as the median 
follow-up time was 3.7 years. There were 752 
events during this period and so the predicted 
probabilities were split into deciles of risk. The 
observed and expected events for each decile 
were plotted on a bar chart (Figure 12). Tests of 
heterogeneity were all significant for each decile 
versus the tenth decile of risk. This is perhaps 
more to do with the fit of the tenth decile than the 
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FIGURE 10  Number of expected and observed liver disease events in the 3 months following LFTs.Results: development of predictive algorithms
36 FIGURE 11  Number of expected and observed liver disease events in the first year following LFTs.
TABLE 13  Calibration statistics using the Grønnesby–Borgan method for various time points of the final liver disease diagnosis models
Time point Group χ2 df p-value
3 months All 10.82 3 0.01
1 8.40 1 0.004
2 0.50 1 0.48
3 0.62 1 0.43
4 – – –
1 year All 6.67 3 0.08
1 1.28 1 0.26
2 0.05 1 0.82
3 2.73 1 0.10
4 – – –
4 years All 15.31 9 0.08
1 8.53 1 0.004
2 9.00 1 0.003
3 6.04 1 0.01
4 7.47 1 0.006
5 9.75 1 0.002
6 9.51 1 0.002
7 6.49 1 0.01
8 8.92 1 0.003
9 6.76 1 0.009
10 – – –
df, degrees of freedom.
χ2 goodness of fit was calculated using –2 × log(likelihood ratio).
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FIGURE 12  Number of expected and observed liver disease events at year 4 following LFTs.
others, as it is clear from the figure that this decile 
does not lie on the trend line of the previous nine 
deciles.
Liver disease mortality
The numbers of expected and observed deaths 
from liver disease within the first 3 months were 
displayed in a bar chart for each half of risk (Figure 
13). Only two groups of risk were used, as only 
20 events occurred in this time period, meaning 
that the minimum number of risk groups were to 
be used. The results of the goodness of fit test are 
shown in Table 14 and show good fit.
For the final model predicting liver mortality from 
1 year after initial LFTs (at the time point of 4 
years), the data were categorised into quintiles of 
predicted probability (as 211 events/40 = 5). Figure 
14 shows the bar chart of expected and observed 
events for each quintile. The goodness of fit test for 
this model was significant (p = 0.02). From Figure 14 
and the heterogeneity results in Table 14 it can be 
seen that there is overprediction at all quintiles.
All cause mortality
There were 979 deaths during the first 3 months of 
the study, meaning that the predicted probabilities 
were categorised into deciles of risk. The numbers 
of expected and observed deaths within the first 
3 months were displayed in a bar chart by decile of 
risk (Figure 15). The results of the goodness of fit 
test are shown in Table 15. From the figure, it looks 
as though the model fits the data well; however, 
the goodness of fit test is highly significant 
(p < 0.001) suggesting poor fit. Deciles 4–9 show 
significant differences from decile 10; this is 
due to overprediction by these deciles, while the 
others slightly underpredict. However, the visible 
difference is small.
The expected and observed deciles of risk of death 
during the period 3 months to 1 year following 
initial LFTs are displayed in Figure 16. A total 
of 1639 patients died during this period. As for 
the previous model, goodness of fit was poor 
(p = 0.004); however, this is not obvious from the 
graph. Heterogeneity was evident for the second, 
third, fifth, sixth and eighth deciles versus the 
tenth decile of risk.
Similarly, a lack of fit is evident (p < 0.001) for 
the long-term model predicting death from 1 
year onwards following the LFTs, with the fifth 
decile showing significant heterogeneity. Figure 17 
illustrated clearly the overprediction of the model 
from the fifth decile onwards.
Discrimination
The discrimination statistics of each of the eight 
models are presented in Table 16. A model with 
an overall c-statistic greater than 0.7 is generally 
deemed good at assigning a greater predicted 
probability to someone who actually has the event 
and a smaller predicted probability to someone 
who does not have the event. With that in mind, 
the models predicting liver disease and all cause 
mortality during the first 3 months after LFTs have Results: development of predictive algorithms
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characteristics required to enter the model 
predicting an event within 3 months are gender, 
age at baseline, Carstairs deprivation score, 
methadone dependency (yes/no) and the five LFT 
results.
Liver disease diagnosis within 3 months
Figure 18 is a plot of predicted probabilities of liver 
disease within 3 months for 16 different cases. The 
probabilities are for contrasting characteristics, i.e. 
the ages of 25 and 50 for males and females living 
in areas with Carstairs scores of –2 (reasonably 
affluent) and 4 (very deprived) and with 
methadone and non-methadone dependency. The 
FIGURE 13  Number of expected and observed liver mortality events in the 3 months following LFTs.
TABLE 14  Calibration statistics using the Grønnesby–Borgan method for various time points of the final liver mortality models
Time point from baseline Group χ2 df p-value
3 months Overall 1.19 1 0.28
1st bitile 0.00 1 1.00a
2nd bitile – – –
4 years Overall 11.82 4 0.02
1st quintile 1.42 1 0.23
2nd quintile 5.05 1 0.02
3rd quintile 8.19 1 0.004
4th quintile 6.24 1 0.01
5th quintile – – –
df, degrees of freedom.
a  Test result differs from trend result because this used the Wald test.
χ2 goodness of fit was calculated using –2 × log(likelihood ratio).
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very good discriminatory power (c = 0.85 and 0.88 
respectively). For the time period of 3 months to 
1 year after LFTs the c-statistic is still acceptable 
for both outcomes, particularly all cause mortality. 
However, for the longer time period of 1 year to 15 
years after initial LFTs the discrimination is poor.
Predicting probabilities 
for specific cases
Predictions based on the patients’ characteristics 
were derived from the liver disease diagnosis 
prediction models over a specified time period. 
From the factors listed in Table 10 the only DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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FIGURE 14  Number of expected and observed liver mortality events at year 4 following LFTs.
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FIGURE 15  Number of expected and observed all cause mortality events in the 3 months following LFTs.
example LFT results for these patients were 70 U/l 
for ALT, 230 U/l for AP, 95 U/l for GGT, 25 µmol/l 
for bilirubin and 40 g/l for albumin. It can be 
seen from Figure 16 that living in a deprived area 
increases the probability of liver disease, especially 
if the patient is a methadone user. Females have a 
greater probability of liver disease diagnosis within 
3 months than males; e.g. a 25-year-old female 
methadone user living in a deprived area has a 
probability of 0.052, whereas a male with the same 
characteristics has a probability of 0.039. Fifty-
year-olds have a lower probability of liver disease 
than 25-year-olds across all equivalent factors 
– even non-methadone users living in affluent 
areas; i.e. for males with these characteristics these 
probabilities are 0.012 and 0.014 respectively. 
However, the 95% CIs overlap, so these differences 
are not statistically significant.
Liver disease within 1 year
The probability of liver disease diagnosis at 1 year 
can also be calculated using the model presented Results: development of predictive algorithms
40
TABLE 15  Calibration statistics using the Grønnesby–Borgan method for various time points of the final all cause mortality models
Time point from baseline Group χ2 df p-value
3 months Overall 40.49 9 < 0.001
1st decile 0.23 1 0.63
2nd decile 0.71 1 0.40
3rd decile 1.71 1 0.19
4th decile 5.65 1 0.02
5th decile 11.86 1 < 0.001
6th decile 16.36 1 < 0.001
7th decile 11.82 1 < 0.001
8th decile 8.06 1 0.005
9th decile 8.64 1 0.003
10th decile – – –
1 year Overall 24.03 9 0.004
1st decile 2.94 1 0.09
2nd decile 5.41 1 0.02
3rd decile 4.46 1 0.03
4th decile 3.83 1 0.05
5th decile 8.67 1 0.003
6th decile 15.64 1 < 0.001
7th decile 2.07 1 0.15
8th decile 8.18 1 0.004
9th decile 3.88 1 0.05
10th decile – – –
4 years Overall 33.06 9 < 0.001
1st decile 0.17 1 0.68
2nd decile 0.23 1 0.63
3rd decile 1.20 1 0.27
4th decile 3.97 1 0.05
5th decile 6.34 1 0.01
6th decile 2.20 1 0.14
7th decile 0.82 1 0.37
8th decile 0.00 1 0.99
9th decile 1.01 1 0.32
10th decile – – –
df, degrees of freedom.
χ2 goodness of fit was calculated using –2×log(likelihood ratio).
in Table 11. This model has some extra covariates 
to the one predicting for the first 3 months. These 
comprise history of gallbladder disorder (yes/no) 
and alcohol dependency (yes/no). Of the LFTs, 
bilirubin and AP were not included. A case example 
is a patient living in an area with a population 
mean Carstairs deprivation score (0.05) who is 
not a methadone user and does not have a history 
of gallbladder disorders. The LFT results of this 
patient were an ALT of 70 U/l (mildly elevated), a 
GGT of 200 µmol/l (mild, bordering on severely 
elevated) and a mildly lowered albumin of 30g/l. DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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FIGURE 16  Number of expected and observed all cause mortality events in the first year following LFTs.
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FIGURE 17  Number of expected and observed all cause mortality events at year 4 following LFTs.
Figure 19 shows the predicted probabilities of 
liver disease diagnosed at 1 year, broken down by 
gender, age (25/50) and alcohol dependency (yes/
no). The probability for an alcohol-dependent 
patient can clearly be seen to be much higher than 
for a non-alcohol-dependent patient. For example, 
the probability of liver disease for a female aged 
50 is doubled with alcohol dependency from 0.038 
(95% CI 0.023–0.063) to 0.074 (95% CI 0.038–
0.141). Also, females have higher risk than males 
over all combinations.
Discussion
This chapter provides the first predictive models 
for liver disease diagnosis and liver mortality 
using a large population data set. They have 
been successfully derived for short time periods 
following an initial batch of LFTs and for the 
more medium term. Models predicting all cause 
mortality following initial LFTs have also been 
derived. For the liver disease-associated models the 
validation was adequate, particularly for the shorter 
time periods.Results: development of predictive algorithms
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TABLE 16  Discrimination statistics using the overall c-statistic for each of the final models
Model outcome Time period c-statistic (95% CI)
Liver disease diagnosis 0–3 months 0.85 (0.76–0.91)
3 months–1 year 0.72 (0.62–0.81)
> 1 year 0.53 (0.48–0.58)
All cause mortality 0–3 months 0.88 (0.85–0.91)
3 months–1 year 0.82 (0.79–0.84)
> 1 year 0.56 (0.55–0.57)
Liver mortality 0–3 months 0.95 (0.66–1.00)
> 3 months 0.49 (0.40–0.59) 
FIGURE 18  Probability (95% CI) of liver disease diagnosis within 3 months after initial LFTs for hypothetical patients. LFT results for 
these patients were 70 U/l for alanine transaminase, 230 U/l for alkaline phosphatase, 95 U/l for gamma-glutamyltransferase, 25 µmol/l 
for bilirubin and 40 g/l for albumin.
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The models predicting events for the shorter time 
periods following initial liver function testing had 
much better discrimination than those modelling 
outcomes after 1 year. This makes statistical and 
clinical sense, as it would be unreasonable to 
expect one batch of LFTs to predict outcome for 
longer time periods from 1 year up to 15 years 
afterwards. The shorter-term models had overall 
c-statistics of 0.85 and 0.72 for outcome of liver 
disease at 3 months and 1 year respectively, and 
0.88 and 0.82 for all cause mortality at 3 months 
and 1 year respectively. This means that the 
probability that the model allocates a high risk 
to those who actually develop liver disease in 3 
months compared with those who do not is 0.85. 
In comparison, the Framingham equation had a 
discrimination of 0.79,38 and a model predicting 
risk of CHD in patients with type 2 diabetes 
reported a discrimination of 0.71.23
Although the Grønnesby–Borgan calibration 
statistics were close to borderline significance 
for the liver disease models (and significant for 
the 3-month model), the charts of predicted 
and observed events by quartile of risk looked 
reasonably close. The data sets were very large 
and so likely to show significance despite good 
calibration. The all cause mortality models DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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FIGURE 19  Probability (95% CI) of liver disease diagnosis within 1 year after initial LFTs for hypothetical patients. The fixed 
characteristics of these patients are: Carstairs score (0.05), not a methadone user, no history of gallbladder disorders, an alanine 
transaminase of 70 U/l (mildly elevated), a gamma-glutamyltransferase of 200 µmol/l (mild, bordering on severely elevated) and a mildly 
lowered albumin of 30g/l.
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had poor goodness of fit results even though 
graphically the 3-month and 1-year models 
appeared to show similar figures for expected 
and observed in each decile. The two extremes of 
the deciles of risk were similar in proportions of 
predicted and observed events. However, the model 
predicting mortality from 1 year after testing was 
not a good fit visually or statistically because of the 
large differences in numbers between predicted 
and observed. Of course, when calibration fails, the 
risk function can be recalibrated using information 
from a separate population.40 As this is the first-
ever predictive model for liver disease it would 
require a separate population to validate and 
possibly recalibrate it.
These models can now be used to estimate 
probabilities of outcomes occurring to patients 
visiting their GP for the first time with raised LFTs 
and no obvious liver disease, to better aid the GP’s 
decision-making process.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 6  
Decision analyses: systematic review of utilities
Introduction
Decision analysis is the formal process whereby 
the probabilities of outcome events, such as liver 
disease, are combined with patients’ preferences 
or values in assessing the optimal decision. The 
approach is most useful in informing clinical 
decisions where the optimal decision is not 
immediately apparent, and for making clinical 
reasoning explicit.41 Hence, these analyses will 
inform the management of patients with an ALFT, 
but who are otherwise well. The probabilities of 
outcomes are generally derived from regression 
analysis of cohort studies of large populations or 
from previous published results. The derivation of 
predictive algorithms from the Tayside population 
in the previous chapter provides robust estimates 
of these probabilities stratified by important 
confounders. For example, probability of liver 
disease rises with increasing transaminases, 
methadone dependency, alcohol dependence and 
deprivation.
In order to carry out decision analyses, health-
state utilities for various health states need to 
be determined. Utilities can be extracted from 
previously published work, but it is likely that 
this form of research is sparse in liver disease. A 
utility of 1 is taken to represent optimal health, 
while 0 represents death. Utilities are combined 
with length of time in a condition or state to give 
quality-adjusted life-years (QALYs), where QALY 
= quality of life multiplied by length of time 
in the state. For example, a commonly quoted 
utility for stroke is 0.75, meaning that 4 years of 
suffering from stroke has a QALY equal to 3 years. 
Alternatives to published results include panels 
of liver disease experts constructing values that 
appear to have face value. Ideally, utilities can be 
obtained directly from patients using quality of life 
utility measures such as the EuroQol 5 dimensions 
(EQ-5D). This instrument is easily used in 
questionnaires and each of the five dimensions has 
three levels, generating 243 theoretically possible 
health states covering mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. 
The prospective questionnaire for patients 
undergoing an LFT and patients undergoing liver 
biopsy provided utility data essential for the cost–
utility analysis in which the decision analysis aims 
to maximise expected utility. This questionnaire 
survey focused on the more serious investigations 
such as liver biopsy, as the utility of a single LFT 
such as bilirubin in an otherwise healthy patient 
is likely to be close to 1. However, prior to these, a 
systematic review of the literature was carried out 
to extract utilities.
Systematic review of 
health-state utilities
Health-state utilities represent an individual’s 
preferred value for specific health states relative 
to full health, whether they are patients suffering 
from the condition in question, physicians or the 
general public. Estimates of utilities for various 
health states in liver disease are essential to assess 
cost-effectiveness/cost–utility of the management 
of liver disease. The health-related quality of life 
of chronic liver disease patients has been shown 
by various studies to be worse than that of healthy 
individuals.42–45
Health-state utilities can be measured directly using 
methods such as the time-trade off (TTO) and the 
standard gamble (SG), and indirectly using health-
state classification systems such as EQ-5D, SF-6D 
and health utility index (HUI); they can also be 
estimated by health-care experts.46–50 Owing to the 
variation in utility assessment methods and states 
of disease, it is problematic to pool utility estimates 
from different studies. Methods of pooling include 
calculating the mean utility, stratifying by method 
and study population, and metaregression analysis. 
The last of these methods involves fitting a model 
with utility estimate as the outcome, adjusting for 
the various factors that influence the variation. 
This is superior to other methods as it allows us 
to assess the importance of these differences in 
study design. There is very little literature on meta-
analysis of utilities and, as far as we know, none on 
liver disease utilities.51–54
To derive estimates of health-state utilities for a 
decision analysis of the primary care management 
of patients with ALFTs without clinically apparent 
liver disease, we conducted a systematic review 
and metaregression of studies of health-state Decision analyses: systematic review of utilities
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utilities in chronic liver disease. We also looked at 
the variation between the study designs used to 
measure utilities, including the methods used and 
the various states of disease.
Methods
Study searching
We conducted a search of the MEDLINE database 
from 1966 to September 2006, including key words 
and subject heading related to liver disease(s) and 
utility measuring tools. EMBASE and CINAHL 
were also searched, as was as the Cochrane Library. 
A manual search was also performed by examining 
the reference sections from papers we found which 
were relevant. We asked three international liver 
experts with experience in quality of life studies 
if they knew of any unpublished studies which 
measured utility in liver disease patients. Two 
replied.
The key words and subject headings used to find 
studies in MEDLINE, EMBASE and CINAHL, 
which measured health-state utilities using Ovid 
(September 2006) were:
1.   Quality of life/
2.   Liver Diseases/
3.   Liver/
4.   hepatitis.mp
5.   cirrhosis.mp
6.   utility$.mp
7.   cost effective$.mp
8.   Euroqol.mp
9.   EQ-5D.mp
10.   EQ5D.mp
11.   SF-6D.mp
12.   SF6D.mp
13.   QWB.mp
14.   Health Utilit$Index.mp
15.   liver.mp
16.  2 or 3 or 4 or 5
17.  6 or 7
18.  1 and 16 and 17
19.  8 or 9 or 10 or 11 or 12 or 13 or 14
20.  15 and 19
21.  18 or 20
Study selection
All abstracts from the search were reviewed and 
the full text of any title or abstract which appeared 
to meet the inclusion criteria was retrieved. Any 
abstract that did not contain enough information 
to judge whether utilities were calculated were 
judged by a liver expert (JD) for exclusion or 
further investigation, i.e. retrieval of the full paper. 
The inclusion criteria were studies in English 
language journals of any design (i.e. case-control, 
randomised controlled trial, cohort, etc.) that have:
1.  measured utility using health-state utility tools 
from liver disease patients, physicians or adults 
with no liver disease, or
2.  estimated health-state utilities for various liver 
diseases by means of expert opinion.
Letters, comments, news articles and non-liver-
related studies were excluded. In addition, studies 
were excluded if they obtained utility estimates 
from the literature, if there was not enough 
information on the derivation of the utility, if 
utility values were not reported or if the same 
population’s utilities were published twice.
Validity assessment
Another reviewer assessed the full papers 
independently and any disagreements about study 
inclusion were resolved by discussion if consensus 
could not be achieved. A reference management 
system (Reference Manager) was used to identify 
and extract duplicate studies.
Study characteristics
Each article that met the inclusion criteria was 
reviewed by an investigator who abstracted 
the following information: year of study, study 
population from whom utility was estimated (and 
its size), country of study, liver disease or disease 
state, utility estimation method, estimated utilities 
and variability of utility measurements. Outcomes 
were mean utilities (with SE or SD and/or 95% CIs) 
or median utilities (with IQR) for each liver disease 
or disease state.
Quantitative data synthesis
If at least three studies presented utilities for 
similar disease states within a specific liver disease 
then they were included in the metaregression 
model.55,56 We fitted dummy variables in our 
model for utility tool used and disease state. The 
importance of each study was accounted for by 
weighting the model using the square of the SE. 
Where the SE was not published, we estimated 
it using other measures from the study, e.g. SD, 
sample size, CIs, etc., if possible. However, if any 
studies did not present data from which the SE 
could be calculated, or at least estimated, then they DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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were excluded. Disease state names varied by study, 
so we grouped those that were close enough to be 
classified as the same, e.g. we grouped Child’s A 
from Younossi et al.57 together with compensated 
cirrhosis. Approval was given to these groups of 
disease states by a liver expert (JD). A hierarchical 
model also allowed us to adjust our estimates for 
the random effects of utility within study. Akaike’s 
information criterion was used to judge the best 
model. Statistical analysis was conducted using 
Microsoft Excel and the SAS (version 8) software 
package.
Results
Search results
From the Ovid MEDLINE search, 79 studies 
satisfied the above search criteria. EMBASE 
identified 169 studies, and CINAHL found only 
three studies. Five further studies were obtained 
by manual searching, and after duplicates were 
removed this left 217 articles. Figure 20 contains 
a flow diagram of exclusions. After the exclusion/
inclusion criteria were applied, 30 studies were 
found to have measured utilities of liver diseases 
or disease states. The full list 50,57–85 is available 
as an appendix from the publication in Medical 
Decision Making (available at http://mdm.sagepub.
com/supplemental/).86 Table 17 lists all of the 
liver diseases and disease states for which utilities 
were found, and shows the number of studies by 
perspective and respondent type, and references 
the studies in which they appear. However, some 
of the studies had disease states which were unique 
to them, meaning that their utilities could not be 
grouped with utilities from other studies for the 
meta-analysis.
Qualitative summary
The details of the 30 studies included in the 
systematic review can be found at www.sagepub.
com/mdm. Of these studies, only one contained a 
TTO-estimated utility for hepatitis A virus (HAV) 
and this was estimated using a postal survey in 
non-HAV adults.58 Four studies estimated utilities 
for hepatitis B virus (HBV) (all by an expert 
FIGURE 20  Flow chart showing the exclusion path from the full search to the studies used in the meta-analysis.
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same population utility published 
twice (n = 2); did not measure utility 
(n = 2); utility not reported (n = 1); 
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panel). These four studies measured utility by 
the following groups – treatment,59 severity of 
symptoms60 and stage of disease.61,62 All four 
studies also used different tools, and only one 
had a large sample size (n = 128);60 the others 
had a sample size of between 4 and 7. Ten studies 
estimated utilities for hepatitis C virus (HCV) (six 
using patient respondents and four using expert 
panels).50,57,61,63–69 Eight of these studies grouped 
utilities into stages of disease such as compensated 
cirrhosis and decompensated cirrhosis. However, 
there were still some differences, e.g. one 
study broke compensated cirrhosis down into 
compensated with normal or near-normal ALT, 
compensated with elevated ALT, compensated 
under treatment and compensated previously 
treated.66
Two studies used up to four tools to estimate 
utilities for the same groups.63,66 The degree of 
variation between the utility values of the different 
methods varied within stages of disease. For 
example, for mild/moderate chronic HCV the 
utilities ranged from 0.70 to 0.79,63 while for liver 
biopsy in cirrhotic patients they ranged from 0.51 
to 0.83.66 These large ranges in utilities were due 
mainly to the use of different methods, SG, TTO 
and visual analogue scale (VAS), with utilities 
derived from the VAS method generally being 
the smallest and those from the TTO and SG 
methods being the largest. In the one HCV study 
which used SG and TTO, the estimates were very 
close for most of the disease states in comparison 
with the VAS estimates, which were much lower.66 
Similar disease states between studies had similar 
utilities for the same method used. For example, 
two studies reported compensated cirrhosis in 
HCV patients using the VAS as having utilities of 
0.65 and 0.66. Using the SG, the same two studies 
found utilities of 0.80 and 0.76.63,66 Five studies 
used an expert panel or physicians to estimate the 
utilities, and only one of these had a large sample 
size (n = 113); the others had an average sample 
size of 6).
Five studies measured utilities for cirrhotic patients 
or chronic liver disease patients.57,64,70–72 Of these, 
two also reported utilities for a subset of HCV 
patients (these were included in the above figures). 
Three studies used chronic liver disease patients 
to estimate utilities,57,64,71 one used an expert 
panel70 and one used both physicians and cirrhotic 
patients.72 Again, patients were grouped into 
various stages of disease between studies, and all 
five studies used different utility measuring tools. 
Three studies used populations of liver transplant 
patients to estimate utilities for both pre and post 
liver transplants73–75 and three estimated utilities 
for post liver transplant only.76–78 Three of these six 
studies found utilities for various time points after 
transplant73–75 and had the largest sample sizes 
(n > 180). One study grouped patients by number 
of transplant, Child–Pugh score and disease 
duration76 and another counted only transplants 
on children and categorised utility by age group 
(< 5 years and ≥ 5 years).78 Interestingly, with the 
exception of the last study, all used the EQ-5D 
method to estimate utilities. It should be noted 
that six of the studies that had an HCV population 
also measured utilities for liver transplantation. 
No studies were found to have estimated utilities 
for alcohol-related liver diseases, primary biliary 
cirrhosis, autoimmune hepatitis or fatty liver 
disease. In addition to the liver disorders for 
which utilities were published (Table 17), other 
liver disease groups for which utilities were 
estimated included patients with colorectal liver 
metastases,79 candidates for liver transplant80 and 
patients with cirrhosis in conjunction with other 
comorbidities.81 Psoriasis patients estimated utilities 
of ALFTs and biopsy,82 and patients with severe 
liver problems treated with a molecular adsorbent 
recirculating system (MARS) also estimated their 
utility.83 Utilities for various complications of liver 
disease were also estimated including hepatic 
encephalopathy, ascites and varices.57,72,84
Twenty-four of the 30 studies (http://mdm.
sagepub.com/supplemental/) were not included 
in the metaregression; 18 were excluded because 
for each disease state within liver disease groups 
there were fewer than three studies; four were 
excluded because they did not have enough data 
to estimate the SE;50,64,65,85 one study used a child 
population78 and one study did not calculate an 
overall EQ-5D value.71 Table 18 contains six studies, 
measuring 40 utilities for HCV states, which were 
included in the metaregression.57,63,66–69 Two of 
these studies used the same population for the 
utility estimates; however, each study published 
results obtained using different tools.67,68 Only HCV 
had enough studies and utilities to be considered 
for a metaregression analysis. The disease states 
included were moderate HCV, compensated 
cirrhosis, decompensated cirrhosis and post liver 
transplant. Where a study did not use the exact 
term ‘moderate HCV’, the closest state to it took 
its place, e.g. ‘mild/moderate HCV’ or ‘HCV with 
no cirrhosis’.57,63 Standard errors were estimated 
for seven utilities as detailed in Table 18. Two of 
the studies were conducted in the US and two in 
Germany, while the others were carried out in Decision analyses: systematic review of utilities
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TABLE 18  Characteristics of studies which have evaluated utilities in hepatitis C virus (HCV) states used in metaregression
Study Year Country n
Disease 
state
Mean utility 
(SE)
Utility 
tool Comments
Chong et al. 200363 2003 Canada 44 HCV 0.70 (0.03) VAS HCV state was 
mild/moderate 0.79 (0.04) SG
0.73 (0.05) HUI3
0.76 (0.04) EQ-5D
24 CC 0.65 (0.04) VAS
0.80 (0.05) SG
0.74 (0.05) HUI3
0.74 (0.05) EQ-5D
9 DC 0.57 (0.08) VAS
0.60 (0.12) SG
0.69 (0.08) HUI3
0.66 (0.10) EQ-5D
30 Post LT 0.65 (0.04) VAS
0.73 (0.06) SG
0.70 (0.04) HUI3
0.69 (0.04) EQ-5D
Sherman et al. 200466 2004 US 124 HCV 0.67 (0.03) VAS HCV state was 
liver biopsy – no 
cirrhosis
0.85 (0.04) TTO
0.81 (0.04) SG
29 CC 0.65 (0.04) VAS
0.90 (0.03) TTO
0.83 (0.04) SG
8 DC 0.66 (0.07) VAS
0.72 (0.12) TTO
0.72 (0.12) SG
10 Post LT 0.62 (0.06) VAS
0.81 (0.10) TTO
0.72 (0.10) SG
Siebert et al. 200167 and 200368 2003 Germany 77 HCV 0.92 (0.02) TVAS Used SE for TVAS 
for EQ-5D as none 
reported. EQ-5D 
values published 
in 2001 and TVAS 
published in 2003
2001 0.76 (0.02) EQ-5D
74 CC 0.89 (0.02) TVAS
0.74 (0.02) EQ-5D
37 DC 0.81 (0.03) TVAS
0.72 (0.03) EQ-5D
8 Post LT 0.86 (0.07) TVAS
0.79 (0.07) EQ-5D
Younossi et al. 200157 2001 US 27a HCV 0.84 (0.03) HUI2 HCV with no 
cirrhosis 14a CC 0.82 (0.04)
7a DC 0.71 (0.10)
Wright et al., 200669 2006 UK 71 HCV 0.66 (0.03) EQ-5D
CC, compensated cirrhosis; DC, decompensated cirrhosis; EQ-5D, EuroQol 5 dimensions; HCV, moderate chronic 
hepatitis C; HUI, health utility index; LT, liver transplant; SG, standard gamble; TTO, time trade-off; TVAS, SG-transformed 
visual analogue scale;46 VAS, visual analogue scale
a These sample sizes were estimated based on the proportions of HCV (no cirrhosis), CC and DC in the whole population 
for this study (n = 120), e.g. 30/120 (= 0.25) were CC in the whole population. Therefore, for the HCV group this was 
estimated as 0.25 × 54 = 13.5, which is rounded to 1. Standard errors were then estimated from the reported SD and the 
estimated sample sizes.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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the UK and Canada. The sample sizes per utility 
estimated ranged from 7 to 77.
Table 19 shows the number of each type of 
health-state utility tool (by perspective type, i.e. 
community or patient) used in all the studies shown 
in http://mdm.sagepub.com/supplemental/ and in 
those six used in the metaregression. The numbers 
are broken down further by the type of respondent. 
Seven different tools were used in studies included 
in the metaregression, the most frequently used 
being the VAS; this was used by nine of the 
studies identified in http://mdm.sagepub.com/
supplemental/ and two in the metaregression. Six 
studies used the TTO overall, with one included in 
the metaregression, while four studies used the SG, 
with two included in the metaregression. The most 
popular indirect method was the EQ-5D with 10 of 
the studies identified in http://mdm.sagepub.com/
supplemental/  (three used in the metaregression) 
utilising the tool. Eight of these studies used the 
UK tariff as the population norm and the other two 
used German and Canadian population norms.63,83 
The HUI versions 2 and 3 were the other two 
indirect methods used in the metaregression, and 
the TTO, SG and transformed VAS were the other 
direct methods. The transformed VAS is the SG-
transformed visual analogue scale, which converts 
VAS scores to SG utilities [u = 1 – (1–v)2.29].46  All of 
the direct utilities included in the metaregression 
were from patient respondents while all of the 
utilities from the classification systems were 
estimated from healthy subjects.
Quantitative summary
Twenty-three per cent of the utilities were 
measured using the EQ-5D method, 20% were 
estimated using the SG and 20% were estimated 
using the VAS. The results of the metaregression 
analysis are presented in Table 20. There was 
no significant difference between the utility of 
compensated cirrhosis in HCV compared with 
moderate HCV. However, decompensated cirrhosis 
in HCV had an estimated utility of 0.08 lower 
than that for moderate HCV (p < 0.001). Post liver 
transplant had an estimated utility of 0.04 lower 
than moderate HCV (p = 0.03). In comparison with 
the estimated utility using the EQ-5D assessment 
method, all except the VAS and the HUI3 had 
significantly higher utility scores. The highest 
utility was estimated from the transformed VAS, at 
0.15 higher than the EQ-5D (p < 0.001). The TTO 
was next highest, with a utility of 0.12 higher than 
the EQ-5D (p < 0.001). The usual VAS method 
had the lowest utility, at 0.07 less than the EQ-5D 
(p < 0.001). HUI3 was the only assessment method 
to differ significantly from the EQ-5D.
The reference group for this model was moderate 
HCV using the EQ-5D method, which had an 
estimated utility of 0.75 and is the intercept in Table 
20. To calculate the utility for any other disease 
state and method combination, the intercept is 
added to the corresponding parameter estimate. 
For example, the estimated pooled utility for 
decompensated cirrhosis in HCV using the 
TTO method is 0.79 (0.747 – 0.075 + 0.116). For 
compensated cirrhosis in HCV using the TTO, the 
estimate is 0.86 (0.747 + 0.001 + 0.116).
Another metaregression model was fitted as above 
but with country added. The only country to 
have utility estimates different from the reference 
country (the US) was the UK which lowered utility 
by 0.1 (p = 0.007). However, as only one utility 
in the model was estimated in the UK and the 
AIC was larger than in the previous model, we 
recommend that only the first model be considered 
robust.
Discussion
This chapter is a concise and thorough systematic 
review of the available literature on health-state 
utilities for liver disease. MEDLINE, EMBASE, 
CINAHL and the Cochrane database were all 
searched and various liver experts were written 
to, from whom we obtained negative responses 
regarding unpublished studies. As far as we know, 
this is the only systematic review of health-state 
utilities in liver disease estimated using utility-
based tools (direct and indirect). We have given an 
evaluation of the variety of studies and the utility 
estimates available to the researcher and decision-
makers in government and the pharmaceutical 
industry.
Our study has produced pooled mean health-state 
utility estimates for four liver disease states in HCV 
patients (moderate HCV, compensated cirrhosis, 
decompensated cirrhosis and post liver transplant). 
To the best of our knowledge, this has not been 
done before. All other disease states did not have 
enough utility estimates to be able to conduct a 
meta-analysis and several studies, particularly those 
where utility is estimated by an expert panel, did 
not report data which enabled us to calculate the 
variance of the utility estimate.62,74,84,85 Therefore, 
their estimates could not contribute to the pooling Decision analyses: systematic review of utilities
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TABLE 19  Number of each utility estimation method used in studies included in systematic review and for metaregression by 
respondent type
Perspective 
type
Utility estimation 
method
Respondent type
Number of 
studies Patients Experts
Non-liver disease 
adults
All Meta All Meta All Meta All Meta
Patient or 
communitya
VAS 9 2 7 2 1 0 1 0
TTO 6 1 3 1 2 0 2 0
SG 4 2 3 2 0 0 1 0
Average SG and TTOb 2 0 0 0 2 0 0 0
Judgementb 2 0 0 0 2 0 0 0
TVASc 1 1 1 1 0 0 0 0
Average VAS and 
TTOb
1 0 0 0 1 0 0 0
Unknown 1 0 0 0 1 0 0 0
Community EQ-5D 10 3 10 3 0 0 0 0
HUI2 2 1 2 1 0 0 0 0
HUI3 1 1 1 1 0 0 0 0
SF-6D 2 0 2 0 0 0 0 0
AQoL 1 0 0 0 1 0 0 0
AQoL, assessment of quality of life instrument;87 EQ-5D, EuroQol 5 dimensions; HUI, health utility index; Meta, 
metaregression; SF-6D, short-form questionnaire; SG, standard gamble; TTO, time trade-off; TVAS, transformed visual 
analogue scale; VAS, visual analogue scale.
a  Whether the method is from a patient or community perspective depends on the respondent type.
b  Study-estimated utilities using the Delphi technique.88
c  VAS transformed to SG using the Torrance transformation (u = 1–(1 – v)2.29).46
TABLE 20  Parameter estimates with standard error and p-value for predictors of utility for hepatitis C virus (HCV)
Variable Parameter SE p-value
Intercept 0.747 0.014 < 0.001
HCV state of disease
Moderate HCV 0
Compensated cirrhosis 0.001 0.014 0.956
Decompensated cirrhosis –0.075 0.017 < 0.001
Post liver transplant –0.038 0.017 0.027
Utility tool
EQ-5D 0
VAS –0.073 0.017 < 0.001
TVAS 0.152 0.020 < 0.001
TTO 0.116 0.023 < 0.001
SG 0.043 0.018 0.025
HUI2 0.076 0.024 0.004
HUI3 –0.006 0.022 0.774
EQ-5D, EuroQol 5 dimensions; HUI, health utility index; SG, standard gamble; TTO, time trade-off; TVAS, transformed 
visual analogue scale; VAS, visual analogue scale.
The reference group for this model is moderate HCV and the EQ-5D, and the estimated utility is the intercept parameter 
estimate, 0.747.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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of mean estimates. The most commonly used utility 
measuring tools were the VAS, EQ-5D, TTO and 
SG.
The main limitation of the studies included was the 
variation in health-state utility estimates due to the 
variety of tools used in each study, which prevented 
the meaningful pooling of other chronic liver 
disease states. This includes the variation between 
indirect89 and direct measures.47 As shown in Table 
19, no fewer than 13 different methods were 
used in all the studies identified in www.sagepub.
com/mdm, and seven were used in the six studies 
selected for meta-analysis. However, seven studies 
used more than one tool on their population, thus 
proving that choosing one ‘gold standard’ utility 
estimating method is not a simple task.63,66,73,76,79,80,82 
Various studies have compared different measures 
of utility, mainly the indirect methods such as 
EQ-5D, SF-6D and HUI, and all have reported 
differences in their estimates, with one study 
measuring utility of rheumatoid arthritis reporting 
values from 0.53 (HUI3) to 0.71 (HUI2).89–92 
The studies in this review have shown systematic 
differences in utility estimates for the same disease 
state using different methods, e.g. utility for 
hepatocellular carcinoma ranged from 0.51 (HUI) 
to 0.65 (EQ-5D) using indirect methods. Therefore, 
metaregression is the only statistically sound way of 
pooling these health-state utilities, as it allows us to 
adjust for the various differences between studies. 
Simply pooling mean utilities by finding the mean 
would not take into account the variation between 
study characteristics. The VAS is strictly not a utility 
measure as it does not have its roots in expected 
utility theory.63 However, it is similar to other utility 
measures and has some advantages, including 
its ease of use, which is probably why it has been 
the most popular.93 We found that the VAS had 
the lowest utility estimates of all the methods, 
with SG and TTO having much higher estimates. 
This is consistent with previous findings.46,51 
The researcher looking for utility estimates of 
liver disease must take into consideration the 
variation between the studies. This includes not 
only variation between the tool used but also the 
type of respondent (patient, health professionals, 
general public), type of perspective (community 
versus patient) and geographical and cultural 
differences. A researcher may decide to use only 
direct measures such as SG or TTO with stronger 
theoretical bases. However, these may not be 
available, and pooling of values from different 
instruments may be the only feasible approach.
In this review, healthy adults only took part in 
the HAV study and in a transplant study as a 
control group;58,77 however, experts and patients 
were involved in each of the other disease states. 
There is good evidence in the literature showing 
systematic differences between these groups, but 
it is not clear which of the groups is the most 
appropriate.57,63,72 Indeed, the study by Wells et 
al.72 shows that physicians’ estimates of utilities are 
significantly lower than those of the patients. It 
has been recommended that the general public’s 
preferences for health states associated with a 
disease should be used where available, and failing 
that, that patient-derived utilities should be used.94 
The formulae used to calculate the utility scores 
from indirect methods such as the EQ-5D, SF-6D 
and HUI are all based on preferences obtained 
from the general public. Therefore, when patients 
complete these classification systems, the utility 
relates to the preference of the community.95 Our 
systematic evaluation and metaregression analysis 
showed significant differences in the patient and 
community perspective methods. Standard gamble 
and TTO (patient perspective methods) estimated 
significantly higher utilities than did the EQ-5D, 
whereas HUI3 did not show a difference (although 
HUI2 did). When perspective type was added to 
the metaregression model, it did not fit because 
instrument type accounted for this already as 
each instrument is based on a perspective type. 
It is therefore recommended that the researcher 
chooses carefully those utility values from a 
population and method that suit their particular 
study.
In conclusion, this chapter has collated all known 
published or unpublished (as far as we know) 
utilities for various liver disease states (see www.
sagepub.com/mdm), and pooled utility estimates 
for four major states of disease for HCV patients 
using various utility assessment methods. Thus, a 
useful resource has been created for researchers 
and decision-makers in government and the 
pharmaceutical industry as well as for the decision 
modelling in this study, which ultimately will 
benefit liver disease patients, GPs, clinicians and 
the health service as a whole.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Chapter 7 
Decision analyses: utilities from the 
patient survey and expert panel
Introduction
In Chapter 6, a systematic review of health-state 
utilities for liver disease was presented along with 
a metaregression analysis of hepatitis C patient 
utilities. This chapter follows on by presenting 
methods and results of estimating those utilities 
which were not found in the review. These include 
surveying patients with ALFTs awaiting further 
investigation and patients awaiting biopsy. These 
patients were asked to complete several quality of 
life-based questionnaires on health-state utilities 
and anxiety. Furthermore, an expert panel of 
hepatologists and GPs completed surveys asking 
them to estimate their opinion of the utility values 
of various liver diseases and disease states. This 
chapter begins by reviewing the various utility 
estimation methods available, moves on to describe 
the details of how the patient and expert surveys 
were carried out and, finally, presents and discusses 
the results.
Methods
Many methods of measuring the quality of life of 
patients exist but these can be generally grouped 
into direct and indirect methods.41 These are 
described below.
Direct utility measuring methods
Time trade-off
The TTO method is intuitively appealing and 
reasonably easy to carry out. The patient or health 
professional is presented with a choice between two 
alternatives that both have a certain outcome. They 
are presented with choosing how many years they 
would be willing to give up in the healthier health 
state (usually completely well) compared with the 
less healthy state.
Standard gamble
The SG method is derived directly from decision 
theory. This also involves two alternatives, one of 
which is the health state to be rated. The gamble 
has two possible outcomes: the best health state, 
which occurs with probability p, and the worst state, 
which has probability 1 – p.
The probability is varied until the rater (patient 
or health professional) is indifferent between the 
alternatives, i.e. indifferent between the alternative 
that is certain and the gamble that might bring the 
best health state. Visual aids have been produced, 
but raters still have difficulty in conceptualising 
probabilities.
Visual analogue scale
Visual analogue scales allow the rater to mark 
directly on a scale their judgement of the utility 
for a particular health state. These may be interval 
scaled, or category scaled.
Indirect utility measuring 
methods
Scores derived from these quality of life measures 
have to be converted to a measure of utility 
through linkage with population preferences, and 
hence are indirect methods.
EuroQol 5 dimensions
The EQ-5D scale was developed in the 1980s as a 
measure of general health. The EQ-5D is a simple 
5-item questionnaire covering mobility, self-care, 
usual activities, pain/discomfort and anxiety/
depression. From this a single index of health 
status is derived in the range 0.0–1.0.
Short-form questionnaire (SF-6D)
This was derived from the SF-36, a 36-item 
questionnaire which seeks responses to questions 
on overall health, how well patients feel and how 
well they can perform their usual activities. Its 
advantage is that it is not preference based and so 
scores can be used directly in cost–utility analyses.
Clinical judgement
In this method a group of clinical experts are asked 
to assign utility values to a set of patient health 
states. These may be hospital specialists or primary 
care practitioners.Decision analyses: utilities from the patient survey and expert panel
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Anxiety measuring
In addition to measuring health-related quality of 
life, anxiety may be induced in the patient awaiting 
a definitive diagnosis or when contemplating an 
invasive procedure such as biopsy. Anxiety in both 
these scenarios was measured using a validated 
state–trait questionnaire.
Patient survey
Pilot study
Prior to the actual survey, a small sample of 19 
patients attending the outpatients liver clinic at 
Ninewells Hospital, Tayside were surveyed for 
their health-state utility and anxiety scores. Two 
indirect methods were chosen for the questionnaire 
because of their known differences in estimation 
(the EQ-5D with its ceiling effect and the SF-6D 
with its floor effect). The TTO method was chosen 
as the direct method. The state–trait anxiety 
questionnaire was also included. In addition, the 
EQ-5D form included the thermometer part (or 
VAS) and the section requesting some patient 
details – age, gender, whether they smoke(d), 
education and employment. The statements chosen 
for the TTO were adapted from those used to 
measure utilities of liver biopsy and liver function 
in psoriasis patients.82
The revised statements for the questionnaire 
booklet were as follows.
Awaiting liver biopsy
When you have a liver biopsy, the doctor uses a 
needle to remove a piece of your liver to check 
for damage. You receive calming and numbing 
medicine, but remain awake. The procedure 
takes about 15 minutes, the actual biopsy only 
a few seconds. For your safety you remain in 
the hospital 6 hours after the biopsy. Possible 
complications are rare (less than 1% of the 
time), but can be serious enough to require 
a longer hospital stay and further treatment. 
Internal bleeding may require transfusion or 
surgery. Some people have pain afterwards 
which may last from 4 hours to 4 days; you will 
be given medication to relieve the pain. Your 
lung may be hit by the needle and collapse. 
There is about 1 chance in 10,000 of dying of 
one of these complications.
With ALFT(s) waiting to be investigated
Liver enzymes are chemicals made by the liver. 
If your liver leaks extra enzymes into the blood, 
a blood test may show high enzyme levels. You 
would feel no different. High concentrations of 
liver enzymes suggest that you may have some 
liver damage, but they do not tell what the 
cause is or how bad if any the damage is. 
The patient was then asked to answer the following 
question after reading the appropriate statement 
above:
Imagine that you are living with this illness for 
12 months. Also, imagine that you can choose 
to live like this for 12 months, or that you can 
choose to give up some of the months of illness 
to live a shorter life but in full health. How 
many months of full health are of equal value 
to 12 months in the health state you have read?
The 19 patients were given the booklet by a 
gastroenterology research nurse and asked to 
complete it while they were waiting to see the 
consultant. The nurse assisted the patients 
with any queries or problems they had with the 
completion of the booklet. Prior to completing 
the questionnaire patients were given a patient 
information sheet (Appendix 10) and asked to sign 
a consent form. The patient’s GP was also sent a 
letter, informing them of their patient’s consent to 
participate, and a copy of the patient information 
sheet.
Afterwards, the patients were given a short 
feedback form asking them if they had any 
problems or suggestions on how to improve the 
questionnaire booklet. There were questions on 
clarity of the questions, repetitiveness, layout and 
time to complete. They were given space to provide 
detailed responses if they so desired. The feedback 
from the pilot study was very helpful and some 
was taken on board for the main survey. The most 
frequent comment was that many patients found 
the wording and appropriateness of the TTO 
question confusing, as many of them did not feel 
particularly ill and were not diagnosed with a liver 
disease. Some also commented to the nurse that it 
worried them. For these reasons, we decided that 
the TTO was not a suitable method for this type 
of patient. We felt that it was more appropriate for 
patients suffering from particular conditions than 
for those who did not feel unwell or did not know 
what was wrong with them. The fact that some were 
worried about the wording of the TTO question 
before going to see the consultant prompted a 
further change to the main survey booklet. It was 
decided to measure the patients’ anxiety scores DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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not only before seeing the specialist, but also 
afterwards, to examine whether there was a change 
in anxiety and, if so, in what direction.
The main study
From 31 October 2005 to 11 December 2006, 
outpatients attending the liver clinic at Ninewells 
Hospital were surveyed using the revised 
questionnaire booklet (Appendix 11). Towards 
the middle of the time period, only 24 patients 
awaiting liver biopsy were recruited. Therefore, 
it was decided to recruit more biopsy patients 
attending the liver clinic at Southampton General 
Hospital. This was led by Steve Ryder, the 
consultant gastroenterologist at the University of 
Southampton, and managed to survey an extra 
21 patients, giving a total of 45 awaiting liver 
biopsy. Tayside successfully surveyed 99 patients 
awaiting further investigation for their ALFTs. 
One patient failed to complete the SF-6D, three 
failed to complete the VAS and two patients did not 
fill in the state–trait anxiety questionnaire before 
consultation. Also, of those liver biopsy patients 
surveyed in Southampton, none completed the 
state–trait after seeing the specialist.
Statistical analysis
The categorical baseline characteristics of the liver 
biopsy patients from Tayside and Southampton 
were compared using Pearson’s chi-squared test 
(correcting for continuity in 2 × 2 tables), to check 
that they could be combined for the analysis 
of utility scores. The means of the continuous 
variables (age, EQ-5D, VAS, SF-6D and state–
trait) were compared using a t-test if they were 
normally distributed or a Mann–Whitney test if 
they were not. The characteristics and scores of the 
two groups of patients (abnormal liver function 
and liver biopsy patients) were then compared. 
Pearson’s or Spearman’s rank correlation method 
was used to examine the relationship between the 
survey results for each patient group.
Multivariate linear regression analysis was also 
conducted to determine which factors, if any, 
predicted each utility score. Statistical analysis 
was carried out using SPSS version 15 (SPSS Inc, 
Chicago, IL).
Expert panel survey
A selection of 18 GPs were emailed and invited 
to join an expert panel to estimate the utilities 
of various liver diseases and disease states. They 
were selected from a database of GPs belonging 
to the Scottish Primary Care Research Network 
(SPCRN) research group. Twelve UK hepatologists 
were also invited, so that the differences in 
opinion between GPs and liver experts could be 
assessed. The questionnaire was emailed as an 
attachment and consisted of a table containing 
30 liver diseases and disease states with space for 
the clinician to enter their estimate of the utility 
score for each, using their own judgement. Experts 
were also asked to give their confidence rating 
of their choice of utility on a scale from 1 to 5. A 
Delphi approach was taken, such that once the first 
round of questionnaires had been received, some 
basic descriptive statistics were calculated and the 
results and a second, similar, questionnaire were 
sent back to the experts. The results, combined 
with their own judgement, helped inform their 
decision for this second round, and allowed them 
to change it if they so wished. Of the 18 GPs and 12 
hepatologists, nine and 10 respectively replied with 
their estimates for the first round. Of these, eight 
GPs and nine hepatologists successfully completed 
the second and final round. It should be noted 
that GPs were also asked to estimate the utilities 
of patients with ALFTs awaiting investigation and 
patients awaiting liver biopsy for comparison with 
patients’ estimates.
Statistical analysis
For the first round of the Delphi process, the 
median and interquartile range of each of the 
utility estimates were calculated for each profession 
(GP and hepatologist), along with the mean 
confidence ratings. Histograms were also plotted 
for each utility estimate. The final questionnaire 
results were analysed and descriptive statistics were 
tabulated. The utility estimates for each round 
were compared for each profession using the 
Wilcoxon signed rank test. The Mann–Whitney test 
was used to compare utility estimates of GPs and 
hepatologists.
Results
Patient survey
The characteristics and utility scores of the patients 
awaiting biopsy from Tayside and Nottingham were 
compared to check that there were no differences 
in these populations, so that their results could be 
combined. The only significant difference found 
was the proportion of males and females (p = 0.04), 
with 29% males from Tayside and 62% males from 
Nottingham. Of the utility scores and anxiety 
measures, only state–trait scores before biopsy 
were significantly different (higher in Nottingham; 
p = 0.03 for state and p = 0.01 for trait). As the Decision analyses: utilities from the patient survey and expert panel
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utility scores were not significantly different 
between areas, it was decided to combine these for 
the liver biopsy group.
The characteristics of the two groups of patients 
are presented in Table 21. Comparison of the 
characteristics of patients with ALFTs and patients 
awaiting biopsy demonstrated that only having a 
degree was statistically significant (p = 0.02) using 
the Pearson’s chi-squared test. Forty-two per cent 
of patients with ALFTs had a degree compared 
with 22% of patients awaiting biopsy. Smoking 
status was almost significantly different between the 
two groups (p = 0.06; 15% of patients with ALFTs 
currently smoking and 27% of patients awaiting 
biopsy).
The comparisons of the two patient groups in 
terms of utility and anxiety scores are displayed in 
Table 22. The VAS score is significantly lower for 
the liver biopsy patients than for the ALFT patients 
(Figure 21). The state and trait parts of the state–
trait anxiety scores before the consultation with 
the specialist are both significantly higher for the 
biopsy patients, indicating more anxiety (Figure 22). 
Although the utilities are also lower for the biopsy 
patients and the state–trait scores after consultation 
are higher, they are not significantly so. Figure 
23 displays box plots of the EQ-5D and SF-6D 
estimated utilities by patient group. The state and 
trait sections of the anxiety measure before and 
after consultation were not significantly different 
for the biopsy patients (p = 0.08 and p = 0.41 for 
state and trait respectively, using the Wilcoxon 
signed rank test). However, they were significantly 
different for the ALFT patients (p = 0.001 and 
p = 0.04 for state and trait respectively), with lower 
anxiety after the consultation.
The EQ-5D and SF-6D utilities were highly 
correlated for ALFT patients (ρ = 0.82, p < 0.001) 
and biopsy patients (ρ = 0.75, p < 0.001). The 
state part of the anxiety questionnaire before 
consultation was highly correlated with its score 
after for both ALFT patients (ρ = 0.62, p = 0.001) 
and biopsy patients (ρ = 0.61, p < 0.001). The 
same result was found for the trait part (ρ = 0.96, 
p < 0.001 for ALFT patients; ρ = 0.88, p < 0.001 
and for liver biopsy patients).
TABLE 21  Sociodemographic comparison of patients awaiting further investigation following ALFTs and liver biopsy
Characteristic ALFT(s) (%) (n = 99) Pre liver biopsy (%) (n = 45)
Mean age (SE) 50.6 (1.5) 50.4 (1.7)
Gender (male) 38 (38) 20 (44)
Smoking status
Current 15 (15) 12 (27)
Ex-smoker 28 (28) 17 (38)
Never 56 (57) 16 (36)
Employment status
Employed 53 (54) 21 (47)
Retired 25 (25) 10 (22)
Housework 11 (11) 10 (22)
Student 3 (3) 0 (0)
Seeking 2 (2) 2 (4)
Other 4 (4) 2 (4)
Missing 1(1) (0)
Education
Further 54 (55) 30 (67)
Degree 42 (42) 10 (22)
Area
Tayside 99 (100) 24 (53)
Nottingham 0 (0) 21 (47)DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 22  Comparison of utilities and anxiety scores from patients with ALFTs and patients awaiting liver biopsy
Tool
ALFT(s) (%) (n = 99) Pre liver biopsy (%) (n = 45) Mann–
Whitney 
p-value n Mean (SE) Median (IQR) n Mean (SE) Median (IQR)
VAS 98 74.6 (1.8) 80.0 (60.0–90.0) 43 64.8 (3.0) 69.0 (50.0–79.0) 0.002
EQ-5D 99 0.79 (0.02) 0.80 (0.69–1.00) 45 0.73 (0.04) 0.80 (0.65–1.00) 0.55
SF-6D 99 0.75 (0.02) 0.80 (0.65–0.89) 44 0.72 (0.02) 0.68 (0.61–0.85) 0.16
State before 99 38.5 (1.4) 38.0 (26.0–48.0) 43 43.0 (1.5) 43.0 (36.0–46.0) 0.03
Trait before 99 37.6 (1.4) 37.0 (26.0–44.0) 43 41.9 (1.5) 44.0 (33.0–47.0) 0.009
State after 99 34.8 (1.4) 32.0 (23.0–41.0) 24 37.3 (2.3) 35.5 (29.0–48.8) 0.16
Trait after 99 36.7 (1.4) 34.0 (25.0–45.0) 24 38.5 (2.5) 37.5 (29.3–48.5) 0.35
EQ-5D, EuroQol 5 dimensions; IQR, interquartile range; SF-6D, short-form questionnaire; VAS, visual analogue scale.
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FIGURE 21  Box plots of the VAS estimates for ALFT patients and liver biopsy patients.
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FIGURE 23  Box plots of the EQ-5D and SF-6D utility scores for ALFT patients and liver biopsy patients.
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Expert panel
The results of the first round of the questionnaire 
analysis are presented in Table 23 for the 
hepatologists. This is the table that was sent to the 
experts for the second round of the Delphi process. 
The results for the GPs are presented in Table 24. 
The final utility estimates from the second round 
are presented in Table 25. There were no significant 
differences between utilities from each round 
for both expert groups. There were, however, 
differences in confidence ratings. For hepatologists, 
confidence increased significantly for the hepatitis 
E utility estimate from a median of 2 to 3 out 
of 5 (p = 0.02). For the utility of non-alcoholic 
steatohepatitis (NASH), confidence increased 
from a median of 2.5 to 3 (p = 0.046). There were 
no significant differences in confidence between 
rounds for the GPs.
In a comparison of expert panels, there were 
significantly higher utilities (better quality of life) 
assigned by hepatologists compared with GPs 
for compensated cirrhosis, post liver transplant, 
primary biliary cirrhosis (PBC) and autoimmune 
hepatitis. On the other hand, GPs rated the 
following with higher utilities than hepatologists: 
alcoholic hepatitis, drug reaction causing jaundice 
and gallstones in common bile duct causing 
jaundice (see Table 25). There was a difference 
in confidence ratings between GPs (median = 2) 
and hepatologists (median = 3) for shock liver 
(p = 0.02).
Summary
This chapter reported the results of the patient 
survey and expert panel regarding utilities. In 
general, patients awaiting biopsy were significantly 
more anxious than those with ALFTs awaiting a 
diagnosis, but post clinic there was little difference 
between the two groups.
In terms of utility, there was also no significant 
difference between those awaiting diagnosis 
following ALFTs and those awaiting biopsy with 
mean (SE) 0.79 (0.02) and mean (SE) 0.73 (0.04) 
respectively based on EQ-5D. However, VAS 
scores for biopsy patients were significantly lower. 
Hepatologists gave estimates of utility similar to 
those of GPs, with the exception of some conditions 
with which they were more familiar. These values 
fill in a number of the gaps in the literature and 
provide estimates to model the decision process in 
primary care as outlined in Chapter 8.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 23  Round one results of hepatologist-estimated utilities
Liver disease/state Median IQR
Mean confidence 
rating
Hepatitis A – acute stage 0.7 0.5–0.8 3.44
Hepatitis B – acute stage 0.5 0.45–0.8 3.44
Hepatitis B – chronic active stage 0.7 0.6–0.8 3.78
Hepatitis B – carrier stage 0.9 0.9–1.0 4.22
Hepatitis C – chronic stage 0.7 0.65–0.8 3.56
Hepatitis D 0.6 0.45–0.85 2.78
Hepatitis E 0.6 0.5–0.9 2.67
Compensated cirrhosis in CLD 0.8 0.65–0.8 3.89
Decompensated cirrhosis in CLD 0.2 0.2–0.4 3.67
Alcoholic liver disease/fatty liver 0.8 0.8–0.85 3.78
Alcoholic hepatitis 0.3 0.3–0.4 3.89
Alcoholic cirrhosis 0.5 0.45–0.6 3.11
NASH 0.8 0.7–0.85 3.63
NAFLD 0.9 0.9–0.925 4.00
PBC 0.8 0.6–0.8 3.44
Idiopathic cirrhosis 0.6 0.55–0.7 3.33
Autoimmune hepatitis 0.7 0.5–0.8 3.33
Haemochromatosis 0.7 0.6–0.85 3.22
Alpha-1-antitrypsin 0.8 0.5–0.9 2.89
Metastatic cancer 0.1 0.1–0.2 4.00
Liver cancer – hepatocellular carcinoma 0.3 0.1–0.45 3.56
Ascites 0.4 0.3–0.4 3.89
Varices 0.4 0.35–0.55 3.33
Encephalopathy 0.2 0.2–0.35 4.00
Pre liver transplant (end-stage liver disease) 0.2 0.2–0.25 4.33
Post liver transplant 0.8 0.75–0.8 3.78
Shock liver 0.2 0.1–0.3 3.00
Drug reaction causing jaundice 0.6 0.5–0.65 3.22
Pancreatic cancer 0.2 0.1–0.25 3.78
Gallstones in common bile duct causing jaundice 0.5 0.45–0.6 3.44
CLD, chronic liver disease; IQR, interquartile range; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic 
steatohepatitis; PBC, primary biliary cirrhosis.Decision analyses: utilities from the patient survey and expert panel
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TABLE 24  Round one results of GP-estimated utilities
Liver disease/state Median IQR
Mean confidence 
rating
ALFTs with possible further investigation 0.90 0.80–0.91 3.50
Awaiting liver biopsy 0.80 0.70–0.80 3.10
Hepatitis A – acute stage 0.60 0.50–0.70 3.20
Hepatitis B – acute stage 0.50 0.48–0.63 3.00
Hepatitis B – chronic active stage 0.70 0.55–0.73 3.10
Hepatitis B – carrier stage 0.85 0.75–0.90 3.50
Hepatitis C – chronic stage 0.60 0.50–0.70 3.10
Hepatitis D 0.70 0.58–0.83 1.50
Hepatitis E 0.75 0.58–0.90 1.60
Compensated cirrhosis in CLD 0.60 0.40–0.66 3.10
Decompensated cirrhosis in CLD 0.25 0.18–0.31 3.40
Alcoholic liver disease/fatty liver 0.70 0.40–0.76 3.50
Alcoholic hepatitis 0.40 0.35–0.70 3.30
Alcoholic cirrhosis 0.45 0.20–0.73 3.40
NASH 0.80 0.65–0.90 2.60
NAFLD 0.80 0.65–0.90 3.22
PBC 0.60 0.40–0.73 3.30
Idiopathic cirrhosis 0.50 0.48–0.73 2.40
Autoimmune hepatitis 0.55 0.48–0.71 2.60
Haemochromatosis 0.60 0.58–0.83 3.30
Alpha-1-antitrypsin 0.60 0.40–0.80 2.10
Metastatic cancer 0.20 0.10–0.23 4.50
Liver cancer – hepatocellular carcinoma 0.25 0.10–0.43 3.90
Ascites 0.40 0.28–0.43 3.40
Varices 0.40 0.30–0.40 3.20
Encephalopathy 0.20 0.18–0.30 3.90
Pre liver transplant (end-stage liver disease) 0.20 0.10–0.30 3.80
Post liver transplant 0.60 0.48–0.70 3.00
Shock liver 0.40 0.25–0.45 1.56
Drug reaction causing jaundice 0.70 0.70–0.90 3.20
Pancreatic cancer 0.20 0.10–0.33 4.10
Gallstones in common bile duct causing 
jaundice
0.60 0.48–0.80 3.30
CLD, chronic liver disease; IQR, interquartile range; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic 
steatohepatitis; PBC, primary biliary cirrhosis.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 25  Comparison of GP- and hepatologist (H)-estimated utilities of liver and liver-related diseases with mean confidence rating
Condition
Expert
Mean SE Median (IQR)
Mann–
Whitney 
p-value
Mean 
confidence 
rating
H (n = 8)
GP (n = 9)
Hepatitis A – acute stage H 0.675 0.042 0.70 (0.55–0.78) 0.54 3.75
GP 0.633 0.041 0.60 (0.50–0.75) 3.67
Hepatitis B – acute stage H 0.575 0.031 0.55 (0.50–0.68) 0.42 3.63
GP 0.533 0.029 0.50 (0.50–0.60) 3.56
Hepatitis B – chronic active stage H 0.688 0.040 0.70 (0.60–0.80) 0.37 3.63
GP 0.644 0.024 0.70 (0.60–0.70) 3.44
Hepatitis B – carrier stage H 0.888 0.013 0.90 (0.90–0.90) 0.06 4.25
GP 0.822 0.022 0.80 (0.80–0.90) 3.56
Hepatitis C – chronic stage H 0.713 0.035 0.70 (0.63–0.78) 0.74 3.75
GP 0.689 0.039 0.70 (0.60–0.75) 3.56
Hepatitis D H 0.600 0.042 0.55 (0.50–0.70) 0.20 2.75
GP 0.678 0.032 0.70 (0.60–0.75) 2.33
Hepatitis E H 0.638 0.032 0.70 (0.53–0.70) 0.32 3.25
GP 0.700 0.041 0.70 (0.60–0.80) 2.33
Compensated cirrhosis in CLD H 0.738 0.046 0.80 (0.63–0.80) 0.03 4.25
GP 0.572 0.045 0.60 (0.45–0.68) 3.44
Decompensated cirrhosis in CLD H 0.325 0.053 0.30 (0.20–0.45) 0.28 4.13
GP 0.233 0.024 0.20 (0.20–0.30) 3.44
Alcoholic liver disease/fatty liver H 0.800 0.027 0.80 (0.73–0.88) 0.09 3.75
GP 0.667 0.060 0.70 (0.55–0.80) 3.22
Alcoholic hepatitis H 0.313 0.030 0.30 (0.30–0.30) 0.01 4.00
GP 0.444 0.038 0.40 (0.40–0.50) 3.33
Alcoholic cirrhosis H 0.600 0.050 0.60 (0.50–0.75) 0.06 3.50
GP 0.450 0.041 0.50 (0.30–0.50) 3.44
NASH H 0.775 0.016 0.80 (0.73–0.80) 0.96 4.00
GP 0.750 0.053 0.80 (0.60–0.85) 3.33
NAFLD H 0.900 0.000 0.90 (0.90–0.90) 0.06 4.00
GP 0.794 0.044 0.80 (0.75–0.90) 3.44
PBC H 0.725 0.045 0.75 (0.63–0.80) 0.05 3.63
GP 0.600 0.033 0.60 (0.55–0.70) 3.56
Idiopathic cirrhosis H 0.700 0.033 0.70 (0.60–0.80) 0.17 3.38
GP 0.622 0.036 0.60 (0.50–0.70) 3.00
Autoimmune hepatitis H 0.700 0.033 0.70 (0.60–0.80) 0.02 3.38
GP 0.567 0.029 0.50 (0.50–0.65) 2.89
Haemochromatosis H 0.738 0.038 0.75 (0.63–0.80) 0.54 3.50
GP 0.706 0.034 0.70 (0.65–0.75) 3.44
Alpha-1-antitrypsin H 0.713 0.058 0.80 (0.60–0.80) 0.20 3.00
GP 0.622 0.046 0.70 (0.50–0.70) 2.89
Metastatic cancer H 0.188 0.030 0.20 (0.10–0.28) 0.89 4.25
GP 0.200 0.044 0.20 (0.10–0.25) 4.33
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Condition
Expert
Mean SE Median (IQR)
Mann–
Whitney 
p-value
Mean 
confidence 
rating
H (n = 8)
GP (n = 9)
Hepatocellular carcinoma H 0.325 0.056 0.30 (0.20–0.50) 0.20 3.75
GP 0.222 0.032 0.20 (0.15–0.30) 4.00
Ascites H 0.375 0.025 0.40 (0.30–0.40) 0.37 3.88
GP 0.333 0.024 0.30 (0.30–0.40) 3.33
Varices H 0.475 0.070 0.40 (0.30–0.68) 0.61 3.75
GP 0.378 0.028 0.40 (0.35–0.40) 3.22
Encephalopathy H 0.275 0.056 0.20 (0.20–0.38) 0.20 3.50
GP 0.178 0.022 0.20 (0.10–0.20) 3.67
Pre liver transplant (end-stage 
liver disease)
H 0.275 0.025 0.30 (0.20–0.30) 0.24 3.88
GP 0.222 0.032 0.20 (0.15–0.30) 3.67
Post liver transplant H 0.763 0.038 0.80 (0.80–0.80) 0.02 3.50
GP 0.606 0.046 0.60 (0.60–0.68) 3.56
Shock liver H 0.325 0.065 0.30 (0.20–0.53) 0.89 3.25
GP 0.300 0.029 0.30 (0.20–0.40) 2.00
Drug reaction causing 
jaundice
H 0.550 0.027 0.50 (0.50–0.60) 0.002 3.00
GP 0.744 0.034 0.80 (0.65–0.80) 4.00
Pancreatic cancer H 0.175 0.025 0.20 (0.10–0.20) 0.96 4.13
GP 0.189 0.039 0.10 (0.10–0.30) 4.00
Gallstones in common bile 
duct causing jaundice
H 0.525 0.037 0.50 (0.43–0.60) 0.04 3.50
GP 0.656 0.050 0.70 (0.60–0.75) 4.00
CLD, chronic liver disease; IQR, interquartile range; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic 
steatohepatitis; PBC, primary biliary cirrhosis.
Significant results in bold.
TABLE 25  Comparison of GP- and hepatologist (H)-estimated utilities of liver and liver-related diseases with mean confidence 
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Chapter 8  
Decision analyses: cost–utility of 
referral for liver disease diagnosis
Introduction
As well as modelling the probability of liver disease 
diagnosis from initial batch of LFTs in primary 
care, it is also important to model the cost–utility 
of various decision pathways that a GP may follow 
in order to diagnose a liver disorder. This will 
determine the pathway that will maximise utility 
while minimising costs. The difference between 
cost-effectiveness and cost–utility is that cost-
effectiveness is the difference in the decision costs 
divided by the difference in years of life saved, 
while cost–utility is the difference in the decision 
costs divided by the QALYs. As, in this analysis, we 
concentrate on the time to the event of liver disease 
diagnosis over a 1-year time horizon (i.e. death is a 
censoring event), it is more appropriate to use cost–
utility analysis because the time horizon is short 
for each decision. Some studies have modelled 
the cost-effectiveness of hepatitis C therapy84,96–98 
and there are some studies of the cost-effectiveness 
of therapies for other liver diseases, including 
hepatitis B62 and variceal bleeding.70 These studies 
use Markov model methods to model hypothetical 
cohorts of patients with liver disease on different 
treatments to find the most cost-effective therapy 
throughout the remainder of their lives and hence 
have a long time horizon. However, no studies exist 
that have modelled the cost–utility of different GP 
decisions from initial LFTs in primary care to liver 
disease diagnosis.
The transition probabilities from one decision to 
the next are almost always taken from the literature 
for all cost-effectiveness studies as a result of the 
difficulty of obtaining a population large enough to 
calculate probabilities. Utility values of liver disease 
or awaiting a diagnosis are also required to adjust 
for the quality of life of the patients. Many studies 
also obtain these from the literature. An exception 
is Wright et al.,69 who surveyed hepatitis C patients 
as part of a hepatitis C randomised controlled trial 
for an economic evaluation of antiviral therapy 
for the disease. Our study has the benefit of direct 
measures of utility (see Chapter 7) and probabilities 
from a large population. Initially, we model cost–
utility of decision making for all patients with an 
ALFT. Secondly, we model cost–utility for those 
with the highest risk of liver disease (top percentile) 
based on the prediction algorithm described in 
Chapter 5.
Methods
A decision tree was used to model the cost–utility 
of GP decisions when a patient presents with no 
obvious liver disease and following a batch of LFTs 
with one or more ALFTs. The time horizon for the 
decision tree is 1 year, with an NHS perspective 
and the outcome modelled is liver disease 
diagnosis or not. The transition probabilities, 
health-state utilities and costs associated with the 
various pathways in the model and how they were 
calculated or estimated are described below.
Decision tree
A decision tree is a structure that models the 
pathway of a patient after a decision has been 
made at the root node (start of the tree) that 
in turn affects the treatment or investigations 
that the patient undergoes. From the root node 
there are two or more decisions which are taken. 
At the end of each decision there are further 
branches emanating which end at chance nodes. 
These branches are the outcomes of any tests or 
procedures that are followed on the way to the 
terminal node, which is the event of interest. Each 
branch (or action) from each chance node must 
therefore have a probability of occurring from 
the last chance node. These are called transition 
probabilities and are generally found from 
literature searches68,85 or through a combination 
of expert opinion and the literature.62,84 In our 
study, we estimated probabilities directly from 
the population cohort. The terminal nodes are 
assigned values related to the outcome measure. 
For example, the values could be crude life 
expectancy or quality-adjusted life expectancy.99 
Often however, it is important to evaluate the 
optimal pathway of different treatments or 
procedures to minimise the cost while also 
maximising effectiveness. This is called a cost-
effectiveness analysis and is a method commonly 
used by health economists and policy researchers. Decision analyses: cost–utility of referral for liver disease diagnosis
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Effectiveness is often measured using years of life 
saved, but often the QALYs are used, these being 
the health-state utility value associated with the 
particular health state multiplied by the length of 
time in that state summed over all of the health 
states. This analysis is generally called cost–utility 
analysis.
The decision tree used in this study does not 
follow a patient having an initial batch of LFTs 
until death. This would involve a Markov model, 
which involves yearly (or monthly) cycles where 
each patient spends his or her time in a particular 
health state, which can change at each cycle, 
until death. In this study, we concentrated on the 
cost–utility of the decisions a GP has to make after 
a patient has initially ALFTs until a diagnosis is 
made. Figure 24 displays the decision tree designed 
for this analysis. The model was built with help 
from experts in primary care (FS), hepatology (JD, 
SR), biostatistics (PTD) and public health (PR). The 
numbers and probabilities displayed in Figure 24 
are based on the whole population after multiple 
imputation had been utilised. Consequently, 
estimates of probabilities are adjusted to reduce 
selection bias, which is inevitable in observational 
data. The root node has patients with abnormal 
tests and there are three decisions a GP can make 
at this stage. These are to retest, refer to secondary 
care or do nothing. From the retest decision chance 
node, there are two possible pathways if the LFTs 
are normal or at least one is abnormal. If they are 
abnormal then they can be referred to secondary 
care where a diagnosis can be made (terminal 
nodes t1 and t2), or not referred within the year. 
For the latter case the terminal node would be 
undiagnosed liver disease (t3) or no undiagnosed 
liver disease (t4). If the retest is normal then it is 
assumed that they are not referred in that year and 
so their terminal nodes are of undiagnosed liver 
disease (t5) or no undiagnosed liver disease (t6). If 
the decision is taken to refer with no retests then 
the terminal nodes are liver disease (t7) and no 
liver disease (t8). If the GP decides to do nothing 
then the terminal nodes are taken as undiagnosed 
liver disease (t9) and no liver disease (t10).
t1 
t2 
t3 
t4 
Liver disease 
74 
No liver disease 
742 
Liver disease 
unknown 
No liver disease 
unknown 
t7 
t8 
t9 
t10 
Liver disease 
113 
No liver disease 
3836 
Liver disease 
unknown 
No liver disease 
unknown 
t5 
t6 
Liver disease 
unknown 
No liver disease 
unknown 
Refer 
816 
Retest 
3843 
Refer 
3949 
Donating 
9444 
Patients with abnormal LFTs 
n = 17,236 
Normal 
1311 
Abnormal 
2532 
0.66
0.32
0.68
0.09
0.91
0.34
0.03
0.97
Do not refer 
1716 
 
FIGURE 24  Decision tree structure with known numbers and probabilities of patients at each node from the Tayside historical cohort. 
Note: The terminal branches with ‘Liver disease unknown’ and ‘No liver disease unknown’ do not have probabilities assigned to them. 
These must be estimated and a sensitivity analysis must be performed for each.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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The transition probabilities at each branch from 
the chance nodes are generally presented below 
each branch and should sum to 1 for each node. 
The costs and QALY values can be presented at the 
end of the terminal nodes, although these are not 
presented in Figure 24.
Transition probabilities
The probabilities at each of the branches 
emanating from the chance nodes of the tree must 
be calculated or estimated. Most of these were 
estimated from the study cohort. The biochemistry 
database contains all LFTs for the patients in this 
cohort, so it is possible to look at the retests and 
see whether these were taken in primary care (in 
which case the ‘retest’ decision arm would be taken) 
or secondary care (in which case the ‘refer’ decision 
arm would be taken). If no LFTs were taken again 
after 1 year then the patients would be in the ‘do 
nothing’ decision arm of the tree. The numbers of 
patients allocated to each arm were found in this 
way and are presented in Figure 24. For example, 
3843 patients out of the 17,236 with ALFTs were 
retested within 1 year. The numbers of patients 
with abnormal or normal retests can then be added 
in the next pair of branches for the ‘retest’ decision 
arm. From this the probability can be calculated 
simply by dividing the number of patients with 
abnormal (or normal) retests by the number 
retested. It can be seen from Figure 24 that 66% 
of patients retested in primary care had abnormal 
results, so the probability is 0.66. By subtraction 
from 1, the probability of normal retests is 0.34. 
The next stage is to look at the third LFT batches 
to determine whether those patients with two 
ALFT batches were retested in secondary care 
within the year (i.e. referred). From the decision 
tree the probability of referral is 0.32. From these 
branches there is one more chance node leading 
to the terminal nodes of liver disease or no liver 
disease. The ELDIT database was used to find 
which of these patients were diagnosed within the 
year and which liver diseases were diagnosed. Of 
those patients retested in primary care and then 
referred, 9% were diagnosed with a liver disease 
within the year (this is the t1 branch). This meant 
that 91% were not diagnosed with liver disease. 
However, it should be noted that they could have 
been diagnosed with some other condition or could 
have died.
Where the GP decided to refer the patient to 
secondary care with no retest, 0.03 or 3% were 
diagnosed with liver disease within the year as 
registered in ELDIT (this is the t7 branch). Those 
patients who were retested with abnormal results 
and then not referred, those who were retested 
with normal results and those for whom the GP did 
nothing within the year all led to terminal nodes 
of undiagnosed liver disease and no undiagnosed 
liver disease. As these patients were not referred or 
retested again within the year it was not possible to 
estimate their probability of liver disease because 
it could be undiagnosed liver disease or no liver 
disease. Therefore, using the probabilities for the 
terminal branches that are already known, these 
undiagnosed probabilities were estimated using 
clinical judgement. The probabilities for these 
events will vary for each, as some patients have 
more severe results than others. For example, 
those patients with an abnormal retest who were 
not referred within the year would have a higher 
probability of liver disease than those who had 
normal retests. However, it would be assumed 
that they would still have a lower probability than 
those with abnormal retests who were referred 
(probability of liver disease = 0.09). Therefore for 
this group it was decided to allocate a probability 
of liver disease of 0.06. For the group of patients 
with normal retests it was decided to allocate a base 
probability of 0.02. This was the overall probability 
of liver disease diagnosis in the whole population. 
The patients who had no further investigations 
within the year were assigned a probability of 
0.05. A sensitivity analysis was performed on these 
probabilities to examine the change if any in cost–
utility.
Costs of tests and procedures
The various tests and procedures involved in the 
investigation of a patient to test for liver problems 
in general practice and secondary care were listed 
and validated by an expert hepatologist (JD). The 
costs of each of these were obtained from different 
sources and these are listed in Table 26. The cost 
of a GP consultation was obtained from the Unit 
Costs of Health and Social Care 2006 report of the 
Personal Social Services Research Unit (PSSRU).100 
This cost was £25 per surgery consultation lasting 
10 minutes and included direct care staff costs and 
qualification costs. The same cost was obtained 
via email communication with the Healthcare 
Information Group, Information Services Division 
(ISD), who have access to the Scottish NHS 
costs book. The cost of taking the blood sample 
in primary care was also accounted for. It was 
assumed that a general practice nurse (including 
qualifications) took the sample, and this cost was 
found to be £9 per procedure from the PSSRU 
Unit Costs of Health and Social Care report. Costs Decision analyses: cost–utility of referral for liver disease diagnosis
68
of analysing the blood for LFT results were taken 
from Appendix 14 of an HTA report investigating 
the economics of hepatitis B treatment (the 
source was collaboration with hepatologists and 
specialist nurses at Southampton General Hospital 
Trust),101 and from the Department of Biochemical 
Medicine at Ninewells Hospital, Dundee. The 
difference in cost between the two sources was 
only 47p, with Ninewells being the cheapest. 
From the biochemistry data set it was possible 
to find the average number of LFT retests per 
patient in primary care to reflect the reality that 
it is unlikely that every patient will have only the 
one retest in primary care before being referred 
to secondary care. The costs of the remaining 
investigations were obtained from the Shepherd et 
al. HTA report.101 These procedures were hepatitis 
B surface antigen tests, hepatitis C tests, antibody 
tests including antismooth muscle, antinuclear 
and antimitochondrial, an ultrasound scan of 
the liver and liver biopsy. The numbers of HBV, 
HCV and antibody tests were available for every 
patient in the population cohort from the ELDIT 
databases of virology and immunology laboratory 
results. The average number of these tests taken 
TABLE 26  Unit costs of items associated with liver disease diagnosis from first LFTs in primary care (by source)
Test/procedure Cost (£)a Cost (£)b Cost (£)c Cost (£)d
GP consultation 25 25
Nurse (GP) per procedure (qualified) 9
LFTs (per batch) 4.12 3.65  
HBV (virology) 11.80
HCV (virology) 12.80
Autoantibodies (immunology) 3.57
Ultrasound scan of liver 119.57 52.36
Daycase for liver biopsy, including:
FBC 2.49
INR 2.70
LFT 4.12
Blood group 3.79
Ultrasound-guided biopsy 141.31
Liver biopsy costs in pathology 176.60
Clerking in patient (30 minutes, Grade D nurse) 6.49
Ward time for recovery 20.28
Total for biopsy 388.05
FBC, full blood count; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalisation ratio.
a  PSSRU Unit Costs of Health and Social Care 2006; www.pssru.ac.uk.100
b  Costs published in HTA report, obtained from clinical guidelines and through discussion between hepatologists/specialist 
nurses at Southampton General Hospital Trust.101
c  Ninewells Hospital biochemistry department, Tayside.
d  Scottish NHS costs book from Information Services Division, Edinburgh.
per patient during the year were used in the costs 
analysis (i.e. it was not simply assumed that each 
patient had one test each). Liver biopsies were also 
available from the ELDIT pathology data set and 
the average number per patient were also taken 
for the costs analysis. Ultrasound was the only test 
for which actual data were not available for the 
patients. However, a hepatologist (JD) assumed 
that every referral would automatically have an 
ultrasound and therefore this assumption was 
taken.
Health-state utilities
Health-state utilities have been discussed and 
estimated in detail in Chapter 7. The life-years 
spent in each health state of a decision model 
needs to be weighted by the quality of life of 
patients in that state. As the decision analysis 
model in this study occurs over only 1 year, the 
actual utility value itself can be used rather than 
multiplying it by the years spent in each health 
state to calculate QALYs, as in most studies. 
However, in this model, the patient moves through 
various health states over the year. For example, DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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consider the pathway in Figure 26 leading to 
terminal node t1. The average time in days per 
patient spent in each health state from initial LFTs 
to retests to referral to liver disease diagnosis (via 
biopsy if taken) is shown in Figure 25 (also shown 
is time to a non-disease diagnosis t2). The health-
state utilities differ for each of these health states 
and they are represented in the diagram as U1 
(for patients with ALFTs), U2 (for patients waiting 
for biopsy) and U3 (for patients with a diagnosis 
of liver disease till the end of the year). The 
overall utility for a patient in this cohort would be 
calculated by multiplying the days spent in each 
state by its respective utility. An adjustment has 
to be made to take account of those biopsied and 
those not biopsied. For example, the overall utility 
for a patient in this group was calculated as:
Utilityt1 = [102 × U1 + 84 × U1 + 
(80 × U2 + 99 × U3) × Bt1/Nt1 + 179 × U3 ×  
(Nt1 – Bt1)/Nt1]/365
where Bt1 is the number of patients having a biopsy 
arm, and Nt1 is the number of patients in this arm 
of the tree.
In this study Bt1 is 34 patients and Nt1 is 74. The 
utility values used for each of the three utilities 
mentioned above were taken from the systematic 
review in Chapter 6 and the patient survey of 
utility in Chapter 7. The values taken were 0.79 
for ALFT patients, 0.73 for patients waiting liver 
biopsy and 0.67 for patients with diagnosed liver 
disease. This third utility was the value for Child’s 
B chronic liver disease from the study by Younossi 
et al.57 The utility value for the event of no liver 
disease was estimated as a weighted average of 
well patients and patients with other disease. 
Therefore, an overall value of 0.8 was estimated 
for this outcome. The other utility values for the 
days with the terminal node events of undiagnosed 
liver disease and no undiagnosed liver disease 
were estimated by clinical experts. Some of these 
undiagnosed events were assumed to have varying 
utility values by decision arm since patients had 
normal LFT retests in one pathway while others 
had ALFT retests resulting in varying severity 
and thus utility of disease. For example, the utility 
value for the event of undiagnosed liver disease 
after an abnormal retest in primary care with no 
referral was estimated as 0.79, the same as that for 
patients with ALFTs awaiting further investigation. 
The same value was assigned to the alternative 
event of no undiagnosed liver disease. For patients 
with a normal retest in primary care the utility 
of undiagnosed liver disease was estimated as 
FIGURE 25  Diagram displaying average time in days between events to assist in utility calculation for the year. (a) Retested in primary 
care then referred; (b) referred from initial LFTs in primary care.Decision analyses: cost–utility of referral for liver disease diagnosis
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0.85, better than those with abnormal retests. 
The utility for no undiagnosed liver disease in 
this arm was estimated as 0.95 as most would be 
assumed to be well. The overall utilities at each 
terminal node for each pathway are presented in 
Table 27. The utilities of patients who do not have 
further investigations were allocated a utility for 
undiagnosed liver disease of 0.67 and 0.90 for the 
alternative. Sensitivity analyses will be performed 
on these estimated utilities.
Cost–utility analysis
The decision tree model was used to estimate the 
patients’ QALY and health-care costs for each of 
the three decisions that a GP can make which may 
or may not lead to a diagnosis of liver disease. 
These decisions were compared using cost–utility 
analysis. The incremental cost–utility ratio (ICUR) 
was calculated, which compared the difference in 
each pair of decision costs divided by the difference 
in QALY. This is the same as measuring the extra 
costs needed for each additional unit of health 
gained for a more expensive but possibly more 
effective decision strategy. The cost–utility ratio is 
presented as cost in pounds per QALY saved.
Sensitivity analyses
Uncertainty in the parameters of a decision analysis 
model and how this uncertainty influences the 
results needs to be estimated. A one-way sensitivity 
analysis was performed on several variables, 
including the probabilities of undiagnosed disease 
and estimated utilities. This involves reanalysing 
the cost–utility using a range of values for these 
parameters. Two-way sensitivity analysis was also 
performed on those parameters which influenced 
the results of the one-way analysis. This examined 
the change in cost–utility by varying the values of 
two parameters at once.
Results
Table 28 summarises the costs for each pathway 
of the decision tree. Tables 29 and 30 give more 
detail for retesting in primary care and referral 
to secondary care pathways. The base-case values 
of the parameters and the range used in those 
involved in the sensitivity analysis are presented 
in Table 27. Table 31 shows the results of the base-
case cost–utility analysis of the decision strategies 
available to a GP for patients with initially ALFTs 
without apparent liver disease. It is clear that the 
decision of doing nothing with these patients has 
the greatest cost–utility as it dominates the other 
two decision choices in both cost and utility, with 
average total cost of zero and a QALY of 0.89. The 
decision with the next-greatest cost–utility was 
to retest in primary care with an average cost of 
£91.44 and a QALY of 0.83. Referral was £42.52 
more expensive than retesting on average and had 
a lower QALY of 0.79. The cost–utility relationship 
for the three strategies is plotted in Figure 26. The 
optimal decision is that closest to the bottom right-
hand corner, i.e. the decision with the lowest cost 
and highest utility is ‘do nothing’.
The sensitivity of the probability of undiagnosed 
liver disease in these patients with no further 
investigations was analysed to see what value would 
change the optimal decision in terms of cost–utility. 
It was never possible to dislodge the ‘do nothing’ 
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TABLE 27  Baseline values of parameters for each pathway and range for sensitivity analysis
Variable Baseline Range
Probability
ALFT after retest 0.66
Referral after abnormal retest 0.32
Liver disease after abnormal retest and referral 0.09 0.09–0.20
Liver disease after abnormal retest and no referral 0.06 0–0.20
Liver disease after normal retest 0.02 0–0.20
Liver disease after referral 0.03 0–0.10
Liver disease after no further investigation 0.05 0–0.40
Utility
Abnormal retest, referral, liver disease 0.74 0.5–0.9
Abnormal retest, referral, no liver disease 0.79 0.5–0.9
Abnormal retest, no referral, liver disease 0.79 0.5–0.9
Abnormal retest, no referral, no liver disease 0.79 0.5–0.9
Normal retest, liver disease 0.83 0.5–0.9
Normal retest, no liver disease 0.91 0.70–0.95
Referral, liver disease 0.70 0.5–0.9
Referral, no liver disease 0.80 0.5–0.9
Do nothing, liver disease 0.67 0.5–0.9
Do nothing, no liver disease 0.90 0.5–0.9
Cost (£)
Abnormal retest, referral, liver disease 459 350–650
Abnormal retest, referral, no liver disease 200 150–400
Abnormal retest, no referral, liver disease 61 40–90
Abnormal retest, no referral, no liver disease 61 40–90
Normal retest, liver disease 50 30–80
Normal retest, no liver disease 50 30–80
Referral, liver disease 265 150–450
Referral, no liver disease 130 50–350
Do nothing, liver disease 0
Do nothing, no liver disease 0
decision as regards cost–utility because the cost was 
always zero. However, with regard to utility only, 
it was possible. The one-way sensitivity analysis 
showed that the probability of undiagnosed liver 
disease in this group would have to be at least 0.32 
before the retest option had better utility (Figure 
27). The ICUR of retest became £41,247 per QALY, 
meaning that the extra cost to increase one unit of 
QALY would have to be £41,247. However, as the 
probability increased, the ICUR decreased quite 
steeply. For example, when the probability became 
0.38 the ICUR was £5709 per QALY. Furthermore, 
these probabilities of undiagnosed liver disease 
occurring in the ‘do nothing’ group are extremely 
high and unlikely. From canvassing GP opinion, it 
was felt that the ‘do nothing’ option was difficult to 
defend ethically. Also, as this option is not the best 
decision clinically for a GP to make if the patient 
is ill, it was decided to conduct further analyses 
excluding this as a possible decision.
Table 32 shows the results of the baseline cost–utility 
analysis of the decision strategies available to a GP 
for patients with initially ALFTs excluding the ‘do 
nothing’ choice. As expected from the previous 
analysis, retesting dominates the alternative Decision analyses: cost–utility of referral for liver disease diagnosis
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TABLE 28  Costs from first LFTs in primary care by different decision pathways
Pathway Mean cost per patient (£)
Retest in primary care Abnormal result; refer See Table 29
Abnormal result; no referral 38.12a  × 1.6b = 60.99
Normal result 38.12a x 1.31c = 49.94
Refer from primary care See Table 30
Do nothing 0
a  Cost of an LFT in primary care, i.e. £25 (GP consultation) + £9 (nurse to take blood) + £4.12 (LFT sample) = £38.12.
b  Mean number of LFT batch retests per patient in those with an abnormal retest and no referral.
c  Mean number of LFT batch retests per patient in those with normal retest.
strategy of referring with the same average costs 
and QALYs as before. Figure 28 shows the final 
decision tree model with its baseline parameter 
values.
Sensitivity analyses
The one-way sensitivity analysis of the probabilities 
(see Table 27) was performed for the values in the 
specified ranges. All values within the ranges of 
all the probabilities did not affect the cost–utility 
ratio, i.e. retesting still dominated referral. The 
results of some of the one-way sensitivity analyses 
are reported in Table 33. All parameters not shown 
in Table 33 are absent because the cost–utility ratio 
for referral was dominated by retesting for all 
sensitivity values. All of utility values entered into 
the one-way sensitivity analysis that were anywhere 
close to the baseline value retained the ICUR 
of referral dominated by retesting. One slight 
exception was the utility value for the referral with 
no liver disease pathway which caused the ICUR 
for referral to be dominated by retesting only until 
the value of 0.82. At a utility of 0.84, the ICUR was 
£5757 per QALY; however, this decreased to a value 
of £648 per QALY at a utility of 0.90. The only 
costing that had an effect on the ICUR was that for 
the same pathway – referral with no liver disease. 
At a costing of £100 the ICUR was still dominated 
by retesting, but at £75 referral overtook retesting 
TABLE 29  Total costs of tests and procedures carried out from referral to secondary care for patients retested abnormal in primary care
Test/procedure
No liver disease within 1 year (n = 742) Liver disease within 1 year (n = 74)
No. of 
patients
No. of 
tests
Total cost 
(£)
Mean cost 
per patient 
(£)
No. of 
patients
No. of 
tests
Total 
cost (£)
Mean cost 
per patient 
(£)
LFT retest in 
secondary carea
742 742 3057.04 4.12 74 74 304.88 4.12
HBV (BsAg) 173 214 2525.20 3.40 53 77 908.60 12.28
HCV 125 149 1907.20 2.57 51 68 870.40 11.76
ANA 149 206 735.42 0.99 42 57 203.49 2.75
AMA 125 159 567.63 0.77 45 62 221.34 2.99
ASMA 124 155 553.35 0.75 43 57 203.49 2.75
Ultrasound scan of 
liverb
742 742 88,720.94 119.57 74 74 8848.18 119.57
Biopsy 10 12 4656.60 6.28 34 46 17,850.30 241.22
Total 102,723.38 138.45 29,410.68 397.44
AMA, antimitochondrial antibody; ANA, antinuclear antibody; ASMA, anti-smooth muscle antibody; BsAg, hepatitis B 
surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus.
a  Assuming one batch of LFTs taken in secondary care.
b  Assuming every patient had one ultrasound (data not available).
A mean cost of £61.18 per patient was added to each cohort to account for repeated LFTs in primary care before referral. 
The cost of a batch of LFTs taken in primary care is £38.12, and the average number of retests was 1.605 per patient. 
Therefore, 38.12 × 1.605 = 61.18.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 31  Baseline cost–utility results (costs per quality-adjusted life year)
Strategy Total costa Total utilitya
Incremental 
cost
Incremental 
utility
Incremental 
cost–utility ratio
Do nothing 0 0.852
Retest in primary care 91.44 0.829 91.44 –0.023 Dominatedb
Refer from primary care 133.96 0.795 133.96 –0.057 Dominatedb
a  Cost and utility are per patient.
b  Dominated means that this decision is more expensive and lower utility than the ‘do nothing’ strategy.
as the best option, with an ICUR of £312 per 
QALY. However, the cost of a referral with its 
investigations is likely to be higher.
A two-way sensitivity analysis was performed on 
these two parameters of cost and utility for the 
pathway of referral with no resulting liver disease 
diagnosis, to look at where retesting has the best 
ICUR and where referral has the best ICUR. Figure 
29 contains four plots of the net benefit adjusted 
for various amounts of willingness to pay (WTP). 
Net benefit measures the increase in utility of one 
decision over another. Willingness to pay is, of 
course, demonstrated from an NHS perspective. 
At smaller WTP amounts, referral is the most cost-
effective choice for the lowest costs in the range 
and for any utility value of referral with resulting 
liver disease diagnosis. As the WTP increases, i.e. 
£5000/QALY, the referral option is more cost-
effective for any cost with utilities in the range 
0.85–0.9 for the referral with resulting liver disease 
diagnosis pathway. However, retesting is more 
cost-effective for all other combinations of cost 
and utility of referral with resulting liver disease 
diagnosis.
High-risk patients
The decision analysis was repeated, but only for 
those in the top percentile (100th) of liver disease 
diagnosis risk. As shown in Chapter 5, a Weibull 
regression model was fitted to derive probabilities 
of liver disease within 1 year of the first LFTs 
in primary care. The model was adjusted for 
significant covariates and interactions, similar 
TABLE 30  Total costs of tests and procedures carried out from referral to secondary care for patients referred after initial LFTs in 
primary care
Test/procedure
No liver disease within 1 year (n = 3836) Liver disease within 1 year (n = 113)
No. of 
patients
No. of 
tests
Total 
cost(£)
Mean cost 
per patient 
(£)
No. of 
patients
No. of 
tests
Total 
cost(£)
Mean cost 
per patient 
(£)
LFT retest in 
secondary carea
3836 3836 15,804.32 4.12 113 113 465.56 4.12
HBV (BsAg) 289 324 3823.20 1.00 53 68 802.40 7.10
HCV 166 170 2176.00 0.57 41 54 691.20 6.12
ANA 291 372 1328.04 0.35 35 60 214.20 1.90
AMA 166 178 635.46 0.17 37 48 171.36 1.52
ASMA 165 177 631.89 0.16 36 47 167.79 1.48
Ultrasound scan of 
liverb
3836 3836 458,670.52 119.57 113 113 13,511.41 119.57
Biopsy 33 39 15,133.95 3.95 29 36 13,969.80 123.63
TOTAL 498,203.38 129.89 29,993.72 265.44
AMA, antimitochondrial antibody; ANA, antinuclear antibody; ASMA, anti-smooth muscle antibody; BsAg, hepatitis B 
surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus.
a  Assuming one batch of LFTs taken in secondary care.
b  Assuming every patient had one ultrasound (data not available).Decision analyses: cost–utility of referral for liver disease diagnosis
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TABLE 32  Baseline cost–utility results without the ‘do nothing’ strategy (costs per quality-adjusted life year)
Strategy Total cost (£)a Total utilitya
Incremental cost 
(£)
Incremental 
utility
Incremental 
cost–utility ratio
Retest in primary 
care
91.40 0.829
Refer from primary 
care
134.00 0.795 42.50 –0.034 Dominatedb
a  Cost and utility are per patient.
b  Dominated means that this decision is more expensive and less effective than the alternative strategy.
0.0 0.1 0.4 0.3 0.2
Probability of undiagnosed liver disease
in ‘do nothing’ group
0.02
0.00
–0.02
–0.04
–0.06
–0.08
–0.10
–0.12
I
n
c
r
e
m
e
n
t
a
l
 
e
f
f
e
c
t
i
v
e
n
e
s
s
Retest
Refer
Do nothing
FIGURE 27  Incremental utility (QALY) adjusted for sensitivity of the probability of undiagnosed liver disease in the ‘do nothing’ strategy.
to those included in the models predicting liver 
disease within 3 months and from 3 months 
to 1 year (see Tables 10 and 11). The predicted 
probabilities were ranked, the top percentile was 
extracted and a separate cost–utility analysis was 
performed in this subgroup.
Out of this cohort of patients (n = 791), 290 
patients were retested within 1 year. The probability 
of an abnormal retest is 0.84. The probability of a 
referral for these patients with an abnormal retest 
is 0.59. Of those patients retested in primary care 
and then referred, 24% were diagnosed with a liver 
disease within the year. Of the 791 patients, 322 
were referred instead of retested by the GP, and 
for these the probability of liver disease was 0.13. 
This meant that 179 patients were not followed 
up within the year. The average time in days per 
patient spent in each health state from initial LFTs 
to retests to referral to liver disease diagnosis (via 
biopsy if taken) is shown in Figure 30 (also shown 
is time to a non-disease diagnosis). The utility 
estimates used in this high-risk cohort for patients 
who had ALFTs awaiting further investigation and 
patients awaiting biopsy were obtained from the 
patient survey results in Table 22. Instead of the 
mean EQ-5D values, the 25th percentile EQ-5D 
values were used. The utility value taken for liver 
disease for the average-risk patients was the value 
for Child’s B chronic liver disease (0.67) from the 
study by Younossi et al.57 However, the estimate for 
this highest risk cohort was calculated by pooling 
the utilities for decompensated cirrhosis from 
various studies.57,72,80 Decompensated cirrhosis 
utility was used as it is assumed that these patients 
are more ill than those with ALFTs. The utilities 
were weighted by the variance and calculated 
using a random-effects model. Owing to the small 
number of utilities it was impossible to adjust 
these models for factors such as utility tool used. 
The resulting pooled utility was estimated as 0.63 
(95% CI 0.53–0.74). All other utility values for the 
decision analysis were slightly lowered to represent 
the morbidity of the cohort of patients. They were DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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FIGURE 28  Decision tree model. Note: c1–c8 are the costs per pathway; Prob1–Prob4 are the probabilities of liver disease diagnosis; 
u1–u8 are the utilities per pathway; # = 1 – Prob.
lowered by multiplying the utilities for average-
risk patients by 0.94. This value was obtained by 
dividing the utility for liver disease used in the 
average-risk patients (0.67) by the utility used for 
high-risk patients (0.63). Table 34 displays all the 
baseline values of the parameters and the ranges 
used for the sensitivity analyses.
Results
The calculations of costs for each pathway of the 
decision tree and the mean cost per patient are 
presented in Tables 35–37. Table 38 shows the results 
of the baseline cost–utility analysis of the decision 
strategies available to a GP for patients in the top 
percentile of liver disease risk. As before, only the 
GP decisions of retest or refer are included in this 
analysis. Whereas before, retesting dominated the 
alternative strategy of referring, for these high-risk 
patients, neither dominated the other. Referral 
was less costly than retesting (by £11.20); retesting 
had a higher average utility, but by a small margin 
(0.001). As a result, the ICUR was £7588/QALY, 
meaning that to increase one QALY would cost 
£7588, by retesting. The cost and effectiveness 
relationship is plotted in Figure 31. The line 
connecting the two strategies means that neither is 
dominant over the other. Figure 32 shows the final 
decision tree model for this cohort.
Sensitivity analyses
The results of the one-way sensitivity analysis of 
the probabilities listed in Table 34 are presented 
in Table 39. For the sensitivity of probabilities, 
referral was less costly than retesting for most 
of the ranges, although retesting had a higher 
average. The probability of liver disease following Decision analyses: cost–utility of referral for liver disease diagnosis
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TABLE 33  One-way sensitivity analysis results of retest vs referral
Variable Baseline value Value
ICUR (£/QALY) for 
referrala
ICUR (£/QALY) for 
retestb
Utility
Abnormal retest, referral, no 
liver disease
0.79 0.5 1901
0.56 3922
0.60 13,483
0.62 Dominatedc
Abnormal retest, no referral, no 
liver disease
0.79 0.50 483
0.60 928
0.70 11,667
0.72 Dominatedc
Normal retest, no liver disease 0.91 0.70 1251
0.75 2455
0.80 64,223
0.8125 Dominatedc
Referral, no liver disease 0.80 0.82 Dominatedc
0.84 5757
0.86 1587
0.90 648
Cost (£)
Referral, no liver disease 130 50 1019
75 312
100 Dominatedc
a  This column is the incremental cost–utility ratio (ICUR) of referral.
b  This column is the ICUR of retest.
c  Dominated means that referral is more expensive and less effective than retesting.
an abnormal retest and referral was 0.24 at 
baseline. At a value of 0.15, retesting actually 
dominated referral; however, for probability 
values of 0.17–0.27, neither dominated (although 
referral was less costly, meaning that ICURs 
existed for retesting and ranged from £102 per 
QALY to £56,383 per QALY) and from 0.29, 
referral dominated retesting. For probabilities of 
liver diseases following abnormal retests and no 
referral, the ICUR did not change from baseline 
value. For probabilities of liver disease following 
normal retests, referral was cheaper than retesting 
(and dominated from a value of 0.18 onwards). 
However, for probabilities near the baseline, the 
ICUR for retesting was reasonably cost-effective. 
Referral dominated retesting for the range 0.05–
0.11 for the probability of liver disease following 
referral; however, at a value of 0.20, retesting 
dominated. For all the utility ranges, referral was 
the cheaper option and dominated retesting for 
most values less than the baseline. The costing for 
the pathway of abnormal retests, referral and liver 
disease diagnosis had a baseline value of £512. At 
a costing of £350–£400, referral was dominated 
by retesting; however, from £425–£700, referral 
was less costly, and the ICUR for retesting ranged 
from £478 to £20,728 per QALY. The baseline cost 
for the pathway of abnormal retests, referral and 
no liver disease diagnosed was estimated at £204 
per patient. At a cost of £150, retesting dominated 
referral; however, for all other costings in the range 
of £175–£400, referral was less costly, and the 
ICUR for retesting ranged from £137 to £57,848 
per QALY. Referral was cheaper for all the other 
ranges of the costs of the other pathways, apart 
from the upper end of the ranges for the costs of 
referral with liver disease (£430–£500) and referral 
with no liver disease (£175–£350) when retesting 
was dominant over referral.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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FIGURE 29  Two-way sensitivity of cost and utility of referral with resulting liver disease diagnosis. (a) Willingness to pay (WTP) = 
£100/QALY; (b) WTP = £500/QALY; (c) WTP = £5000/QALY; (d) WTP = £25,000/QALY.
A two-way sensitivity analysis was performed on the 
two parameters of cost for the pathway of referral 
with no resulting liver disease diagnosis and the 
probability of liver disease following referral. This 
was because the cost for this particular pathway 
changed to retesting being dominant over referral 
very close to the baseline cost at which referral was 
less costly. The probability of liver disease following 
referral should be accurate as it is based on actual 
observed data; however, at a probability of 0.20, 
retesting dominates referral and so is also close to 
the baseline probability of 0.13. Figure 33 contains 
three plots of the net monetary benefit adjusted for 
various amounts of WTP. At smaller WTP amounts, 
the referral option has the acceptable ICUR for the 
lowest costs in the range and for any probability 
of referral with liver disease diagnosis between 
0.05 and 0.20 (Figure 33a). The baseline cost and 
probability are marked in the chart, and for this 
particular WTP they are within the referral strategy. 
As the WTP increases, i.e. £5000/QALY, the referral 
option is most cost-effective for low to mid costs 
and lower probabilities, and low costs and high 
probabilities (Figure 33b). At a high WTP of £25000/
QALY, the referral option is cost-effective for low to 
high costs with low probabilities; however, retesting 
is better for mid to high probabilities at any cost 
and for low probabilities and high costs (Figure 
33c). The baseline values for this WTP chart are 
clearly in the retesting strategy this time.
Discussion
The cost–utility analysis showed that retesting 
a patient’s LFTs in primary care following an 
abnormal batch of LFTs with no obvious liver 
disease was dominant over referring the patient Decision analyses: cost–utility of referral for liver disease diagnosis
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straight away. The average total cost for retesting 
was £91 with a utility of 0.83, while for referral 
these figures were £134 and 0.79 respectively. 
However, the two-way sensitivity analysis showed 
that if the WTP of the health service is high 
enough then the referral option may be optimal. 
For example, if the WTP is £5000/QALY and the 
cost of the referral pathway terminating in liver 
disease diagnosis is the baseline cost of £130 and 
the utility is 0.05 QALYs higher than the baseline 
of 0.80, then the best strategy is to refer (see Figure 
29c). Even at a WTP of £1000/QALY with the same 
baseline cost and a utility of 0.88, to refer is the 
optimal decision. A WTP any lower than £1000/
QALY would favour retesting for the baseline cost 
and any utility. The issue of the WTP level to use 
in decision making is controversial. In the US, the 
maximum cost–utility ratio considered acceptable 
is $50,000/QALY (approximately £25,000),102 while 
bodies such as the National Institute for Health 
and Clinical Excellence (NICE) and Scottish 
Medicines Consortium (SMC) have an upper limit 
of £20,000–£30,000 per QALY, below which is 
considered acceptable cost-effectiveness.
Some of the assumptions in this cost–utility analysis 
are that only one batch of LFTs was analysed 
before referral to secondary care, that everyone 
referred had an ultrasound and that no other 
tests (not included in the costs) were performed as 
regards liver screening in primary care. However, 
the sensitivity analysis of costs should deal with 
this appropriately by adjusting the baseline value 
for a specified range. As mentioned above, the 
only factor affecting the dominance of the retest 
strategy is the WTP of the health service. As these 
patients are being screened for liver disease and 
at that point not diagnosed suggests that perhaps 
the health service WTP might not be as high as 
the £25,000 (in the range of just acceptable for 
new treatments), especially if they are relatively 
well patients. The probabilities of undiagnosed 
liver disease were difficult to estimate, but using 
the probabilities of liver disease after referral, a 
reasonable baseline value was taken. The range of 
values used in the sensitivity analyses was also quite 
wide and did not affect the ICUR dominance of 
retesting.
For those patients belonging in the top percentile 
of liver disease risk, however, the cost–utility results 
differed. Retesting was slightly more expensive 
but had a marginally higher QALY, resulting 
in an ICER of £7588 per QALY. The sensitivity 
analysis mainly showed referral as the cheapest 
strategy and retesting as the most effective. For 
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many parameters, referral dominated one end of 
the range but retesting was the most cost-effective 
option on the other side of the baseline value. 
Therefore, it is difficult to establish which is the 
most cost-effective strategy based on the sensitivity 
analysis. The ICERs for retesting were relatively 
low in comparison with the NICE threshold of 
£20,000–£30,000 per QALY. However, it is unclear 
whether this cut-off would apply to patients with 
no clinically obvious liver disease. Retesting would 
prevent increased anxiety which could occur if 
patients were referred needlessly (i.e. they could 
have retested normal). A weakness of this analysis 
is the use of ‘averaged’ or pooled values of utilities 
for decompensated cirrhosis from the literature 
review (see Chapter 7) for the top percentile of 
risk, when a number of different instruments were 
used. The ideal would have been an estimate of a 
representative sample using SG or another direct 
measure, but this was not available for the decision 
tree. The sensitivity analysis suggests that this was 
not critical to the results, as referral dominated for 
most scenarios.
This is the first cost–utility analysis to look at 
diagnosis of liver disease from initial LFTs in 
primary care. The strengths are that actual 
retrospective data were used to calculate 
probabilities of abnormal/normal retests, of referral 
and of liver disease in those referred. Utilities of 
patients with ALFTs awaiting further investigation 
and of patients awaiting biopsy were also estimated 
by survey at the liver outpatient clinic at Ninewells 
Hospital and also at Nottingham Hospital. Costs 
TABLE 34  Baseline values of parameters and the range for sensitivity analysis for patients in 100th percentile of liver disease risk
Variable Baseline Range
Probability
ALFT after retest 0.84
Referral after abnormal retest 0.59
Liver disease after abnormal retest and referral 0.24 0.15–0.35
Liver disease after abnormal retest and no referral 0.16 0.05–0.25
Liver disease after normal retest 0.05 0–0.20
Liver disease after referral 0.13 0.05–0.20
Utility
Abnormal retest, referral, liver disease 0.65 0.5–0.9
Abnormal retest, referral, no liver disease 0.73 0.5–0.9
Abnormal retest, no referral, liver disease 0.69 0.5–0.9
Abnormal retest, no referral, no liver disease 0.69 0.5–0.9
Normal retest, liver disease 0.79 0.5–0.9
Normal retest, no liver disease 0.87 0.70–0.95
Referral, liver disease 0.64 0.5–0.9
Referral, no liver disease 0.74 0.5–0.9
Cost (£)
Abnormal retest, referral, liver disease 512 350–700
Abnormal retest, referral, no liver disease 204 150–400
Abnormal retest, no referral, liver disease 80 55–105
Abnormal retest, no referral, no liver disease 80 55–105
Normal retest, liver disease 49 30–80
Normal retest, no liver disease 49 30–80
Referral, liver disease 317 150–500
Referral, no liver disease 139 50–350Decision analyses: cost–utility of referral for liver disease diagnosis
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TABLE 35  Costs from first LFTs in primary care by different decision/result pathways for patients in 100th percentile of risk
Pathway Mean cost per patient (£)
Retest in primary care
Abnormal result; refer See Table 36
Abnormal result; no referral 38.12a × 2.11b = 80.43
Normal result 38.12a  × 1.28c = 48.79
Refer from primary care See Table 37
Do nothing 0
a  Cost of an LFT in primary care, i.e. £25 (GP consultation) + £9 (nurse to take blood) + £4.12 (LFT sample) = £38.12.
b  Mean number of LFT batch retests per patient in those with an abnormal retest and no referral.
c  Mean number of LFT batch retests per patient in those with normal retest.
of investigations were obtained from various 
sources.100,101
The cost–utility analysis concluded that retesting 
may be the best option for all patients presenting 
with an abnormal test, but with otherwise no 
clinically obvious liver disease, with regard to 
saving money for the NHS while maximising the 
QALYs of patients. Having a retest in primary care 
has a probability of being normal of one-third. 
This also has the benefit of causing the patient less 
anxiety than being investigated in secondary care, 
particularly if the retest is indeed normal. However, 
using the predictive algorithms derived in this 
study, there is the potential to identify high-risk 
patients and the cost–utility of the top percentile 
indicated that neither decision was dominant. 
To retest depends on the WTP of the NHS for 
this group of patients. If the standard UK WTP 
of £20,000–£30,000 per QALY for drug therapy 
applies, then retesting is still the most cost-effective 
option for high-risk patients. However, if the WTP 
is lower (< £7000) then referral may be the most 
cost-effective option.
TABLE 36  Costs of tests from referral to secondary care for patients in 100th percentile of liver disease risk retesting abnormal in 
primary care
Test/procedure
No liver disease within 1 year (n = 110) Liver disease within 1 year (n = 34)
No. of 
patients
No. of 
tests
Total 
cost (£)
Mean cost per 
patient (£)
No. of 
patients
No. of 
tests
Total 
cost (£)
Mean cost 
per patient 
(£)
LFT retest in 
secondary carea
110 110 453.20 4.12 34 34 140.08 4.12
HBV (BsAg) 30 35 413.00 3.75 28 45 531.00 15.62
HCV 19 22 281.60 2.56 27 39 499.20 14.68
ANA 23 31 110.67 1.01 22 30 107.10 3.15
AMA 20 24 85.68 0.78 22 29 103.53 3.05
ASMA 20 24 85.68 0.78 21 27 96.39 2.84
Ultrasound scan 
of liverb
110 110 13,152.70 119.57 34 34 4065.38 119.57
Biopsy 2 2 776.10 7.06 17 25 9701.25 285.33
Total 15,358.63 139.63 15,243.93 448.36
AMA, antimitochondrial antibody; ANA, antinuclear antibody; ASMA, anti-smooth muscle antibody; BsAg, hepatitis B 
surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus.
a  Assuming one batch of LFTs taken in secondary care.
b  Assuming every patient had one ultrasound (data not available).
A mean cost of £64.42 per patient was added to each cohort to account for repeated LFTs in primary care before referral. 
The cost of a batch of LFTs taken in primary care is £38.12, and the average number of retests was 1.69 per patient. 
Therefore, 38.12 × 1.69 = 64.42.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 38  Baseline cost–utility results for 100th percentile of liver disease risk patients (costs per quality-adjusted life year)
Strategy Total costa Total utilitya Incremental cost Incremental utility ICUR (£/year)
Refer from 
primary care
162.20 0.727
Retest in primary 
care
173.40 0.728 11.10 0.00147 7588
ICUR, incremental cost–utility ratio.
a  Cost and utility are per patient.
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FIGURE 31  Cost (£) vs utility (quality-adjusted life-year) of the two decision choices for a GP .
TABLE 37  Total costs of tests carried out from referral to secondary care for patients in 100th percentile of liver disease risk referred 
after initial LFTs in primary care
Test/procedure
No liver disease within 1 year (n = 281) Liver disease within 1 year (n = 41)
No. of 
patients
No. of 
tests
Total 
cost (£)
Mean cost 
per patient 
(£)
No. of 
patients
No. of 
tests
Total 
cost (£)
Mean cost per 
patient (£)
LFT retest in 
secondary carea
281 281 1157.72 4.12 41 41 168.92 4.12
HBV (BsAg) 47 62 731.60 2.60 24 29 342.20 8.35
HCV 35 36 460.80 1.64 19 27 345.60 8.43
ANA 40 49 174.93 0.62 14 29 103.53 2.53
AMA 31 34 121.38 0.43 15 21 74.97 1.83
ASMA 31 34 121.38 0.43 15 21 74.97 1.83
Ultrasound scan 
of liverb
281 281 33,599.17 119.57 41 41 4902.37 119.57
Biopsy 6 7 2716.35 9.67 14 18 6984.90 170.36
Total 39,083.33 139.08 12,997.46 317.02
AMA, antimitochondrial antibody; ANA, antinuclear antibody; ASMA, anti-smooth muscle antibody; BsAg, hepatitis B 
surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus.
a  Assuming one batch of LFTs taken in secondary care.
b  Assuming every patient had one ultrasound (data not available).Decision analyses: cost–utility of referral for liver disease diagnosis
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FIGURE 32  Decision tree model for patients in the top percentile of liver disease risk.
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TABLE 39  One-way sensitivity analysis results of retest vs referral
Variable Baseline value Value
ICUR (£/QALY) 
for referrala
ICUR (£/QALY) 
for retestb
Probability
Abnormal retest, referral, liver disease 0.24 0.15 Dominated
0.17 102
0.21 2465
0.27 56,383
0.29–0.35 Dominated
Abnormal retest, no referral, liver disease 0.16 0.05–0.25 7588
Normal retest, liver disease 0.05 0.00 5285
0.08 10,275
0.16 184,244
0.18–0.20 Dominated
Referral, liver disease 0.13 0.05–0.11 Dominated
0.12 27,584
0.19 62
0.20 Dominated
Utility
Abnormal retest, referral, liver disease 0.65 0.5–0.62 Dominated
0.64 39,934
0.76 766
0.90 357
Abnormal retest, referral, no liver disease 0.73 0.5–0.72 Dominated
0.74 2129
0.82 315
0.90 170
Abnormal retest, no referral, liver disease 0.69 0.50–0.66 Dominated
0.68 12,146
0.80 1480
0.90 855
Abnormal retest, no referral, no liver disease 0.69 0.50–0.68 Dominated
0.70 2555
0.80 335
0.90 179
Normal retest, liver disease 0.79 0.5–0.6 Dominated
0.62 102,720
0.80 7196
0.90 4745
Normal retest, no liver disease 0.87 0.70–0.86 Dominated
0.88 3729
0.95 818
continuedDecision analyses: cost–utility of referral for liver disease diagnosis
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Variable Baseline value Value
ICUR (£/QALY) 
for referrala
ICUR (£/QALY) 
for retestb
Referral, liver disease 0.64 0.50 567
0.56 939
0.62 2739
0.66–0.90 Dominated
Referral, no liver disease 0.74 0.50 53
0.72 591
0.76–0.90 Dominated
Cost (£)
Abnormal retest, referral, liver disease 512 350–400 Dominated
425 478
550 8578
700 20,728
Abnormal retest, referral, no liver disease 204 150 Dominated
175 137
250 19,374
400 57,848
Abnormal retest, no referral, liver disease 80 55 6634
105 8510
Abnormal retest, no referral, no liver disease 80 55 2578
105 12,429
Normal retest, liver disease 49 30 7486
80 7758
Normal retest, no liver disease 49 30 5643
80 10,819
Referral, liver disease 317 150 22,374
290 9980
395 685
430–500 Dominated
Referral, no liver disease 139 50 60,364
150 1119
175–350 Dominated
a  This column is the ICUR of referral.
b  This column is the ICUR of retest.
TABLE 39  One-way sensitivity analysis results of retest vs referral (continued)DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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FIGURE 33  Two-way sensitivity of cost of referral with no resulting liver disease and probability of referral with liver disease diagnosis. 
(a) Willingness to pay (WTP) = £500/QALY; (b) WTP = £5000/QALY; (c) WTP = £25,000/QALY. Note: The lines crossing on each 
chart are the baseline cost (£139.08) and probability used (0.13).
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Chapter 9  
Discussion
U
sing the data-linkage capabilities in Tayside, 
Scotland, a large population database of LFTs 
in primary care (n = 95,977) linked with outcomes 
of liver disease diagnosis as well as mortality was 
created. From this resource a number of predictive 
algorithms have been developed. Further work will 
seek to develop these into user-friendly decision 
aids. Cost–utility analyses indicated that identifying 
high-risk patients for immediate referral to 
secondary care would be cost-effective. The results 
of this study will be widely disseminated to primary 
care as well as hospital gastrointestinal specialists 
through publications and presentations at local and 
national meetings and the project website This will 
facilitate optimal decision making for the benefit of 
both the patient and the NHS.
Strengths and limitations
One of the main strengths of this study is the size 
of cohort, which we believe to be one of the largest 
in the world. Kim et al.12 describe a larger cohort, 
but it appears to have fewer covariates, considers 
only ALT/AST as predictors and considers only 
mortality as an end point. One limitation is the low 
level of ethnic minorities in Tayside, and so caution 
is needed in extrapolating these results to these 
groups.
Our length of follow-up had a maximum of 15 
years and a median of 4 years. This may not 
appear to be very long. However, this is more 
than adequate to predict over 1 or 2 years. The 
data demonstrated lower discrimination and 
calibration to predict outcomes over more than 1 
year. This makes clinical sense in that it would not 
be expected that a single initial batch of LFTs could 
predict outcomes over the long term. In order to 
develop clinical prediction aids this is more than 
adequate.
Observational data may have the limitation that 
not all participants in the cohort are investigated 
with a full liver screen and hence, some individuals 
with early liver disease or precursors would not be 
detected. This verification bias is well known in 
cancer studies and we used the method developed 
by Begg et al.28 to estimate the probability of 
verification and weight the results by the inverse of 
this probability as well as using multiple imputation 
methods.28–30 In this way, verification bias is 
reduced, but may not be completely eliminated. 
The method of multiple imputation used to impute 
the missing data for the LFTs is widely accepted 
as the ‘gold standard’ technique for dealing with 
this problem.30,34 Eighty-nine per cent of patients 
were not tested for GGT and so had their GGT 
results imputed using this procedure.30,34 Although 
this may sound an extremely large amount of 
‘missingness’ it should be argued that a large 
number of patients (10,484 patients) still had GGT 
measured and that this number should be large 
enough to predict the missing GGT for the other 
patients who had all other covariates present at that 
stage, assuming these were missing at random. In 
30 multiple imputations, the relative efficiency for 
GGT was 97%, on a par with the relative efficiency 
to predict the missing data of the other LFTs.
In the survival models, it can be seen that the 
HRs for LFTs (severely elevated and moderately 
elevated versus normal) for liver disease and 
mortality were very large for the first 3-month 
period and became lower from 3 months to 1 year 
and lower still after 1 year. This was evidence of 
non-proportionality and consequently we split the 
final predictive models into different time periods. 
The effect of alcohol dependency increased 
with time, reflecting the longer latency period 
associated with alcoholism to liver disease. Drug 
dependency was only significantly predictive of 
liver disease from 1 year onwards.
For liver mortality, aside from gender and age, only 
a history of biliary tract disorders was predictive 
within 3 months. From 3 months, alcohol 
dependency was again the strongest and only 
predictor apart from age and gender, with HRs 
> 10 for each LFT-adjusted model. The fact that 
alcohol dependency is such a strong predictor, even 
though we have probably underestimated it, as it 
was based on hospitalisation rather than alcohol 
intake, shows how important this factor is in liver 
mortality.
Survival models showed that all the tests have 
high HRs relating to outcomes of liver disease and Discussion
88
mortality from liver disease. The fact that many 
interaction terms were included in the prediction 
models indicates that the pattern of ALFTs is 
important. Of 667 people who had a severely 
elevated transaminase 11.8% were diagnosed with 
chronic liver disease (with an HR of 12), and a mild 
elevation of the test had a high hazard of > 4 for 
developing chronic liver disease, suggesting that 
transaminase may be a good predictor. For any 
mortality cause, albumin was the best predictor as 
expected, given that a lowered albumin is heavily 
associated with morbidity.34 Transaminase had 
the lowest HR for mortality, although it was still 
significantly predictive. The long-term effects of 
alcohol and drug dependency are also evident for 
any cause of death as they are significant predictors 
from 1 year after the start of the study.
We were able to perform cost–utility analyses 
using probabilities taken directly from analyses of 
the cohort. This is a major strength as these are 
usually estimated from published studies with many 
assumptions made. The analyses also benefited 
from direct measurement of utility for patients 
awaiting a diagnosis and those undergoing biopsy. 
As far as we know there are no other published 
measurements in these groups. A potential 
weakness of the cost–utility analyses is that the ‘no 
liver disease’ outcome included those with other 
conditions (such as biliary disease, cancer, CVD) as 
well as those who died. In fact, the ‘well’ dominate 
this group and taking a weighted average for the 
whole group makes no difference to the analysis. 
The sensitivity analysis allowed us to explore a 
range of utilities and costs for this group and this 
made little difference. It would be useful for future 
work to consider cost–utility for individual liver 
conditions such as HCV as well as other non-liver 
conditions. The results of the cost–utility analyses 
demonstrated that the optimal decision given an 
abnormal test in those with no obvious liver disease 
was to retest. In addition, in those in the top 
percentile of risk of liver disease, neither retesting 
nor referral were dominant. The decision to retest 
depends on the WTP of the NHS, given that 
retesting has an ICUR of £7588/QALY.
To sum up, our study suggests that;
•	 GGT should be included in the batch of LFTs 
in primary care.
•	 If the patient has no obvious liver disease and a 
low or moderate risk of liver disease, retesting 
is the most cost-effective decision.
•	 If the patient with ALFTs in primary care has a 
high risk, the decision to retest depends on the 
WTP of the NHS. At a WTP of £7000, retesting 
is still the most cost-effective decision.
•	 Results suggest that cut-offs for LFTs are 
arbitrary and that in developing decision 
aids it is important to treat the LFT results as 
continuous.
Further research
The following are suggestions for further research 
in order of priority:
1.  We have developed proposals for further work 
to the Chief Scientist Office of Scotland to 
develop a feasible, usable computer decision 
support system (CDSS) intervention to assist 
the management of ALFTs in primary care. 
We seek to identify how the algorithms can 
be adapted into a CDSS for GPs, and made 
efficient, feasible and usable in general 
practice.
2.  In assessing the highest-risk percentile, it is 
noteworthy that 23% (n = 179) received neither 
retesting nor referral within 1 year, and we 
could speculate that earlier investigation may 
have been worthwhile in this group. In this 
case, the predictive algorithm could act as 
a useful decision aid for referral. We could 
explore further varying the cut-off point 
for determining high risk and subsequent 
recommendation of referral.
3.  Having developed a usable CDSS there is 
still the question of whether a CDSS for the 
management of ALFTs would improve decision 
making, if it would be more cost-effective 
in the long run and if developing a cluster 
randomised trial would be appropriate.
4.  As abnormal liver tests are often a sign of 
general illness and not necessarily liver disease, 
this extensive data set could be analysed with 
other non-liver disease end points such as 
CHD and cancer, for example.
Potential impact on and 
benefit to the NHS
Abnormal liver enzymes may indicate liver injury 
which is asymptomatic in the early stages and 
subsequent testing may diagnose symptomatic liver 
disease. The probability of disease is unknown. The 
sequence of subsequent tests is at the discretion of 
the practitioner. The evidence-based care pathway 
would provide clinical sequencing for subsequent 
testing and follow-up, thus maximising the DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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probability of correct diagnosis and eliminating 
unnecessary expense to the NHS and unwanted 
patient trauma. From this work a decision support 
system could be developed and used in conjunction 
with an electronic results communications system. 
Tayside is a lead site for Scotland’s Electronic 
Clinical Communications Initiative that has the 
philosophy of a single clinical web-based repository 
linked to the locally developed Area Community 
Health Index. The Tayside Core Network connects 
every GP practice and hospital within Tayside with 
a single access to NHSNet, and presently has 88 
sites with over 4000 PCs connected. This proposal 
could be developed, within the information 
technology framework established by the Board 
and the Trusts, to ensure that the decision support 
system this project develops can be adequately 
supported by them and to demonstrate the 
practicality for the wider NHS. Ultimately, this 
would lead to assessment of cost-effectiveness of 
the CDSS in a cluster randomised study to provide 
a sound evidence base.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Appendix 1  
Indications for LFTs with no obvious liver 
disease and consequent investigations
Indications Investigations
None LFTs
Other monitoring, (e.g. cholesterol) Bilirubin
Health check Albumin
Tired all the time Liver enzyme tests
Nausea ALT
Alcohol abuse AST
Unwell AP
Health check GGT
Abdominal ultrasound
Haematology and clotting
Immunology
ASMA, ANA, AMA, ANCA
Virology
HBV antibodies and DNA
HCV antibodies and RNA
Antibodies to other viruses
Biochemistry
Ferritin
Immunoglobulins
Alpha-1-antitrypsin
Caeruloplasmin
Genetics
Haemochromatosis genotype
Gilbert’s genotype
Radiology
CT scan 
MRI
Endoscopy
Liver biopsy
ALT, alanine transaminase; AMA, antimitochondrial antibody; ANA, antinuclear antibody; ANCA; antineutrophilic 
cytoplasmic antibody; AP , alkaline phosphatase; ASMA; anti-smooth muscle antibody; AST, aspartate aminotransferase; CT, 
computerised tomography; DNA, deoxyribonucleic acid; GGT, gamma-glutamyltransferase; HBV, hepatitis B virus; HCV, 
hepatitis C virus; MRI, magnetic resonance imaging; RNA, ribonucleic acid.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Appendix 2  
Possible outcomes following ALFTs
No retest
LFTs normalise without intervention
LFTs normalise after alcohol and/or weight reduction advice
Acute hepatitis A–E, Epstein–Barr virus (EBV), cytomegalovirus 
(CMV), toxoplasmosis
Chronic hepatitis B or C carrier/disease
Gallstones
Shock liver
Postoperative cholestasis
Acute fatty liver of pregnancy
Cholestasis of pregnancy
ALFT due to adverse drug reaction
Non-alcoholic fatty liver disease (NAFLD)
Non-alcoholic steatohepatitis (NASH)
Alcoholic liver disease/fatty liver
Alcoholic hepatitis
Alcoholic cirrhosis
Idiopathic cirrhosis
Primary biliary cirrhosis (PBC)
Autoimmune hepatitis
Haemochromatosis
Alpha-1-antitrypsin
Metastatic cancer
Liver cancer
Pancreatic cancer
Paraneoplasmic syndrome
Congestive heart failure
Systemic inflammatory conditions (arthritis, vasculitis, etc.)DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Appendix 3  
ICD-9/ICD-10 codes for liver disease, 
comorbidities and other outcomes
Disease ICD-9 ICD-10 Other source/notes
Liver disease diagnosis
Hepatitis B Virology
Hepatitis C Virology
Autoimmune hepatitis 571.4 K73.0, K73.2, K73.8, K73.9 Pathology, immunology 
(positive ASM)
Cirrhosis 571.2, 571.5, 571.6 K70.3, K74.3–K74.6, K76.1 Pathology
Primary biliary cirrhosis Pathology, immunology 
(positive AMA), 
biochemistry (positive 
GGT, positive AP)
Alcoholic cirrhosis As cirrhosis + 291, 303, 
305.0
As cirrhosis + F10 SMR1/SMR4 ICD codes 
for alcohol
Alcoholic hepatitis 571.1 K70.1 Pathology
Alcohol-related liver disease Any liver disease codes + 
alcohol codes
Any liver disease codes + 
alcohol codes
Pathology
Fatty liver disease 571.0, 571.8 K70.0, K76.0 Pathology
Hepatocellular carcinoma 155.0, 155.2 C22.0, C22.2–C22.9 Pathology (ICD from 
SMR1/SMR6)
Wilson’s disease 275.1 E83.0
Haemochromatosis 275.0, 285.0 D64.2, E83.1 Pathology
Alpha-1-antitrypsin Biochemistry (positive 
alpha-1-antitrypsin)
Complications
Oesophageal varices 456.1, 456.2 I85.9, I98.2A Endoscopy records
Bleeding 456.0 I85.0
Gastric varices I86.4
Ascites 789.5 R18X
Encephalopathy 572.2 K72.9
Portal hypertension Any complication, 572.3 Any complication, K76.6
Diseases of gallbladder and biliary tract
Cholelithiasis 574 K80
Other disorders of gallbladder 575 K81–K82
Other disorders of biliary 
tract
576 K83
Cholangiocarcinoma 155.1, 156–157, 230.8 (in 
situ)
C22.1, C23–C25, D01.5 (in 
situ)
ICD from SMR1/SMR6
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Disease ICD-9 ICD-10 Other source/notes
Comorbidities
Ischaemic heart disease 410–414 I20–I25
Other cancers 140–208, 230–234 (exclude 
cholangiocarcinoma and 
hepatocellular codes)
C00–D09 (exclude 
cholangiocarcinoma and 
hepatocellular codes)
Diabetes 250 E10–E14
Respiratory 466, 480–496 J10–J18, J20, J40X–J47X, 
J66–J67
Renal 584–586 N17–N19X, I12.0
Stroke 430–438 I60–169
Other liver conditionsa
Acute/subacute necrosis 570.9
Alcoholic liver damage 
(unspecified)
571.3 K70.9
Chronic hepatitis 571.4
Non-alcoholic CLD 
(unspecified)
571.9
Abscess of liver 572.0 K75.0
Hepatorenal syndrome 572.4 K76.7
Other sequelae of CLD 572.8
Other liver disorder, e.g. 
hepatoptosis
573.8 K76.8
Unspecified liver disorder 573.9 K76.9
Alcoholic hepatic failure K70.4
Acute/subacute hepatic failure K72.0
Chronic hepatic failure K72.1
Occlusion of vena cava 453.2 I82.2
Portal vein thrombosis 452 I81
Hepatitis B O70 B16, B18.0, B18.1
Hepatitis C O70 B17.1, B18.2
Other viral hepatitis O70 B17–B19
AMA, anti-mitochondrial antibody; AP , alkaline phosphatase; ASMA, anti-smooth muscle antibody; ACLD, chronic liver 
disease; GGT, gamma-glutamyltransferase; SMR, Scottish Morbidity Record.
a  Only on death certificate.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Appendix 4  
Liver disease diagnosis
TABLE 40  Liver disease diagnosis by albumin level
Liver disease
Albumin [n (%)]
Population 
(%) Normal Mild Severe Missing
Viral hepatitis
HAV 5 (0.01) 0 (0.00) 0 (0.00) 0 (0.00) 5 (< 0.01)
HBV 28 (0.03) 2 (0.12) 1 (0.42) 1 (0.13) 32 (0.03)
HBV (recovered) 32 (0.03) 2 (0.12) 2 (0.84) 0 (0.00) 36 (0.04)
HCV 93 (0.10) 6 (0.35) 0 (0.00) 6 (0.76) 105 (0.11)
HCV (recovered) 12 (0.01) 0 (0.00) 0 (0.00) 1 (0.13) 13 (0.01)
Unspecified viral hepatitis without 
coma
1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Other hepatitis
Autoimmune hepatitis
– Definite 72 (0.08) 1 (0.06) 2 (0.84) 0 (0.00) 75 (0.08)
– Possible 2 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 2 (< 0.01)
– Probable 4 (< 0.01) 1 (0.06) 0 (0.00) 0 (0.00) 5 (< 0.01)
Granulomatous hepatitis 2 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 2 (< 0.01)
Hepatitis in viral diseases elsewhere 10 (0.01) 0 (0.00) 0 (0.00) 0 (0.00) 10 (0.01)
Hepatitis (unspecified) 23 (0.02) 1 (0.06) 0 (0.00) 0 (0.00) 24 (0.03)
Non-specific reactive hepatitis 1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Alcohol-related liver disease 217 (0.23) 11(0.64) 4 (1.69) 8 (1.01) 240 (0.25)
Alcoholic hepatitis 32 (0.03) 1 (0.06) 0 (0.00) 1 (0.13) 34 (0.04)
Alcoholic cirrhosis 53 (0.06) 3 (0.18) 1 (0.42) 3 (0.38) 60 (0.06)
Cirrhosis 169 (0.18) 8 (0.47) 2 (0.84) 3 (0.38) 182 (0.19)
Primary biliary cirrhosis
Definite 15 (0.02) 0 (0.00) 0 (0.00) 0 (0.00) 15 (0.02)
Possible 37 (0.04) 1 (0.06) 0 (0.00) 0 (0.00) 38 (0.04)
Probable 77 (0.08) 2 (0.12) 2 (0.84) 0 (0.00) 81 (0.08)
Hepatocellular carcinoma 61 (0.07) 5 (0.29) 2 (0.84) 0 (0.00) 68 (0.07)
Fatty liver disease 74 (0.08) 3 (0.18) 1 (0.42) 1 (0.13) 79 (0.08)
Haemochromatosis 15 (0.02) 0 (0.00) 0 (0.00) 1 (0.13) 16 (0.02)
Alpha-1-antitrypsin 14 (0.02) 1 (0.06) 0 (0.00) 0 (0.00) 15 (0.02)
Others
Abscess of liver 15 (0.02) 5 (0.29) 0 (0.00) 0 (0.00) 20 (0.02)
Acute/subacute hepatic failure 8 (0.01) 0 (0.00) 0 (0.00) 1 (0.13) 9 (0.01)
Acute/subacute necrosis 1 (< 0.01) 1 (0.06) 0 (0.00) 0 (0.00) 2 (< 0.01)
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Liver disease
Albumin [n (%)]
Population 
(%) Normal Mild Severe Missing
Chronic passive congestion 1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Hepatic infarction 2 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 2 (< 0.01)
Hepatic sclerosis 1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Hepatorenal syndrome 7 (0.01) 0 (0.00) 0 (0.00) 0 (0.00) 7 (0.01)
Liver disorders in other diseases 
elsewhere
1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Non-alcoholic chronic liver disease 
(unspecified)
5 (0.01) 0 (0.00) 0 (0.00) 0 (0.00) 5 (0.01)
Hepatoptosis 41 (0.04) 1 (0.06) 0 (0.00) 0 (0.00) 42 (0.04)
Other sequelae 4 (< 0.01) 2 (0.12) 0 (0.00) 1 (0.13) 7 (0.01)
Toxic liver disease 3 (< 0.01) 1 (0.06) 0 (0.00) 0 (0.00) 4 (< 0.01)
Unspecified liver disorder 23 (0.02) 0 (0.00) 0 (0.00) 0 (0.00) 23 (0.02)
Complications 136 (0.15) 7 (0.41) 1 (0.42) 2 (0.25) 146 (0.15)
Varices 44 (0.05) 0 (0.00) 0 (0.00) 2 (0.25) 46 (0.05)
Ascites 61 (0.07) 4 (0.23) 0 (0.00) 0 (0.00) 65 (0.07)
Encephalopathy 26 (0.03) 2 (0.12) 1 (0.42) 0 (0.00) 29 (0.03)
Total patients 1005 (1.08) 51 (2.98) 15 (6.33) 19 (2.41) 1090 (1.14)
CLD, chronic liver disease; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus.
TABLE 40  Liver disease diagnosis by albumin level (continued)DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 41  Liver disease diagnosis by transaminase level
Liver disease
Transaminase [n (%)]
Population 
(%) Normal Mild Severe Missing
Viral hepatitis
HAV 2 (< 0.01) 0 (0.00) 2 (0.30) 1 (< 0.01) 5 (< 0.01)
HBV 15 (0.02) 4 (0.09) 4 (0.60) 9 (0.04) 32 (0.03)
HBV (recovered) 13 (0.02) 5 (0.11) 1 (0.15) 17 (0.08) 36 (0.04)
HCV 38 (0.06) 23 (0.52) 22 (3.30) 22 (0.10) 105 (0.11)
HCV (recovered) 11 (0.02) 0 (0.00) 0 (0.00) 2 (0.01) 13 (0.01)
Unspecified viral hepatitis without 
coma
1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Other hepatitis
Autoimmune hepatitis
– Definite 22 (0.03) 5 (0.11) 6 (0.90) 42 (0.19) 75 (0.08)
– Possible 0 (0.00) 0 (0.00) 0 (0.00) 2 (0.01) 2 (< 0.01)
– Probable 1 (< 0.01) 2 (0.05) 0 (0.00) 2 (0.01) 5 (< 0.01)
Granulomatous hepatitis 1 (< 0.01) 0 (0.00) 1 (0.15) 0 (0.00) 2 (< 0.01)
Hepatitis in viral diseases elsewhere 1 (0.01) 0 (0.00) 0 (0.00) 9 (0.04) 10 (0.01)
Hepatitis (unspecified) 12 (0.02) 0 (0.00) 2 (0.30) 10 (0.04) 24 (0.03)
Non-specific reactive hepatitis 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01) 1 (< 0.01)
Alcohol-related liver disease 83 (0.12) 42 (0.95) 13 (1.95) 102 (0.45) 240 (0.25)
Alcoholic hepatitis 17 (0.02) 4 (0.09) 1 (0.15) 12 (0.05) 34 (0.04)
Alcoholic cirrhosis 18 (0.03) 12 (0.27) 4 (0.60) 26 (0.12) 60 (0.06)
Cirrhosis 59 (0.09) 35 (0.79) 7 (1.05) 81 (0.36) 182 (0.19)
Primary biliary cirrhosis
Definite 5 (0.01) 5 (0.11) 4 (0.60) 1 (< 0.01) 15 (0.02)
Possible 33 (0.05) 0 (0.00) 0 (0.00) 5 (0.02) 38 (0.04)
Probable 38 (0.06) 12 (0.27) 5 (0.75) 26 (0.12) 81 (0.08)
Hepatocellular carcinoma 26 (0.04) 6 (0.14) 3 (0.45) 33 (0.15) 68 (0.07)
Fatty liver disease 26 (0.04) 15 (0.34) 5 (0.75) 33 (0.15) 79 (0.08)
Haemochromatosis 6 (0.01) 6 (0.14) 1 (0.15) 3 (0.01) 16 (0.02)
Alpha-1-antitrypsin 10 (0.01) 1 (0.02) 0 (0.00) 4 (0.02) 15 (0.02)
Others
Abscess of liver 11 (0.01) 2 (0.05) 1 (0.15) 6 (0.03) 20 (0.02)
Acute/subacute hepatic failure 4 (0.01) 0 (0.00) 1 (0.15) 4 (0.02) 9 (0.01)
Acute/subacute necrosis 1 (< 0.01) 0 (0.00) 0 (0.00) 1 (< 0.01) 2 (< 0.01)
Chronic passive congestion 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01) 1 (< 0.01)
Hepatic infarction 1 (< 0.01) 0 (0.00) 0 (0.00) 1 (< 0.01) 2 (< 0.01)
Hepatic sclerosis 1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Hepatorenal syndrome 5 (0.01) 1 (0.02) 0 (0.00) 1 (< 0.01) 7 (0.01)
Liver disorders in other diseases 
elsewhere
0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01) 1 (< 0.01)
Non-alcoholic CLD (unspecified) 1 (< 0.01) 0 (0.00) 0 (0.00) 4 (0.02) 5 (0.01)
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Liver disease
Transaminase [n (%)]
Population 
(%) Normal Mild Severe Missing
Hepatoptosis 13 (0.02) 3 (0.07) 3 (0.45) 23 (0.10) 42 (0.04)
Other sequelae 3 (< 0.01) 1 (0.02) 0 (0.00) 3 (0.01) 7 (0.01)
Toxic liver disease 3 (< 0.01) 0 (0.00) 0 (0.00) 1 (< 0.01) 4 (< 0.01)
Unspecified liver disorder 6 (0.01) 5 (0.11) 3 (0.45) 9 (0.04) 23 (0.02)
Complications 55 (0.08) 22 (0.50) 8 (1.20) 61 (0.27) 146 (0.15)
Varices 20 (0.03) 8 (0.18) 2 (0.30) 16 (0.07) 46 (0.05)
Ascites 22 (0.03) 10 (0.23) 3 (0.45) 30 (0.13) 65 (0.07)
Encephalopathy 13 (0.02) 2 (0.05) 3 (0.45) 11 (0.05) 29 (0.03)
Total patients 427 (0.63) 150 (3.38) 79 (11.84) 434 (1.92) 1090 (1.14)
CLD, chronic liver disease; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 42  Liver disease diagnosis by gamma-glutamyltransferase (GGT) level
Liver disease
GGT [n (%)]
Population 
(%) Normal Mild Severe Missing
Viral hepatitis
HAV 0 (0.00) 0 (0.00) 0 (0.00) 5 (0.01) 5 (< 0.01)
HBV 3 (0.03) 2 (0.18) 2 (0.38) 25 (0.03) 32 (0.03)
HBV (recovered) 4 (0.05) 1 (0.09) 1 (0.19) 30 (0.04) 36 (0.04)
HCV 13 
(0.15)
5 (0.46) 6 (1.13) 81 (0.09) 105 (0.11)
HCV (recovered) 3 (0.03) 0 (0.00) 0 (0.00) 10 (0.01) 13 (0.01)
Unspecified viral hepatitis without coma 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01) 1 (< 0.01)
Other hepatitis
Autoimmune hepatitis
– Definite 8 (0.09) 0 (0.00) 5 (0.95) 62 (0.07) 75 (0.08)
– Possible 0 (0.00) 0 (0.00) 0 (0.00) 2 (< 0.01) 2 (< 0.01)
– Probable 0 (0.00) 1 (0.09) 0 (0.00) 4 (< 0.01) 5 (< 0.01)
Granulomatous hepatitis 0 (0.00) 1 (0.09) 0 (0.00) 1 (< 0.01) 2 (< 0.01)
Hepatitis in viral diseases elsewhere 0 (0.00) 0 (0.00) 0 (0.00) 10 (0.01) 10 (0.01)
Hepatitis (unspecified) 2 (0.02) 1 (0.09) 0 (0.00) 21 (0.02) 24 (0.03)
Non-specific reactive hepatitis 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01) 1 (< 0.01)
Alcohol-related liver disease 32 (0.36) 17 (1.55) 45 (8.51) 146 (0.17) 240 (0.25)
Alcoholic hepatitis 6 (0.07) 2 (0.18) 7 (1.32) 19 (0.02) 34 (0.04)
Alcoholic cirrhosis 6 (0.07) 2 (0.18) 13 (2.46) 39 (0.05) 60 (0.06)
Cirrhosis 14 (0.16) 8 (0.73) 21 (3.97) 139 (0.16) 182 (0.19)
Primary biliary cirrhosis
Definite 0 (0.00) 1 (0.09) 1 (0.19) 13 (0.02) 15 (0.02)
Possible 5 (0.06) 0 (0.00) 0 (0.00) 33 (0.04) 38 (0.04)
Probable 6 (0.07) 4 (0.37) 10 (1.89) 61 (0.07) 81 (0.08)
Hepatocellular carcinoma 6 (0.07) 2 (0.18) 5 (0.95) 55 (0.06) 68 (0.07)
Fatty liver disease 7 (0.08) 4 (0.37) 2 (0.38) 66 (0.08) 79 (0.08)
Haemochromatosis 2 (0.02) 2 (0.18) 1 (0.19) 11 (0.01) 16 (0.02)
Alpha-1-antitrypsin 0 (0.00) 1 (0.09) 0 (0.00) 14 (0.02) 15 (0.02)
Others
Abscess of liver 1 (0.01) 4 (0.37) 1 (0.19) 14 (0.02) 20 (0.02)
Acute/subacute hepatic failure 1 (0.01) 0 (0.00) 0 (0.00) 8 (0.01) 9 (0.01)
Acute/subacute necrosis 1 (0.01) 0 (0.00) 1 (0.19) 0 (0.00) 2 (< 0.01)
Chronic passive congestion 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01) 1 (< 0.01)
Hepatic infarction 0 (0.00) 0 (0.00) 0 (0.00) 2 (< 0.01) 2 (< 0.01)
Hepatic sclerosis 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01) 1 (< 0.01)
Hepatorenal syndrome 0 (0.00) 0 (0.00) 0 (0.00) 7 (0.01) 7 (0.01)
Liver disorders in other diseases 
elsewhere
0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01) 1 (< 0.01)
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Liver disease
GGT [n (%)]
Population 
(%) Normal Mild Severe Missing
Non-alcoholic CLD (unspecified) 1 (0.01) 0 (0.00) 1 (0.19) 3 (< 0.01) 5 (0.01)
Hepatoptosis 3 (0.03) 0 (0.00) 0 (0.00) 39 (0.05) 42 (0.04)
Other sequelae 1 (0.01) 1 (0.09) 0 (0.00) 5 (0.01) 7 (0.01)
Toxic liver disease 1 (0.01) 0 (0.00) 0 (0.00) 3 (< 0.01) 4 (< 0.01)
Unspecified liver disorder 2 (0.02) 2 (0.18) 5 (0.95) 14 (0.02) 23 (0.02)
Complications 10 (0.11) 9 (0.82) 15 (2.84) 112 (0.13) 146 (0.15)
Varices 6 (0.07) 4 (0.37) 3 (0.57) 33 (0.04) 46 (0.05)
Ascites 1 (0.01) 2 (0.18) 8 (1.51) 54 (0.06) 65 (0.07)
Encephalopathy 1 (0.01) 2 (0.18) 2 (0.38) 24 (0.03) 29 (0.03)
Total patients 103 (1.16) 55 (5.03) 88 (16.64) 844 (0.99) 1090 (1.14)
CLD, chronic liver disease; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 43  Liver disease diagnosis by alkaline phosphatase (AP) level
Liver disease
AP [n (%)]
Population 
(%) Normal Mild Severe Missing
Viral hepatitis
HAV 3 (< 0.01) 1 (0.01) 1 (0.30) 0 (0.00) 5 (< 0.01)
HBV 23 (0.03) 8 (0.08) 1 (0.30) 0 (0.00) 32 (0.03)
HBV (recovered) 31 (0.04) 4 (0.04) 1 (0.30) 0 (0.00) 36 (0.04)
HCV 81 (0.09) 18 (0.19) 2 (0.61) 4 (0.55) 105 (0.11)
HCV (recovered) 11 (0.01) 1 (0.01) 0 (0.00) 1 (0.14) 13 (0.01)
Unspecified viral hepatitis without 
coma
1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Other hepatitis
Autoimmune hepatitis
– Definite 49 (0.06) 25 (0.26) 1 (0.30) 0 (0.00) 75 (0.08)
– Possible 2 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 2 (< 0.01)
– Probable 4 (< 0.01) 1 (0.01) 0 (0.00) 0 (0.00) 5 (< 0.01)
Granulomatous hepatitis 2 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 2 (< 0.01)
Hepatitis in viral diseases elsewhere 8 (0.01) 2 (0.02) 0 (0.00) 0 (0.00) 10 (0.01)
Hepatitis (unspecified) 18 (0.02) 5 (0.05) 1 (0.30) 0 (0.00) 24 (0.03)
Non-specific reactive hepatitis 1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Alcohol-related liver disease 143 (0.17) 84 (0.88) 6 (1.82) 7 (0.97) 240 (0.25)
Alcoholic hepatitis 17 (0.02) 14 (0.15) 2 (0.61) 1 (0.14) 34 (0.04)
Alcoholic cirrhosis 27 (0.03) 30 (0.31) 1 (0.30) 2 (0.28) 60 (0.06)
Cirrhosis 121 (0.14) 54 (0.56) 5 (1.52) 2 (0.28) 182 (0.19)
Primary biliary cirrhosis
Definite 1 (< 0.01) 7 (0.07) 7 (2.12) 0 (0.00) 15 (0.02)
Possible 38 (0.04) 0 (0.00) 0 (0.00) 0 (0.00) 38 (0.04)
Probable 42 (0.05) 36 (0.38) 3 (0.91) 0 (0.00) 81 (0.08)
Hepatocellular carcinoma 44 (0.05) 17 (0.18) 7 (2.12) 0 (0.00) 68 (0.07)
Fatty liver disease 60 (0.07) 17 (0.18) 1 (0.30) 1 (0.14) 79 (0.08)
Haemochromatosis 11 (0.01) 4 (0.04) 0 (0.00) 1 (0.14) 16 (0.02)
Alpha-1-antitrypsin 12 (0.01) 3 (0.03) 0 (0.00) 0 (0.00) 15 (0.02)
Others
Abscess of liver 11 (0.01) 9 (0.09) 1 (0.19) 0 (0.00) 21 (0.02)
Acute/subacute hepatic failure 8 (0.01) 1 (0.01) 0 (0.00) 0 (0.00) 9 (0.01)
Acute/subacute necrosis 1 (< 0.01) 1 (0.01) 0 (0.00) 0 (0.00) 2 (< 0.01)
Chronic passive congestion 1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Hepatic infarction 2 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 2 (< 0.01)
Hepatic sclerosis 1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Hepatorenal syndrome 5 (0.01) 1 (0.01) 1 (0.30) 0 (0.00) 7 (0.01)
Liver disorders in other diseases 
elsewhere
1 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (< 0.01)
Non-alcoholic CLD (unspecified) 4 (< 0.01) 0 (0.00) 1 (0.30) 0 (0.00) 5 (0.01)
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Liver disease
AP [n (%)]
Population 
(%) Normal Mild Severe Missing
Hepatoptosis 36 (0.04) 5 (0.05) 1 (0.30) 0 (0.00) 42 (0.04)
Other sequelae 5 (0.01) 1 (0.01) 0 (0.00) 1 (0.14) 7 (0.01)
Toxic liver disease 4 (< 0.01) 0 (0.00) 0 (0.00) 0 (0.00) 4 (< 0.01)
Unspecified liver disorder 15 (0.02) 7 (0.07) 1 (0.30) 0 (0.00) 23 (0.02)
Complications 103 (0.12) 37 (0.39) 4 (1.21) 2 (0.28) 146 (0.15)
Varices 37 (0.04) 7 (0.07) 0 (0.00) 2 (0.28) 46 (0.05)
Ascites 46 (0.05) 18 (0.19) 1 (0.30) 0 (0.00) 65 (0.07)
Encephalopathy 18 (0.02) 9 (0.09) 2 (0.61) 0 (0.00) 29 (0.03)
Total patients 758 (0.89) 278 (2.90) 40 (12.12) 14 (1.94) 1090 (1.14)
CLD, chronic liver disease; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 44  Liver disease diagnosis by bilirubin level
Liver disease
Bilirubin [n (%)]
Population (%) Normal Mild Missing
Viral hepatitis
HAV 3 (0.01) 2 (0.03) 0 (0.00) 5 (< 0.01)
HBV 30 (0.04) 2 (0.03) 0 (0.00) 32 (0.03)
HBV (recovered) 32 (0.04) 4 (0.06) 0 (0.00) 36 (0.04)
HCV 90 (0.11) 5 (0.08) 10 (0.16) 105 (0.11)
HCV (recovered) 10 (0.01) 1 (0.02) 2 (0.03) 13 (0.01)
Unspecified viral hepatitis without coma 1 (< 0.01) 0 (0.00) 0 (0.00) 1 (< 0.01)
Other hepatitis
Autoimmune hepatitis
– Definite 67 (0.08) 6 (0.10) 2 (0.03) 75 (0.08)
– Possible 0 (0.00) 1 (0.02) 1 (0.02) 2 (< 0.01)
– Probable 5 (0.01) 0 (0.00) 0 (0.00) 5 (< 0.01)
Granulomatous hepatitis 2 (< 0.01) 0 (0.00) 0 (0.00) 2 (< 0.01)
Hepatitis in viral diseases elsewhere 9 (0.01) 1 (0.02) 0 (0.00) 10 (0.01)
Hepatitis (unspecified) 18 (0.02) 3 (0.05) 3 (0.05) 24 (0.03)
Non-specific reactive hepatitis 1 (< 0.01) 0 (0.00) 0 (0.00) 1 (< 0.01)
Alcohol-related liver disease 183 (0.22) 46 (0.72) 11 (0.18) 240 (0.25)
Alcoholic hepatitis 26 (0.03) 7 (0.11) 1 (0.02) 34 (0.04)
Alcoholic cirrhosis 41 (0.05) 17 (0.27) 2 (0.03) 60 (0.06)
Cirrhosis 145 (0.17) 31 (0.49) 6 (0.10) 182 (0.19)
Primary biliary cirrhosis
Definite 12 (0.01) 2 (0.03) 1 (0.02) 15 (0.02)
Possible 34 (0.04) 1 (0.02) 3 (0.05) 38 (0.04)
Probable 71 (0.09) 8 (0.13) 2 (0.03) 81 (0.08)
Hepatocellular carcinoma 55 (0.07) 11 (0.17) 2 (0.03) 68 (0.07)
Fatty liver disease 71 (0.09) 5 (0.08) 3 (0.05) 79 (0.08)
Haemochromatosis 13 (0.02) 2 (0.03) 1 (0.02) 16 (0.02)
Alpha-1-antitrypsin 15 (0.02) 0 (0.00) 0 (0.00) 15 (0.02)
Others
Abscess of liver 17 (0.02) 3 (0.05) 0 (0.00) 20 (0.02)
Acute/subacute hepatic failure 9 (0.01) 0 (0.00) 0 (0.00) 9 (0.01)
Acute/subacute necrosis 0 (0.00) 2 (0.03) 0 (0.00) 2 (< 0.01)
Chronic passive congestion 1 (< 0.01) 0 (0.00) 0 (0.00) 1 (< 0.01)
Hepatic infarction 2 (< 0.01) 0 (0.00) 0 (0.00) 2 (< 0.01)
Hepatic sclerosis 1 (< 0.01) 0 (0.00) 0 (0.00) 1 (< 0.01)
Hepatorenal syndrome 5 (0.01) 2 (0.03) 0 (0.00) 7 (0.01)
Liver disorders in other diseases elsewhere 1 (< 0.01) 0 (0.00) 0 (0.00) 1 (< 0.01)
Non-alcoholic CLD (unspecified) 4 (< 0.01) 1 (0.02) 0 (0.00) 5 (0.01)
Hepatoptosis 39 (0.05) 3 (0.05) 0 (0.00) 42 (0.04)
Other sequelae 4 (< 0.01) 2 (0.03) 1 (0.02) 7 (0.01)
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Liver disease
Bilirubin [n (%)]
Population (%) Normal Mild Missing
Toxic liver disease 3 (< 0.01) 0 (0.00) 1 (0.02) 4 (< 0.01)
Unspecified liver disorder 20 (0.02) 3 (0.05) 0 (0.00) 23 (0.02)
Complications 111 (0.13) 30 (0.47) 5 (0.08) 146 (0.15)
Varices 39 (0.05) 5 (0.08) 2 (0.03) 46 (0.05)
Ascites 51 (0.06) 11 (0.17) 3 (0.05) 65 (0.07)
Encephalopathy 19 (0.02) 10 (0.16) 0 (0.00) 29 (0.03)
Total patients 913 (1.09) 131 (2.06) 46 (0.75) 1090 (1.14)
CLD, chronic liver disease; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Appendix 5  
Weibull regression results for survival 
from first LFT to liver disease diagnosis
TABLE 45  Transaminase – comparing complete data analysis with two missing data methods
Variable
Complete data Weighted Imputed
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Transaminase result (vs normal)
Mild 5.07 (4.08–6.31) < 0.001 4.83 (3.99–5.85) < 0.001 4.23 (3.55–5.04) < 0.001
Severe 15.32 (11.24–20.87) < 0.001 14.87 (11.33–19.52) < 0.001 12.67 (9.74–16.47) < 0.001
Gender  
(male vs female)
1.08 (0.92–1.26) 0.35 1.11 (0.97–1.27) 0.13 1.04 (0.92–1.18) 0.51
Age 1.01 (1.01–1.02) < 0.001 1.01 (1.01–1.02) < 0.001 1.01 (1.01–1.02) < 0.001
Carstairs score 1.06 (1.04–1.08) < 0.001 1.06 (1.04–1.08) < 0.001 1.05 (1.03–1.07) < 0.001
Gallbladder disorder 1.90 (1.07–3.38) 0.03 1.82 (1.09–3.05) 0.02 – –
Alcohol dependent 4.01 (3.14–5.11) < 0.001 3.99 (3.23–4.93) < 0.001 4.48 (3.70–5.42) < 0.001
Methadone user 6.43 (4.16–9.94) < 0.001 6.63 (4.51–9.74) < 0.001 4.52 (3.07–6.65) < 0.001
Drug abuse 1.76 (1.05–2.97) 0.03 1.72 (1.10–2.71) 0.02 2.25 (1.51–3.36) < 0.001
HR, hazard ratio.Appendix 5
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TABLE 46  GGT – comparing complete data analysis with two missing data methods
Variable
Complete data Weighted Imputed
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
GGT result (vs normal)
Mild 4.00 (2.78–5.76) < 0.001 3.80 (3.17–4.55) < 0.001 2.54 (2.17–2.96) < 0.001
Severe 12.35 (8.25–18.49) < 0.001 14.88 (12.16–18.21) < 0.001 13.44 (10.71–16.87) < 0.001
Gender (male vs 
female)
0.96 (0.74–1.25) 0.79 1.12 (0.99–1.26) 0.07 1.08 (0.96–1.22) 0.21
Age 1.02 (1.01–1.02) < 0.001 1.01 (1.01–1.02) < 0.001 1.02 (1.01–1.02) < 0.001
Carstairs score 1.04 (1.01–1.08) 0.02 1.05 (1.04–1.07) < 0.001 1.04 (1.02–1.06) < 0.001
Comorbidity (vs no comorbidity)
IHD – – 0.36 (0.25–0.53) < 0.001 – –
Stroke – – 0.32 (0.15–0.71) 0.005 – –
Cancer – – 0.53 (0.33–0.86) 0.01 – –
Medication 3 months pre LFT
Statins – – 1.50 (1.05–2.14) 0.03 – –
NSAIDs – – 0.70 (0.57–0.87) 0.001 – –
Alcohol dependent 2.98 (2.16–4.10) < 0.001 3.39 (2.83–4.05) < 0.001 2.62 (2.17–3.17) < 0.001
Drug abuse – – – – 2.60 (1.73–3.90) < 0.001
Methadone user 3.88 (1.91–7.89) < 0.001 5.60 (4.04–7.77) < 0.001 4.13 (2.80–6.10) < 0.001
GGT, gamma-glutamyltransferase; HR, hazard ratio; IHD, ischaemic heart disease; NSAIDs, non-steroidal inflammatory 
drugs.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Appendix 6  
Weibull regression results for survival 
from first LFT to liver mortality
TABLE 47  Transaminase – comparing complete data analysis with two missing data methods
Variable
Complete data Weighted Imputed
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Transaminase result (vs normal)
Mild 6.21 (3.78–10.20) < 0.001 6.06 (3.93–9.35) < 0.001 5.41 (3.80–7.71) < 0.001
Severe 8.72 (4.08–18.66) < 0.001 9.44 (4.85–18.37) < 0.001 7.17 (3.75–13.70) < 0.001
Gender (male vs female) 1.50 (1.02–2.20) 0.04 1.44 (1.03–2.01) 0.03 1.42 (1.08–1.87) 0.01
Age 1.04 (1.03–1.06) < 0.001 1.04 (1.03–1.06) < 0.001 1.03 (1.02–1.04) < 0.001
Carstairs score 1.06 (1.00–1.11) 0.04 1.07 (1.02–1.12) 0.006 1.05 (1.02–1.09) 0.004
IHD – – 1.68 (1.02–2.77) 0.04 – –
Biliary tract disorder 8.22 (1.11–60.95) 0.04 8.46 (1.67–42.90) 0.01 – –
Alcohol dependent 8.52 (4.87–14.90) < 0.001 8.64 (5.31–14.05) < 0.001 8.69 (6.33–12.89) < 0.001
HR, hazard ratio; IHD, ischaemic heart disease.
TABLE 48  GGT – comparing complete data analysis with two missing data methods
Variable
Complete data Weighted Imputed
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
GGT result (vs normal)
Mild 4.56 (2.05–10.15) < 0.001 5.94 (3.92–9.02) < 0.001 4.89 (3.43–6.99) < 0.001
Severe 15.34 (6.38–36.91) < 0.001 18.31 (11.55–29.02) < 0.001 25.32 (15.27–41.97) < 0.001
Gender (male vs 
female)
1.70 (0.90–3.21) 0.10 1.11 (0.83–1.48) 0.50 1.39 (1.06–1.82) 0.02
Age 1.05 (1.03–1.07) < 0.001 1.05 (1.04–1.06) < 0.001 1.04 (1.03–1.05) < 0.001
Carstairs score 1.09 (1.00–1.18) 0.04 1.19 (1.14–1.25) < 0.001 1.04 (1.00–1.08) 0.04
Comorbidity (vs no comorbidity)
Respiratory – – 2.75 (1.63–4.61) < 0.001 – –
Diabetes – – 9.12 (5.99–13.89) < 0.001 – –
Antibiotic use 3 
months pre LFTs
– – 0.48 (0.28–0.83) 0.008 – –
Alcohol dependent 5.10 (2.55–10.19) < 0.001 3.44 (1.25–9.42) 0.02 3.92 (2.73–5.61) < 0.001
GGT, gamma-glutamyltransferase; HR, hazard ratio.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Appendix 7  
Weibull regression results for survival 
from first LFT to all cause mortality
TABLE 49  Transaminase – comparing complete data analysis with two missing data methods
Variable
Complete data Weighted Imputed
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Transaminase result (vs normal)
Mild 1.38 (1.25–1.52) < 0.001 1.37 (1.26–1.49) < 0.001 1.35 (1.26–1.44) < 0.001
Severe 1.86 (1.52–2.27) < 0.001 1.83 (1.53–2.18) < 0.001 1.88 (1.58–2.23) < 0.001
Gender (male vs 
female)
1.50 (1.42–1.58) < 0.001 1.51 (1.45–1.58) < 0.001 1.44 (1.39–1.50) < 0.001
Age (+1 year) 1.09 (1.09–1.09) < 0.001 1.09 (1.09–1.09) < 0.001 1.09 (1.09–1.09) < 0.001
Carstairs score 1.03 (1.02–1.04) < 0.001 1.03 (1.02–1.04) < 0.001 1.03 (1.03–1.04) < 0.001
Comorbidity (vs no comorbidity)
IHD 1.25 (1.16–1.36) < 0.001 1.27 (1.18–1.35) < 0.001 1.32 (1.24–1.39) < 0.001
Renal 2.16 (1.53–3.07) < 0.001 2.18 (1.61–2.93) < 0.001 1.90 (1.46–2.46) < 0.001
Respiratory 1.56 (1.41–1.74) < 0.001 1.54 (1.41–1.69) < 0.001 1.63 (1.51–1.75) < 0.001
Diabetes 1.36 (1.16–1.59) < 0.001 1.32 (1.15–1.52) < 0.001 1.50 (1.34–1.67) < 0.001
Stroke 1.58 (1.41–1.78) < 0.001 1.61 (1.46–1.77) < 0.001 1.61 (1.48–1.75) < 0.001
Cancer 1.56 (1.44–1.69) < 0.001 1.53 (1.43–1.65) < 0.001 1.52 (1.43–1.62) < 0.001
Biliary cancer 12.23 (3.06–48.96) < 0.001 12.66 (4.01–39.99) 0.004 13.96 (4.50–43.31) < 0.001
Medication 3 months pre LFT
Statins 0.61 (0.52–0.70) < 0.001 0.61 (0.52–0.70) < 0.001 0.55 (0.48–0.63) < 0.001
NSAIDs – – – – 1.08 (1.03–1.14) 0.004
Antibiotics 1.27 (1.18–1.36) < 0.001 1.25 (1.18–1.33) < 0.001 1.14 (1.08–1.20) < 0.001
Alcohol dependent 2.25 (2.00–2.54) < 0.001 2.27 (2.05–2.51) < 0.001 1.97 (1.80–2.15) < 0.001
Drug abuse – – – – 1.55 (1.17–2.05) 0.002
Methadone user 1.66 (1.08–2.56) 0.02 1.76 (1.21–2.55) 0.003 1.62 (1.20–2.20) 0.002
HR, hazard ratio; NSAIDs, non-steroidal inflammatory drugs.Appendix 7
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TABLE 50  GGT – comparing complete data analysis with two missing data methods
Variable
Complete data Weighted Imputed
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
GGT result (vs normal)
Mild 1.69 (1.44–1.99) < 0.001 1.64 (1.52–1.77) < 0.001 1.56 (1.48–1.63) < 0.001
Severe 2.63 (2.18–3.19) < 0.001 2.43 (2.19–2.69) < 0.001 2.90 (2.61–3.23) < 0.001
Gender (male vs 
female)
1.31 (1.16–1.47) < 0.001 1.39 (1.33–1.44) < 0.001 1.39 (1.33–1.44) < 0.001
Age (+ 1 year) 1.09 (1.08–1.09) < 0.001 1.09 (1.09–1.09) < 0.001 1.09 (1.09–1.09) < 0.001
Carstairs score 1.03 (1.02–1.05) < 0.001 1.03 (1.02–1.03) < 0.001 1.03 (1.02–1.03) < 0.001
Comorbidity (vs no comorbidity)
IHD 1.26 (1.04–1.52) 0.02 1.11 (1.05–1.18) < 0.001 1.33 (1.26–1.41) < 0.001
Renal – – 2.47 (1.77–3.45) < 0.001 1.43 (1.10–1.85) 0.007
Respiratory 1.59 (1.25–2.01) < 0.001 1.81 (1.68–1.95) < 0.001 1.69 (1.57–1.82) < 0.001
Diabetes – – 1.21 (1.10–1.34) < 0.001 1.50 (1.34–1.68) < 0.001
Stroke – – 1.45 (1.32–1.59) < 0.001 1.61 (1.48–1.76) < 0.001
Cancer 2.43 (2.01–2.94) < 0.001 2.22 (2.09–2.36) < 0.001 1.59 (1.50–1.70) < 0.001
Biliary cancer 8.92 (1.25–63.60) 0.03 12.26 (4.18–35.96) < 0.001 13.51 (4.36–41.91) < 0.001
Biliary disease (vs no biliary disease)
Cholelithiasis – – 0.40 (0.31–0.52) < 0.001 – –
Medication 3 months pre-LFT
Statins 0.58 (0.35–0.94) 0.03 0.65 (0.58–0.74) < 0.001 0.56 (0.49–0.65) < 0.001
NSAIDs – – 0.92 (0.87–0.98) 0.005 – –
Antibiotics – – 1.09 (1.03–1.15) 0.003 1.14 (1.08–1.20) < 0.001
Alcohol dependent 2.00 (1.67–2.41) < 0.001 2.27 (2.08–2.49) < 0.001 1.52 (1.39–1.67) < 0.001
Drug abuse 1.93 (1.08–3.44) 0.03 1.92 (1.51–2.44) < 0.001 1.62 (1.22–2.14) < 0.001
Methadone user – – 1.86 (1.36–2.56) < 0.001 1.58 (1.17–2.14) 0.003
IHD, ischaemic heart disease; HR, hazard ratio.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Appendix 8  
Weibull regression results for survival 
from first LFT to liver disease diagnosis 
for time points 0–3 months, 3 months 
to 1 year and over 1 year
TABLE 51  Albumin
Variable
Baseline to 3 months 3 months to 1 year Over 1 year
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Albumin result (vs normal)
Mild 10.89 (6.19–19.17) < 0.001 4.29 (2.27–8.10) < 0.001 1.48 (0.87–2.52) 0.15
Severe 35.20 (15.60–79.45) < 0.001 3.25 (0.45–23.55) 0.24 2.89 (0.93–9.00) 0.07
Gender (male vs female) 1.23 (0.91–1.66) 0.18 1.10 (0.80–1.50) 0.55 1.18 (1.02–1.36) 0.03
Age (+1 year) 1.00 (0.99–1.01) 0.73 1.01 (1.00–1.02) 0.007 1.01 (1.01–1.02) < 0.001
Carstairs score 1.08 (1.04–1.13) < 0.001 1.06 (1.02–1.11) 0.005 1.03 (1.01–1.05) 0.003
Comorbidity (vs no comorbidity)
Respiratory – – – – 1.45 (1.00–2.10) 0.052
Gallbladder disorder – – 2.90 (1.17–7.20) 0.02 – –
Alcohol dependent 3.00 (1.77–5.10) < 0.001 3.88 (2.27–6.62) < 0.001 6.64 (5.30–8.33) < 0.001
Drug abuse – – – – 2.68 (1.75–4.12) < 0.001
Methadone user 7.47 (3.39–16.49) < 0.001 7.17 (2.97–17.33) < 0.001 3.72 (2.28–6.05) < 0.001
HR, hazard ratio.Appendix 8
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TABLE 52  Alkaline phosphatase (AP)
Variable
Baseline to 3 months 3 months to 1 year Over 1 year
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
AP result (vs normal)
Mild 7.26 (4.68–11.28) < 0.001 3.82 (2.55–5.73) < 0.001 2.10 (1.74–2.53) < 0.001
Severe 55.56 
(25.65–120.32)
< 0.001 23.11 (10.15–52.63) < 0.001 5.85 (3.27–10.49) < 0.001
Gender (male vs female) 1.41 (1.04–1.92) 0.03 1.20 (0.88–1.64) 0.26 1.25 (1.08–1.45) 0.003
Age (+1 year) 1.01 (1.00–1.02) 0.02 1.02 (1.01–1.03) < 0.001 1.02 (1.01–1.02) < 0.001
Carstairs score 1.07 (1.03–1.12) 0.001 1.06 (1.01–1.10) 0.01 1.03 (1.01–1.05) 0.01
Comorbidity (vs no comorbidity)
Respiratory – – – – 1.51 (1.04–2.19) 0.03
Gallbladder disorder – – 2.67 (1.08–6.60) 0.03 – –
Alcohol dependent 2.49 (1.48–4.20) < 0.001 3.33 (1.97–5.64) < 0.001 6.20 (4.95–7.76) < 0.001
Drug abuse – – – 2.47 (1.60–3.79) < 0.001
Methadone user 8.97 (4.05–19.88) < 0.001 7.67 (3.17–18.56) < 0.001 3.78 (2.32–6.16) < 0.001
HR, hazard ratio.
TABLE 53  Bilirubin
Variable
Baseline to 3 months 3 months to 1 year Over 1 year
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Bilirubin result (vs normal)
Mild 3.59 (2.35–5.48) < 0.001 2.01 (1.24–3.25) 0.005 1.72 (1.36–2.19) < 0.001
Gender (male vs female) 1.13 (0.83–1.54) 0.43 1.06 (0.78–1.45) 0.70 1.15 (1.00–1.34) 0.06
Age (+1 year) 1.01 (1.00–1.02) 0.07 1.01 (1.01–1.02) 0.001 1.01 (1.01–1.02) < 0.001
Carstairs score 1.09 (1.05–1.14) < 0.001 1.07 (1.02–1.11) 0.003 1.03 (1.01–1.05) 0.002
Comorbidity (vs no comorbidity)
Respiratory – – – – 1.45 (1.00–2.11) 0.049
Gallbladder disorder – – 2.85 (1.15–7.07) 0.02 – –
Alcohol dependent 3.07 (1.80–5.22) < 0.001 3.84 (2.25–6.54) < 0.001 6.53 (5.21–8.18) < 0.001
Drug abuse – – – – 2.81 (1.83–4.31) < 0.001
Methadone user 10.03 (4.48–22.44) < 0.001 7.91 (3.26–19.21) < 0.001 3.79 (2.33–6.18) < 0.001
HR, hazard ratio.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 54  Transaminase
Variable
Baseline to 3 months 3 months to 1 year Over 1 year
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Transaminase result (vs normal)
Mild 6.95 (4.33–11.15) < 0.001 6.37 (4.03–10.08) < 0.001 3.42 (2.75–4.25) < 0.001
Severe 46.90 (23.63–93.07) < 0.001 19.92 (10.06–39.41) < 0.001 5.90 (3.95–8.82) < 0.001
Gender (male vs female) 0.99 (0.73–1.35) 0.97 0.92 (0.67–1.26) 0.62 1.09 (0.94–1.26) 0.26
Age (+1 year) 1.01 (1.00–1.02) 0.07 1.01 (1.01–1.02) 0.002 1.01 (1.01–1.02) < 0.001
Carstairs score 1.09 (1.05–1.14) < 0.001 1.07 (1.02–1.12) 0.003 1.03 (1.01–1.05) 0.002
Comorbidity (vs no comorbidity)
Respiratory disease – – – – 1.49 (1.03–2.16) 0.04
Gallbladder disorder – – 2.90 (1.17–7.18) 0.02 – –
Alcohol dependent 2.14 (1.27–3.59) 0.004 2.96 (1.75–5.00) < 0.001 5.69 (4.54–7.12) < 0.001
Drug abuse – – – – 2.74 (1.78–4.22) < 0.001
Methadone user 8.26 (3.73–18.29) < 0.001 7.68 (3.17–18.62) < 0.001 3.59 (2.20–5.88) < 0.001
HR, hazard ratio.
TABLE 55  Gamma-glutamyltransferase (GGT)
Variable
Baseline to 3 months 3 months to 1 year Over 1 year
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
GGT result (vs normal)
Mild 5.91 (3.75–9.32) < 0.001 3.81 (2.54–5.73) < 0.001 1.84 (1.53–2.23) < 0.001
Severe 58.36 
(28.92–117.77)
< 0.001 26.63 (14.13–50.18) < 0.001 6.64 (4.96–8.88) < 0.001
Gender (male vs female) 0.96 (0.71–1.30) 0.78 0.96 (0.70–1.30) 0.78 1.14 (0.99–1.32) 0.08
Age (+1 year) 1.01 (1.00–1.02) 0.002 1.02 (1.01–1.03) < 0.001 1.02 (1.01–1.02) < 0.001
Carstairs score 1.07 (1.02–1.12) 0.002 1.06 (1.01–1.10) 0.01 1.03 (1.01–1.05) 0.009
Comorbidity (vs no comorbidity)
Respiratory – – – – 1.56 (1.08–2.27) 0.02
Gallbladder disorder – – 2.85 (1.15–7.06) 0.02 – –
Alcohol dependent – – – – 3.99 (3.16–5.03) < 0.001
Drug abuse – – – – 3.09 (2.00–4.79) < 0.001
Methadone user 8.51 (3.88–18.65) < 0.001 7.83 (3.25–18.88) < 0.001 3.29 (2.00–5.41) < 0.001
HR, hazard ratio.DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Appendix 9  
Predictive algorithms for liver 
disease and all cause mortality
TABLE 56  Final model predicting risk of liver mortality within 3 months after first LFTs
Parameter Coefficient (95% CI) p-value
Intercept 15.184 (9.468–20.900) < 0.001
Gender (male vs female) –0.677 (–1.396 to 0.041) 0.06
Age –0.014 (–0.034 to 0.006) 0.17
Biliary tract disorder history (yes vs no) –2.454 (–4.132 to –0.777) 0.004
Log (AP) –1.081 (–1.611 to –0.551) < 0.001
Albumin/SD 0.414 (0.183–0.646) < 0.001
Log (bilirubin) –1.557 (–2.471 to –0.643) < 0.001
Scale 0.652 (0.434–0.979)
AP , alkaline phosphatase.
Discrimination: overall C (95% CI) was 0.95 (0.66–1.00).
TABLE 57  Final model predicting risk of liver mortality from 3 months after first LFTs
Parameter Coefficient (95% CI) p-value
Intercept 5.076 (–1.182 to 11.334) 0.11
Gender (male vs female) –0.027 (–0.254 to 0.200) 0.81
Age –0.017 (–0.025 to –0.010) < 0.001
Carstairs score –0.031 (–0.059 to –0.002) 0.04
Cancer history (excludes liver and biliary) (yes vs no) –0.519 (–1.021 to –0.017) 0.04
Alcohol dependent (yes vs no) 3.560 (1.092–6.028) 0.005
Log (transaminase) 3.241 (0.876–5.607) 0.007
Log (GGT) 2.502 (1.472–3.533) < 0.001
Albumin/SD –0.119 (–0.471 to 0.234) 0.51
Log (bilirubin) 3.711 (1.019–6.404) 0.007
Log (transaminase) × log (bilirubin) –1.731 (–2.680 to –0.782) < 0.001
Log (transaminase) × log (GGT) –0.780 (–1.192 to –0.367) < 0.001
Albumin/SD × log (bilirubin) 0.198 (0.062–0.334) 0.004
Log (GGT) × log (bilirubin) –1.402 (–1.843 to –0.961) < 0.001
Log (transaminase) × log (GGT) × log (bilirubin) 0.366 (0.208–0.525) < 0.001
Alcohol dependent × Albumin/SD –0.397 (–0.592 to –0.203) < 0.001
Scale 0.772 (0.693–0.860)
GGT, gamma-glutamyltransferase.
Discrimination: overall C was 0.49 (95% CI 0.40–0.59).Appendix 9
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TABLE 58  Final model predicting risk of all cause mortality within 3 months after first LFTs
Parameter Coefficient (95% CI) p-value
Intercept –3.820 (–13.727 to 6.088) 0.45
Gender (male vs female) –1.023 (–1.646 to –0.400) 0.001
Age –0.136 (–0.173 to –0.099) < 0.001
Carstairs score 0.124 (0.013–0.234) 0.03
Statins prescribed 3 months prior to baseline (yes vs no) 0.717 (0.202–1.232) 0.006
NSAIDs prescribed 3 months prior to baseline (yes vs no) 1.551 (0.296–2.806) 0.02
IHD history (yes vs no) –0.258 (–0.448 to –0.068) 0.008
Renal disease history (yes vs no) –0.618 (–1.159 to –0.078) 0.03
Respiratory disease history (yes vs no) –0.394 (–0.623 to –0.166) < 0.001
Stroke history (yes vs no) –1.337 (–2.207 to –0.467) 0.003
Cancer history (excludes liver and biliary) (yes vs no) –5.722 (–7.486 to –3.958) < 0.001
Log (AP) 1.591 (–0.737 to 3.919) 0.18
Log (GGT) 2.446 (0.916–3.976) 0.002
Albumin/SD 1.299 (0.986–1.613) < 0.001
Log (bilirubin) 6.431 (2.185–10.677) 0.003
Albumin/SD × log (bilirubin) –0.094 (–0.166 to –0.023) 0.01
Log (AP) × log (bilirubin) –1.131 (–2.083 to –0.179) 0.02
Log (GGT) × log (bilirubin) –1.230 (–1.905 to –0.555) < 0.001
Log (AP) × albumin/SD –0.106 (–0.169 to –0.042) 0.001
Log (AP) × log (GGT) –0.483 (–0.840 to –0.125) 0.008
Log (AP) × log (GGT) × log (bilirubin) 0.226 (0.074–0.378) 0.004
Age × cancer history 0.045 (0.031–0.060) < 0.001
Gender × log (bilirubin) 0.370 (0.106–0.634) 0.006
Age × log (AP) 0.017 (0.009–0.025) < 0.001
NSAIDs × albumin/SD –0.160 (–0.269 to –0.050) 0.004
Cancer history × albumin/SD 0.147 (0.039–0.256) 0.008
Stroke history × log (GGT) 0.235 (0.016–0.454) 0.04
Carstairs score × albumin/SD –0.013 (–0.022 to –0.003) 0.01
Scale 0.926 (0.871–0.984)
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase; IHD, ischaemic heart disease; NSAIDs, non-steroidal 
inflammatory drugs.
Discrimination: overall C was 0.88 (95% CI 0.85–0.91).DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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TABLE 59  Final model predicting risk of all cause mortality from 3 months to 1 year after first LFTs
Parameter Coefficient (95% CI) p-value
Intercept 11.717 (5.857–17.578) < 0.001
Gender (male vs female) –1.323 (–1.974 to –0.671) < 0.001
Age –0.126 (–0.183 to –0.070) < 0.001
Carstairs score –0.170 (–0.258 to –0.083) < 0.001
Statins prescribed 3 months prior to baseline (yes vs no) 0.496 (0.145–0.848) 0.006
IHD history (yes vs no) 2.272 (0.389–4.154) 0.02
Renal disease history (yes vs no) –1.033 (–1.556 to –0.511) < 0.001
Respiratory disease history (yes vs no) –2.990 (–5.108 to –0.871) 0.006
Stroke history (yes vs no) –0.554 (–0.778 to –0.330) < 0.001
Cancer history (excludes liver and biliary) (yes vs no) –4.669 (–5.671 to –3.667) < 0.001
Biliary cancer history (yes vs no) 23.352 (0.311–46.393) 0.047
Methadone user (yes vs no) –0.805 (–1.563 to –0.046) 0.04
Log (transaminase) 0.200 (0.089–0.310) < 0.001
Log (AP) –1.328 (–2.401 to –0.255) 0.02
Albumin/SD 1.150 (0.739–1.560) < 0.001
Log (AP) × albumin/SD –0.089 (–0.165 to –0.012) 0.02
Gender × age 0.010 (0.002–0.019) 0.02
Age × cancer history 0.052 (0.039–0.065) < 0.001
Age × log (AP) 0.019 (0.011–0.027) < 0.001
Age × albumin/SD –0.003 (–0.006 to –0.001) 0.02
IHD history × log (AP) –0.549 (–0.959 to –0.139) 0.009
Respiratory disease history × log (AP) 0.538 (0.076–0.999) 0.02
Age × biliary cancer history –0.333 (–0.611 to –0.055) 0.02
Age × Carstairs score 0.002 (0.001–0.003) 0.001
Scale 1.083 (1.034–1.135)
AP , alkaline phosphatase; IHD, ischaemic heart disease.
Discrimination: overall C was 0.82 (95% CI 0.79–0.84).Appendix 9
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TABLE 60   Final model predicting risk of all cause mortality from 1 year after first LFTs
Parameter Coefficient (95% CI) p-value
Intercept 1.078 (–9.181 to 11.336) 0.84
Gender (male vs female) –0.562 (–0.766 to –0.358) < 0.001
Age –0.128 (–0.144 to –0.112) < 0.001
Carstairs score –0.065 (–0.091 to –0.039) < 0.001
Statins prescribed 3 months prior to baseline (yes vs no) 3.506 (1.636–5.376) < 0.001
IHD history (yes vs no) –1.083 (–1.452 to –0.714) < 0.001
Respiratory disease history (yes vs no) –1.171 (–1.592 to –0.751) < 0.001
Diabetes history (yes vs no) –1.283 (–1.967 to –0.599) < 0.001
Stroke history (yes vs no) –1.344 (–2.020 to –0.669) < 0.001
Cancer history (excludes liver and biliary) (yes vs no) –1.933 (–2.375 to –1.491) < 0.001
Biliary cancer history (yes vs no) –2.340 (–3.935 to –0.744) 0.004
Alcohol dependent (yes vs no) 3.470 (–4.489 to –2.451) < 0.001
Drug dependent (yes vs no) –1.553 (–2.236 to –0.869) < 0.001
Log (transaminase) 5.582 (2.469–8.695) < 0.001
Log (AP) 3.257 (0.727–5.787) 0.01
Log (GGT) 0.017 (–1.368 to 1.401) 0.98
Albumin/SD 0.969 (0.202–1.737) 0.01
Log (transaminase) × albumin/SD –0.266 (–0.496 to –0.036) 0.02
Log (transaminase) × log (AP) –1.364 (–2.123 to –0.605) < 0.001
Log (transaminase) × log (GGT) –0.147 (–0.632 to 0.338) 0.55
Log (AP) × albumin/SD –0.264 (–0.461 to –0.067) 0.009
Log (GGT) × albumin/SD 0.135 (0.042–0.227) 0.004
Log (AP) × log (GGT) –0.341 (–0.478 to –0.203) < 0.001
Log (transaminase) × log (AP) × albumin/SD 0.077 (0.018–0.137) 0.01
Log (transaminase) × log (GGT) × albumin/SD –0.035 (–0.067 to –0.002) 0.04
Log (transaminase) × log (AP) × log (GGT) 0.109 (0.065–0.154) < 0.001
Gender × age 0.003 (0.001–0.006) 0.02
Age × respiratory disease history 0.010 (0.004–0.016) < 0.001
Age × IHD history 0.011 (0.006–0.016) < 0.001
Age × diabetes history 0.013 (0.003–0.022) 0.008
Age × stroke history 0.013 (0.004–0.022) 0.005
Age × cancer history 0.021 (0.015–0.027) < 0.001
Age × alcohol dependent 0.025 (0.020–0.031) < 0.001
Age × drug dependent 0.020 (0.008–0.032) < 0.001
Age × log (AP) 0.013 (0.009–0.016) < 0.001
Statins × albumin/SD –0.248 (–0.392 to –0.103) < 0.001
Alcohol dependent × log (AP) 0.298 (0.085–0.510) 0.006
Age × Carstairs score 0.001 (0.000–0.001) < 0.001
Carstairs score × stroke history 0.031 (0.007–0.055) 0.01
Scale 0.814 (0.801–0.827)
AP , alkaline phosphatase; GGT, gamma-glutamyltransferase; IHD, ischaemic heart disease.
Discrimination: overall C was 0.56 (95% CI 0.55–0.57).DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Development of a decision support tool to facilitate primary care management of 
patients with abnormal liver function tests without clinically apparent liver disease
Abnormal liver function test study
We invite you to participate in a research project. We believe it to be of potential importance. However, 
before you decide whether or not you wish to participate, we need to be sure that you understand firstly 
why we are doing it, and secondly what it would involve if you agree. We are therefore providing you with 
the following information. Read it carefully and be sure to ask any questions you have, and, if you want, 
discuss it with outsiders. We will do our best to explain and to provide any further information you may 
ask for now or later. You do not have to make an immediate decision.
Liver function tests (LFTs) are routinely requested by GPs, and are often the gateway to further 
investigations. Little is known of the consequences in people with an initial abnormal liver function test 
(ALFT). Further investigations may reveal liver disease or may reveal nothing.
The NHS has therefore asked us to find out the best way of managing patients with an ALFT with the 
ultimate aim of reducing unnecessary procedures, costs to the patients and costs to the NHS. To do this, 
we need your help.
We would like to invite you to join the study.
•	 The purpose of this part of the study is to try to measure the possible anxiety induced following an 
invitation for a diagnostic procedure.
•	 It is up to you to decide whether to join. If you decide not to (or if after joining the study you 
subsequently decide to withdraw from it) you are completely free to do so, without giving a reason, 
and it will not affect your future care.
If you do agree to join the study, then this is what will happen to you.
•	 Before you see the specialist, we will give you a booklet containing five short questionnaires that you 
will be asked to complete and a research nurse will take you through the questions. The first four 
questionnaires should be completed before seeing the specialist. The last one should be completed 
after you see the specialist.
•	 The questions will cover your state of health and quality of life at the moment and some personal 
questions, e.g. sex, age, etc.
•	 The total time involved should be approximately 20 minutes.
Finally, we would like to emphasise these aspects of your role in the study, should you join it:
•	 Participation in this study is entirely voluntary and you are free to refuse to take part or to withdraw 
from the study at any time without having to give a reason and without this affecting your future 
medical care or your relationship with medical staff looking after you.
•	 No particular benefit can be guaranteed for you by your contribution to this study. However, your 
input is invaluable to benefit future patients whose management may be improved by the results of 
this study.
Appendix 10  
Patient volunteer information sheetAppendix 10
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The Tayside Committee on Medical Research Ethics, which has responsibility for scrutinising all proposals 
for medical research on humans in Tayside, has examined the proposal and has raised no objections from 
the point of view of medical ethics. It is a requirement that your records in this research, together with any 
relevant medical records, be made available for scrutiny by monitors from NHS Tayside.
The results of this study will be published in medical journals. Individuals will not be identified in any 
report. We will inform your GP if you agree to participate. A summary sheet of the results will be sent to 
all participating GPs and it will also be available on the web. You may keep this page for your information. 
Thank you very much for helping us to learn more about effective and appropriate management of 
patients following an ALFT. If you require further information or wish to discuss any issue you can contact 
Dr Peter Donnan (01382 000000) or Dr John Dillon (01382 000000).DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Appendix 11  
Patient survey of health-state utilities 
for ALF and liver biopsy  
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EQ-5D Questionnaire
By placing a tick in one box in each group below, please indicate which statements best describe your own 
health state today.
Mobility                 Please  ONE box
I have no problems in walking about
I have some problems in walking about
I am confined to bed



Self-care                Please  ONE box
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself



Usual activities (e.g. work, study, housework, family or leisure activities)  Please  ONE box
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities



Pain/discomfort               Please  ONE box
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort



Anxiety/depression               Please  ONE box
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed


DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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SF-6D Questionnaire
By placing a tick in one box in each group below, please indicate which statements best describe your own 
health state today.
Physical functioning                Please  ONE box
Your health does not limit you in vigorous activities
Your health limits you a little in vigorous activities
Your health limits you a little in moderate activities
Your health limits you a lot in moderate activities
Your health limits you a little in bathing and dressing
Your health limits you a lot in bathing and dressing






Role limitations                 Please  ONE box
You have no problems with your work or other regular daily activities as a result of your physical 
health or any emotional problems
You are limited in the kind of work or other activities as a result of emotional problems
You accomplish less than you would like as a result of emotional problems
You are limited in the kind of work or other activities as a result of your physical health and 
accomplish less than you would like as a result of emotional problems





Social functioning                Please  ONE box
Your health limits your social activities none of the time
Your health limits your social activities a little of the time
Your health limits your social activities some of the time
Your health limits your social activities most of the time
Your health limits your social activities all of the time




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Pain                    Please  ONE box
You have no pain
You have pain but it does not interfere with your normal work (both outside the home and 
housework)
You have pain that interferes with your normal work (both outside the home and housework) 
a little bit
You have pain that interferes with your normal work (both outside the home and housework) 
moderately
You have pain that interferes with your normal work (both outside the home and housework) 
quite a bit
You have pain that interferes with your normal work (both outside the home and housework) 
extremely






Mental health                   Please  ONE box
You feel tense or downhearted and low none of the time
You feel tense or downhearted and low a little of the time
You feel tense or downhearted and low some of the time
You feel tense or downhearted and low most of the time
You feel tense or downhearted and low all of the time





Vitality                    Please  ONE box
You have a lot of energy all of the time
You have a lot of energy most of the time
You have a lot of energy some of the time
You have a lot of energy a little of the time
You have a lot of energy none of the time




DOI: 10.3310/hta13250  Health Technology Assessment 2009; Vol. 13: No. 25
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Self-evaluation questionnaire : STAI Form Y-1
Instructions  A number of questions that people have used to describe themselves are given below. Read 
each statement and then tick the appropriate answer to the right of the statement to indicate how you feel 
right now, that is, at this moment. There are no right or wrong answers. Do not spend too much time on any 
one statement but give the answer that seems to describe your present feelings best.
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1. I feel calm    
2. I feel secure    
3. I am tense    
4. I feel strained    
5. I feel at ease    
6. I feel upset    
7. I am presently worrying over 
possible misfortunes
   
8. I feel satisfied    
9. I feel frightened    
10. I feel comfortable    
11. I feel self-confident    
12. I feel nervous    
13. I am jittery    
14. I am indecisive    
15. I am relaxed    
16. I feel content    
17. I am worried    
18. I feel confused    
19. I feel steady    
20. I feel pleasant    Appendix 11
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Self-evaluation questionnaire : STAI Form Y-2
Instructions  A number of questions that people have used to describe themselves are given below. Read 
each statement and then tick the appropriate answer to the right of the statement to indicate how you 
generally feel. There are no right or wrong answers. Do not spend too much time on any one statement but 
give the answer that seems to describe your present feelings best.
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21. I feel pleasant    
22. I feel nervous and restless    
23. I feel satisfied with myself    
24. I wish I could be as happy as others seem to 
be
   
25. I feel like a failure    
26. I feel rested    
27. I feel ‘calm, cool and collected’    
28. I feel that difficulties are piling up so that I 
cannot overcome them
   
29. I worry too much over something that 
doesn’t really matter
   
30. I am happy    
31. I have disturbing thoughts    
32. I lack self-confidence    
33. I feel secure    
34. I make decisions easily    
35. I feel inadequate    
36. I am content    
37. Some unimportant thought runs through my 
mind and bothers me
   
38. I take disappointments so keenly that I can’t 
put them out of my mind
   
39. I am a steady person    
40. I get in a state of tension or turmoil as I think 
over my recent concerns and interests
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Feedback
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your views about this report.
The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish  
your comments. If you prefer, you can send your comments  
to the address below, telling us whether you would like  
us to transfer them to the website.
We look forward to hearing from you.